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General Introduction 

Introduction 
1.1 PSORIASIS, A CLINICAL DESCRIPTION 
Various aspects of the aetiology, pathogenesis, clinical manifestations and therapies 
have been described extensively in literature. A summary of these aspects will be given 
in order to provide the outlines for the aims of this thesis. For a more detailed account 
on these subjects, the reader is referred to textbooks on general dermatology and on 
psoriasis[1,2]. 
1.2 PREVALENCE AND EPIDEMIOLOGY 
Psoriasis is a common non-infectious skin disorder. In Caucasians, the prevalence of 
psoriasis is around two percent of the general population[3]. The male to female ratio 
is about 1:1 [4-6]. Prevalence has a racial variability, indicating the necessity of a certain 
genetic background[7-10]. It has been reported that psoriasis is present in two distinct 
forms, one of which is hereditary with early onset, and the other is sporadic and 
becomes manifest at older age[ll,12]. 
1.3 AETIOLOGY 
The complex phenotype of psoriasis is caused by a combination of hereditary and 
environmental factors[2]. 
The lifetime risk to become psoriatic patient when one or several family members 
are affected, is given in Table 1. 
Family members suffering f rom psoriasis Risk (%) 
one parent, no brothers ore sisters 10 
none of parents, one brother or sister 7 
one parent, one brother or sister 16 
none of parents, two brothers or sisters 16 
both parents 50 
family of the second degree 4 
family of the third degree 1-2 
Table 1. Lifetime risk of getting psoriasis[7]. 
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The genetic factors involved in the development of psoriasis are not yet fully 
clarified. Associations have been found with several HLA-genes (B13, B17, B27. Cw6. 
DR7), the apolipoprotein Ε-gene. the alpha-1-antitrypsin-inhibitor gene, and the gene 
for the interleukin-1-receptor antagonistic3,14]. 
The results of a genetic analysis of psoriasis suggests that psoriasis is inherited as a 
polygenic multifactorial trait[13]. However, some authors suggest other modes of 
¡nheritance[15]. Recently a gene involved in psoriasis susceptibility was localised to the 
distal region of chromosome 17q[16]. This study demonstrates that in some families 
psoriasis susceptibility is due to variation at a single major gene locus. 
The age on which the first signs of psoriasis become apparent, varies 
considerably[17,18]. The condition may become apparent in early childhood, as well 
as in the elderly. In the majority of patients, however, the first manifestations are 
before 25 years of age[7]. 
Several environmental factors have been identified which play an important role in 
the initiation of the first signs of psoriasis in a genetically predisposed patient 
(Table 2). 
Predisposing factors 
Systemic factors Local factors 
Systemic infections Skin infections 
Stress Other skin disease 
Hypocalcemia Trauma 
Medication Local therapies 
applied to the skin 
Table 2. Predisposing factors for development or exacerbation of psoriasis[19]. 
Systemic factors can play a role in the initiation of psoriasis as well as in the 
exacerbation. Focal infections of the upper respiratory tract, such as tonsillitis or 
sinusitis, may cause the clinical picture of guttäte psoriasis, or may exacerbate chronic 
plaque psoriasis. Bacterial superantigens may induce the inflammatory changes in this 
initial phase. The relevance of psychological stress in psoriasis is not yet fully 
understood. It is possible, however, that it is a co-factor determining the clinical course 
of psoriasis[20,21]. Hypocalcaemia is known to exacerbate psoriasis. Several drugs 
(such as lithium carbonate, beta blockers, antimalarial compounds, angiotensin 
converting enzyme inhibitors, and non-steroidal antiinflammatory drugs such as 
indomethacin), are known to exacerbate psoriasis. 
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Local factors can initiate the appearance of psoriatic manifestations. The observation 
that local irritation or trauma of the skin can exacerbate psoriasis was first described by 
Koebner in 1883 and is hence called the Koebner phenomenon. The Koebner 
phenomenon is observed in 25% of patients[22]. 
1.4 CLINICAL MANIFESTATIONS 
/. 4.1 Cenerà/ description[23] 
In general, the clinical appearance of psoriasis vulgaris permits a diagnosis "à vue". It is 
characterised by sharply demarcated erythematosquamous lesions varying in size from 
pinpoint lesions to palm-sized, or even larger plaques, as demonstrated in Figures 1 
and 2. 
Figure 1. Clinical picture of psoriasis vulgaris: sharply demarcated 
erythematosquamous plaques. 
Figure 2. Psoriasis vulgaris: in detail. 
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Larger plaques may have developed from several smaller lesions which have 
coalesced, adopting polycyclic. annular, or gyrate configurations Occasionally, a 
generalised psoriatic erythroderma occurs The psoriatic lesion consists of three basic 
morphologic elements erythema, induration, and scaling 
After scratching the superficial scales, one can observe the "candle phenomenon", 
which consists of detachment of scales from the psoriatic lesion, appearing like wax 
flakes scraped from a candle If one continues scraping after removal of the scaly 
material, one can remove a coherent moist sheet from the lesion This so called "last 
cuticle phenomenon" consists of a thin layer of epidermis, just overlying the dermal 
papillae On removal of the last cuticle, the "Auspitz's phenomenon" can be observed, 
which consists of pinpoint spotty bleeding The induration of a psoriatic lesion can 
easily be assessed on palpation, and is caused by epidermal thickening and cutaneous 
inflammation 
The erythema is rich, and salmon-pink-like in colour Occasionally a clear "whitish" 
penlesional zone can be observed the halo of Woronoff[24] Some authors indicated 
this zone around the sharply demarcated lesions as vasoconstriction, and others as 
depigmentation[25]. 
The relative contribution of erythema, induration, and scaling may vary 
considerably Therefore psoriasis has several distinct clinical pictures, based on 
variation in morphological characteristics of the individual lesion Psoriatic 
manifestations are categorised by size, clinical aspect, and localisation of the lesion 
The droplet-like guttäte psoriatic lesions are small, whereas chronic plaque psoriasis 
consists of coin-sized (nummular), to palm-sized or larger erythematosquamous 
plaques The guttäte lesions may lack scaling, whereas an excessive overproduction of 
scales occurs in elephantine psoriasis Lesions may be restricted to specific areas such as 
the scalp, or generalised like in psoriatic erythroderma 
14 2 Subtypes of psoriasis 
(I) Chronic plaque psoriasis is the most common manifestation in adults, accounting 
for 90% of cases The lesions usually show a symmetrical distribution over the body, 
and predilection sites are the scalp, elbows, knees, and sacral region (II) Guttäte 
psoriasis is characterised by a disseminated distribution of small droplet-like lesions 
with little or no scaling It is most frequently observed in children and young 
adolescents, and is often preceded by an infection of the upper respiratory tract[19] 
(111) The pustular manifestations of psoriasis are less common The distribution pattern 
can be localised, like in pustulosis palmoplantaris, or generalised, like in psoriasis 
pustulosa generalisata ('von Zumbusch'-type)[26]. 
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(IV) Psoriatic erythroderma is a rare condition which may be triggered by a drug 
eruption, withdrawal of corticosteroids, or by antipsonatic therapies such as dithranol 
The skin becomes universally and uniformly erythematous with variable scaling[27] 
The condition may be complicated by hypothermia, dehydration, and protein loss 
14 3 Additional manifestations 
Psoriatic nail changes are common and occur in 10-78% of cases[28 30] They consist 
of distal onycholysis, subungual hyperkeratosis, surface changes, and discoloration of 
the nail plate Psoriasis can be associated with arthntis[31] Psoriatic arthropathy is 
found in 5-10% of cases[32] Peripheral joints and the spine are most commonly 
affected 
14 4 Clinical course 
The clinical course of psoriasis is unpredictable and characterised by exacerbations and 
remissions However, psoriasis can also remain stable for several years and long 
lasting complete remissions have been reported as well[21] Genetic predisposition and 
presence of triggering factors are important in the course of psoriasis No definitive 
cure is possible, however, prognosis is good with respect to clinical symptoms, due to 
many available therapeutic possibiIities[23] 
14 5 Differential diagnosis 
For the differential diagnosis one should consider seborrhoeic dermatitis which may 
have considerable clinical similarity However, seborrhoeic dermatitis is usually 
characterised by more yellowish and greasy scales, and a different body distribution 
(presternal, interscapular, intertnginous areas, and the face) In isolated psoriasiform 
plaques which show an asymmetrical distribution with elevation of the margin of the 
plaque, the possibility of an epidermomycosis should be considered When plaques are 
not sharply demarcated, show brownish discoloration and a cigarette-paper like 
atrophy, parapsoriasis or a cutaneous lymphoma has to be considered Lichen ruber 
planus (LRP) shows violet-coloured papules with polygonal shape and a glistening 
surface Mucosal changes are frequently present The clinical picture of LRP is usually 
distinctive, however, in the verrucous variants confusion with psoriasis is well possible 
and additional histological examinations are required to verify the diagnosis 
In case of nummular lesions covering the trunk and proximal part of the extremities, 
pityriasis rosea and secondary syphilis have to be considered Histological serological 
and mycological investigations might be helpful in case of an atypical presentation of 
psoriasis In extensive psoriasis, the distinction from pityriasis rubra pilaris may cause 
difficulties 
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1.5 HISTOPATHOLOGY 
The main histological features of the psoriatic phenotype are an increased epidermal 
hyperproIiferation[33], altered differentiation and keratmisation in combination with 
an increased cutaneous inflammation[34,35] 
The histological aspects of psoriasis vulgaris may vary considerably, depending on 
the stage of development of the lesion The histological characteristics of early 
pinpoint lesions and the margin of actively spreading psoriatic plaques are 
pathognomonic for psoriasis Histological features of the centre of a chronic psoriatic 
plaque are usually non specific The earliest pinpoint macules or papules show 
capillary dilation and oedema of the papillary dermis, with a perivascular 
mononuclear inflammatory infiltrate Besides lymphocytes, also many 
polymorphonuclear leukocytes (PMN) are present in the upper region of the dermal 
papillae Migration of mononuclear cells into the lower parts of the epidermis occurs 
After development of transient spongiosis, focal changes occur in the upper part of the 
epidermis consisting of vacuolisation and disappearance of keratohyalin granules in the 
stratum granulosum In addition to focal absence of the granular layer the corneocytes 
in the stratum corneum persist to contain nuclear remnants (parakeratosis) In an early 
stage of the lesion and in active psoriasis polymorphonuclear leukocytes (PMN) 
extravasate and penetrate into the epidermis accumulating as spongiform pustules of 
Kogoj and Munro microabscesses Figures 3 and 4 illustrate these "psoriasis specific" 
PMN accumulations[36,37] 
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Figure 3. Haematoxylin and eosin staining of a spongiform micropustule of Kogoj 
(magnification 400x). 
Figure 4. Haematoxylin and eosin staining of a Munro microabscess (arrowhead) 
(magnification 400x). 
The spongi form pustule consists of remnants o f eosinophilic epidermal strands w i t h 
PMN accumulat ion, and is also known as the "squirt ing papillae phenomenon" . 
Accumulat ion of P M N in the epidermis is accompanied by parakeratotic zones. The 
dermo-epidermal interface has changed w i th thickening of epidermal rete-ridges and 
hypertrophy of the dermal papillae. The epidermis overlying these dermal papillae is 
th in . 
M u n r o microabscesses, the spongiform pustules of Kogoj , co-occurrence of or tho-
and para-keratotic foci , in combinat ion w i t h suprapapillary epidermal thinning and 
hyperplasia of the rete-ridges, are diagnostic for psoriasis. 
The histopathology of pustular forms of psoriasis is dominated by migrat ion of 
PMN and lymphocytes f rom the capillaries in the papil lary dermis into the epidermis, 
and the fo rmat ion of sterile macropustules just be low the stratum corneum. There is a 
relative abundance o f P M N . 
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Keratinocytes ¡η the centre of a pustule undergo cytolysis. leaving a cavity. The 
other epidermal changes observed in pustular forms of psoriasis are similar to those 
seen in psoriasis vulgaris. 
1.6 THERAPIES 
Psoriasis may appear as many different manifestations and between individuals there 
may be marked differences. A choice from the various treatment modalities can be 
made and the treatment regimen should be tailor made to the individual patient, 
depending on severity and extent of body involvement, clinical manifestation of 
psoriasis and the activities of daily life of the patient. Treatment must always be in 
accordance to the severity of the disorder, and never be more demanding than 
psoriasis itself. Emotional support, reassurance, and additional information to the 
patient about the nature of the disorder and the therapy are of great importance. At 
present the perspective on therapeutic possibilities is quite favourable. There is a vast 
array of possible antipsoriatic treatment modalities. However, modes of action are not 
yet fully elucidated and so far, treatment remains to be symptomatic. Before 
institution of treatment it is important to eliminate environmental factors involved in 
initiation or maintenance of the disorder (like upper respiratory tract infections, and 
psoriasis aggravating drugs like beta blockers, antimalarial compounds, or lithium). 
/. 6.1 Topica/ therapy 
For most patients with psoriasis, topical treatment is the most important approach. In 
general, systemic side effects of topical treatments are limited. 
Vitamin D3-analogues 
Since 1992 calcipotriol is available for the treatment of psoriasis. Substantial clinical 
efficacy makes it the first choice treatment in chronic plaque psoriasis. In a placebo-
controlled randomised trial calcipotriol ointment (50^g/g) applied twice daily proved 
to be of benefit in 74% of patients[38]. It resulted in a reduction of 
polymorphonuclear leukocytes (PMN) within one week of treatment, epidermal 
proliferation decreased after two weeks, and a significant reduction in cutaneous T-
lymphocytes and cytokeratin-16 expression was observed after four weeks of 
treatment[39]. 
In a long-term safety study, calcipotriol proved to induce optimal results within the 
first eight weeks of treatment, and it proved to be safe and effective over longer 
treatment periods, provided that less than 100 g of ointment is used per week. 
Calcipotriol caused skin irritation in 2 0 % of patients which was the reason for 
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discontinuation in 5% of cases[40]. Calcipotriol proved to be equally effective as 
betamethasone-17-valerate and dithranol, both established topical treatments of 
plaque psoriasis[41-44]. Combination of calcipotriol with phototherapy (UVB), or 
photochemotherapy (PUVA), proved to be safe and more effective than either of the 
therapies alone[45,46]. 
Calcipotriol should not be used in unstable expanding psoriasis, pustular forms of 
psoriasis, or psoriatic erythroderma for the risk of irritation. For the same reason it 
should not be used in the face, nor in body flexures. 
Tar therapy 
This is probably the oldest topical treatment of psoriasis. Crude coal tar (pix 
lithanthracis) is a mixture of aromatic hydrocarbons extracted from coal by heating 
under absence of oxygen[47]. It has beneficial effects in the treatment of psoriasis. A 
great variation in biological activity of various tar components has been 
demonstrated[48]. Therefore, standardisation of treatment is difficult. Over the past 
century it has been an important treatment modality in particular for in patient 
treatment[49]. It is especially effective in the treatment of itching (unstable, guttäte) 
psoriasis. Goeckerman combined tar therapy with the use of low dose ultraviolet 
radiation: this constituted the mainstay of in-patient treatment for more than fifty 
years [50]. 
Tar therapy is safe, but staining of clothes as well as the pronounced odour, are 
delimiters to its use[51-53]. Adverse reactions may occur at high concentrations and 
consist of folliculitis and skin irritation which is aggravated by UVA. Tar is applied in 
paste or ointment in concentrations ranging from 1-5%. Solutio carbonis detergens 
which is the alcoholic extract of crude coal tar, leaves minimal stains in fabric and can 
also be used in a cream base, however, it is substantially less effective. Solutio carbonis 
detergens is used in concentrations ranging from 5-20%, optionally in combination 
with topical corticosteroids. 
Corticosteroids 
Topical corticosteroids are an important treatment modality for psoriasis since 
1963[54]. The mode of action may involve direct effects on epidermal proliferation, 
suppression of the synthesis of inflammatory mediators, and modulation of cells 
present in the inflammatory infiltrate by regulation of several aspects of the 
immunological process. Patients often favour this treatment because it is easy to apply, 
cosmetically acceptable, and gives good clinical results. Clearance of a lesion can be 
achieved within two to three weeks. Potent corticosteroids (class 111 and IV) are 
extremely effective, however these should preferably be reserved for intervention 
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therapy and not for long-term use In general, corticosteroids are applied twice daily 
Alternatively, intermittent treatment for only a few days per week is a frequently used 
schedule[55] Side effects after chronic corticosteroid abuse can be irreversible and 
consist of teleangiectasia, purpura, and striae distensae Other side effects that were 
observed after chronic application are hypertrichosis, perioral dermatitis, and allergic 
contact dermatitis Potent corticosteroids can cause suppression of serum Cortisol 
levels[56] and should therefore only be used in limited amounts (45 to 90 g of 
ointment per week), nor should these compounds be applied to extended body 
surfaces After prolonged and repeated application of topical corticosteroids the 
therapeutic response may diminish 
There are no data available on long-term safety and efficacy of potent 
corticosteroids for topical use, and therefore quantification of the above mentioned 
phenomena is not yet possible However, adverse effects are known and are 
frequently observed Corticosteroids applied under occlusive hydrocolloid dressings 
constitute a novel and potent therapeutic approach in the treatment of individual 
psoriatic plaques that are resistant to therapy[57] This treatment is being well 
tolerated and corticosteroid application needs only be repeated after one week 
Topical corticosteroids can easily be combined with other treatment modalities 
Dithranol 
In 1916 dithranol (also known as cignohn or anthralm l,8-dihydroxy-9-anthrone) was 
developed and introduced by Unna as a treatment for psonasis[l] The mode of action 
is through induction of free oxygen radicals, inducing mild cutaneous inflammation 
which is associated with the therapeutic effects Dithranol is an unstable compound 
that is being inactivated by oxidation over a period of several weeks to several 
months Stability of dithranol heavily depends on the properties of the vehiculum in 
which it has been manufactured. 
Skin penetration improves with increasing lipophility of the vehiculum[58) 
Oxidation and therefore mactivation of dithranol is easily recognised by a yellow-
brownish discoloration of the dithranol The mode of action of dithranol is probably 
not a single selective mechanism Interference with epidermal growth and 
inflammation has been reported In dithranol treatment the initial concentration is to 
be chosen sufficiently low, ranging from 0 5-3%, in order to prevent excessive skin 
irritation and inflammation[59] During therapy, the dithranol concentration is 
gradually increased to the extent that slight skin irritation is maintained Dithranol can 
be applied in short contact treatment regimens, which make it suitable for use in a 
day-care unit or at home Dithranol therapy is extremely effective in the treatment of 
psoriasis in 90% of patients a complete to nearly complete clearance can be achieved 
18 
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Adverse effects of dithranol consist of excessive skin irritation due to use of too high 
concentrations or too extended application periods, and irreversible staining of clothes 
and household equipment[60] Ingram described a combined therapy in 1953, 
consisting of tar baths, UVB phototherapy, followed by the application of dithranol 
Dithranol treatment is considered to be the safest alternative, and can easily be 
combined with other antipsonatic treatments In particular the combination with 
phototherapy is commonly used 
16 2 Phototherapy 
Ultraviolet radiation has a pronounced therapeutic effect in psoriasis A prudent choice 
from the ultraviolet spectrum, however, is decisive for the clinical outcome 
Ultraviolet В (UVB, band width 290-320 nm) has substantial photodynamic potential 
and penetrates the dermo-epidermal junction of the skin[61,62] 
The therapeutic efficacy of ultraviolet A (UVA, band width 320 400 nm) is limited 
Radiation penetrates into the dermis, however, the photon energy of this type of 
radiation is too limited for a substantial antipsonatic effect In contrast, by using UVA 
in combination with topical or systemic psoralens (PUVA) which are photo-sensitisers 
substantial antipsonatic effects are observed Ultraviolet radiation activates the 
arachidonic acid cascade, stimulates the proliferation-associated enzyme ornithine 
decarboxylase, and induces the formation of sunburn cells in actively cycling 
keratmocytes[63] For both UVB and PUVA treatment regimens goes that doses should 
be increased until slight skin irritation is observed Phototherapy is used in guttäte 
and extensive chronic plaque psoriasis In spite of the fact that there are studies 
showing carcinogenic effects of UVB therapy, in vivo UVB treatment seems safe in 
humans[64] 
Contraindications for this photo(chemo)therapy are photodermatoses, co 
medication with phototoxic potential, history of skin malignancies or excessive sun 
induced skin damage, a family history of malignant melanoma, or previous treatments 
with X ray radiation or arsenic Photochemotherapy (PUVA) is more effective than 
phototherapy (UVB) Adverse effects are erythema, skin burn, bullae formation 
nausea, itching, hyperpigmentation, PUVA lentigines. and hypertrichosis Squamous 
cell carcinoma has been reported after chronic PUVA treatment[65,66] Other adverse 
events after chronic treatment are cataract, and hepatotoxicity 
PUVA can be considered if topical treatments and UVB proved to be ineffective 
PUVA therapy is indicated, in generalised pustular psoriasis and palmoplantar 
pustulosis, in addition to the indications mentioned above A recent development is 
the use of bath-PUVA In Scandinavian countries it has been practised already for 
years, and advantages seem to be the lesser extent of systemic adverse effects in 
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combinat ion w i t h a decreased risk in development of squamous cell carcinoma of the 
skin, as compared to conventional PUVA therapy[65,67] 
16 3 Systemic Therapy 
Systemic treatment is indicated if psoriasis cannot be managed by topical treatments 
and photo(chemo)therapy In particular in severe and extensive chronic plaque 
psoriasis, erythrodermic and pustular forms of psoriasis, systemic treatment may 
prov ide adequate control of psoriasis 
Systemic treatments are prescribed by dermatologists according to standardised 
operat ing procedures[68] For guidelines the readers are referred to t w o previous 
theses[69,70] 
Methotrexate 
The folic acid antagonists in the treatment of psoriasis were first described in 1951 [71] 
Methotrexate (Emthexate", Ledertrexate") is very effective in treatment of the various 
clinical manifestations of psonasis[72] 
Methotrexate interferes w i th DNA, RNA, and protein synthesis Cycling cells remain 
in G l , and cells in the S-phase of the cell cycle are ki l led, resulting in a decrease of the 
total number of cycling cells Methotrexate inhibits polymorphonuclear leukocyte 
Chemotaxis at dosages which are effective in psonasis[73] Usually dosing is instituted 
according to the Weinstein schedule (dosing in three gifts at twelve hourly intervals) 
At our department a maximum dosage of 15 mg per week is advised although 
higher dosing is reported in literature Acute adverse effects are dose dependent and 
consist of nausea, anorexia, hair loss, leukopenia, thrombopenia and megaloblast 
anaemia After chronic treatment, methotrexate can cause liver fibrosis and cirrhosis 
For this reason, a l iverbiopsy for histology is performed after every 1500 mg 
methotrexate (cumulative dose) Methotrexate has mutagenic potential , therefore, 
contraception is obl igatory in both female and male patients 
Other contra indications are significant renal or hepatic pathology, active infections, 
hypoplasia of the bone mar row, gastric ulcer, ulcerative colitis, drugs that are k n o w n 
to interfere w i t h methotrexate metabolism, and excessive alcohol intake Even dur ing 
long-term treatment, regular check ups at four- to six weekly intervals remain 
mandatory 
Acitretin 
As a monotherapy, the synthetic retmoic acid derivative acitretin (Neotigason^) has a 
preferential therapeutic effect in erythrodermic psoriasis and pustular forms of 
psonasis[74] In chronic plaque psoriasis, the combinations of acitretin w i t h 
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phototherapy (UVB) or photochemotherapy (PUVA), are extremely effective 
Retinoids exert antiproliferative effects in the treatment of psonasis[75,76] They 
inhibit the migration of polymorphonuclear leukocytes into the psoriatic epidermis, as 
well as the antibody-dependent cell-mediated cytotoxic reaction of PMN[77,78] 
Doses may vary from 0 5 to 1 mg per kg body weight per day Adverse effects are 
dose dependent and consist of dry mucosal membranes, dry lips, epistaxis, 
conjunctivitis Other adverse effects are peeling of the palms and soles, pruritus, hair 
loss, thinning of the epidermis, decreased colour vision and nocturnal blindness, and 
hyperlipidaemia Occasionally, hepatitis and osteophytic bone changes have been 
reported Acitretin has teratogenic potential and stores in fatty tissue after 
reestenfication. Therefore, women with child bearing potential should use adequate 
contraception, and should not get pregnant within the first two years after cessation of 
acitretin therapy The teratogenic potential of acitretin has no adverse effects on semen 
production in males Additional contraindications to therapy are significant hepatic 
disease, and hyperlipidaemia During treatment, liver enzymes, serum-cholesterol and 
triglyceride levels should be checked at regular intervals Active questioning and X-ray 
examinations are required to detect hyperostoses in an early stage 
Cyclosporin 
Cyclosporin (Neoral®) is a relatively new antipsonatic drug, which has proven to be 
effective in the treatment of all clinical manifestations of psonasis[79] The mode of 
action of cyclosporin A in psoriasis is supposed to be an inhibition of CD4+ T-
lymphocyte function. However, there are studies showing additional functions of 
cyclosporin A, including effects on keratmocytes Dosage is started at three to five mg 
per kg body weight per day, and is tapered as soon as clinical improvement occurs 
Adverse effects are nefrotoxicity, hypertension, gingival hyperplasia, hypertrichosis 
tremor, and hyperlipidaemia[80] Contraindications are nefrotoxic, cytotoxic or 
immunosuppressive co-medication, radiation therapy including photo(chemo)therapy, 
malignancies, active infections, immunodeficiencies, epilepsy, pregnancy, renal 
dysfunction, and uncontrollable hypertension Patients should be seen for check-up at 
four- to six-weekly intervals and haematological parameters, hepatic and renal 
functions, and blood pressure should be assessed[81] 
16 4 New and experimental antipsonatic treatment modalities 
New drugs are being developed in the constant search for antipsonatic therapies with 
a better therapeutic index In addition to calcipotnol as mentioned in section 1 5 1 
other vitamin D3 derivatives for topical use such as calcitnol (1,25-dihydroxy 
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vitamin D3), and tacalcitol (1,24-dihydroxy vitamin D3) are under investigation for 
clinical efficacy and tolerability in the treatment of psonasis[82,83] Development of 
new vitamin D3 analogs remains worthwhile in order to find compounds with a better 
therapeutic-toxic ratio 
Another promising novel drug in the systemic treatment of severe and extensive 
plaque psoriasis is the imidazole derivative liarozole[84] It inhibits the cytochrome Ρ 
450 dependent 4 hydroxylation of retinóte acid which is the physiological breakdown 
of all-fra/zr-retinoic acid In previous studies liarozole has shown to rise the intracellular 
retinoid concentration in humans In the treatment of severe plaque psoriasis liarozole 
has proven to have therapeutic potential Further studies are underway to establish the 
safety and clinical tolerability of liarozole as a new antipsonatic treatment modality 
Recently, a new compound became available, R-85355 (Janssen Cilag, Beersse, 
Belgium) It is a inhibitor of the enzyme 5-lipoxygenase Another promising drug is the 
new and specific LTB4 receptor antagonist (LY293111, Lilly Research Laboratories, 
Indianapolis, USA, also known as VML295, Vanguard Medica Limited, Guildford, Great 
Britain) 
In vitro it proved to be a potent and specific inhibitor of the LTB4 receptor which 
blocked the induction of CDllb/CD18 integrm up-modulation on LTB4 stimulated 
neutrophils[85] 
In the present thesis further study will be carried out on the cytochrome Ρ 450 
inhibitor liarozole, the 5-lipoxygenase inhibitor R-85355, and the LTB4 receptor 
antagonist LY293111 / VML295 
1.7 CELLULAR ASPECTS OF INFLAMMATION 
The pathogenesis of psoriasis comprises various components the suprabasal epidermal 
compartment with abnormal and premature keratmisation, and the germinative 
epidermal compartment characterised by an increased recruitment of cycling cells In 
epidermis and dermis there is an accumulation of leukocytes that have extravasated 
from peripheral blood, which is accompanied by a vast array of inflammatory 
mediators and increased expression of various adhesion molecules In the dermal 
compartment there is increased angiogenesis and proliferation of fibroblasts with an 
abnormal expression of extracellular matrix molecules In involved psoriatic skin the 
endoglin expression is markedly increased Endoglin is a glycoprotein with 
transforming growth factor beta (TGF-ß) binding capacity, and is predominantly 
expressed on endothelial cells In psoriasis TGF-ß plays a role in the extravasation of 
peripheral blood mononuclear cells[86,87] For more detailed accounts the reader is 
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referred to a recent review[88] In this thesis the emphasis will be put on inflammation 
and inflammation control in psoriasis 
/ 7 / Cellular infiltrate 
The inflammatory infiltrate of the psoriatic lesion vanes with the manifestation of 
psoriasis, and the developmental phase of the lesion[34] Important subpopulations of 
infiltrating cells are polymorphonuclear leukocytes, monocytes/macrophages, and Τ 
lymphocytes, which are distributed in the upper dermis, the dermoepidermal junction 
zone, and the epidermis Immunophenotypica! studies have shown that infiltrate cells 
are in the activated state and express a variety of adhesion molecules and cytokines 
172 Polymorphonuclear leukocytes (PMN) 
A hallmark of the psoriatic inflammatory infiltrate is the presence of PMN adopting 
the specific configurations of spongiform pustules of Kogoj in the epidermis, and 
Munro microabscesses in the stratum corneum[89] PMN infiltration is most 
pronounced in guttäte or unstable spreading plaque type psoriasis and is maximal in 
pustular forms of psonasis[28,90] These pustules are sterile Accumulation of PMN in 
chronic plaque psoriasis is associated with parakeratosis, as Munro microabscesses were 
found exclusively in parakeratotic areas of the epidermis 
Furthermore, in this manifestation of psoriasis a marked PMN infiltrate was found 
in 49% of patients, which is compatible with a cyclic change in PMN exocytosis as 
histologically substantiated in squirting papillae[91] 
Psoriatic PMN have been shown to have an enhanced antibody dependent cell 
mediated cytotoxicity, Chemotaxis, and respiratory burst activity[92 93] However 
PMN functions proved to be dependent on the activity of the psoriatic process 
Patients with stable plaques proved to have a decreased PMN function, in contrast to 
patients with active psoriasis who showed an increase in PMN function[94] 
PMN adhesion to psoriatic epidermis was found to be greatly enhanced compared 
to normal skin Adhesion was most pronounced in areas were expression of 
intercellular adhesion molecule 1 (1CAM-1, CD54) was strongest[95] It is possible that 
ICAM-1 serves as an anchoring structure for PMN in the psoriatic epidermis 
PMN activation may be due to a number of different mediators of inflammation In 
psoriatic scale extracts, components of the activated complement cascade, mainly 
consisting of complement split product 5a (C5a) have been identified Other factors 
found were the potent cytokine mediators interleukin 8 (IL8), GRO a. and arachidonic 
acid metabolites such as leukotnene B4[96-98] 
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1 7.3 Monocytes / Macrophages 
Monocytes and tissue macrophages are consistently present in all manifestations of 
psoriasis, and mainly localised around b lood vessels in the dermis Only very 
sporadically they are found in the suprabasal layers of lesionai skin By some authors 
monocytes have been recognised for being the first leukocytes to migrate f rom the 
circulation into the skin in the initial stages of psonasis[99] Functional activities of 
peripheral b lood monocytes have been extensively studied in psoriatic patients, 
however, in format ion on phenotypic and functional characteristics of monocytes 
residing w i th in psoriatic lesions is l imited[92,100] 
In about t w o thirds of psoriatic lesions, lining macrophages may be found They 
have been termed according to their band like appearance directly beneath the basal 
membrane[101,102] In more than one third of patients, l ining macrophages can be 
observed as a single cell layer under the tips of the epidermal rete ridges Phenotypical 
characterisation revealed that lining macrophages express monocyte markers like 
C D l l a , CD14, and CD36, but lack Langerhans cell markers CDIa and factor Xll la which 
are markers for dermal dendrocytes Lining macrophages strongly express HLA DR 
which may indicate an activational state Electron microscopy of lining macrophages 
revealed cellular protrusions through the basement membrane that we ie in contact 
w i t h basal keratmocytes 
Through this configuration monocytes may directly influence keratmocyte g rowth 
by excretion of mediators like interleukm-6 and 8[103 105] Psoriatic basal 
keratmocytes have been shown to express monocyte chemotactic protein 1 (MCP-1) 
which could account for monocyte recruitment[106] 
174 Dendritic cells 
Dendritic cells w i th in the epidermis comprise both Langerhans and non Langerhans 
cells, of which the latter may represent an epidermotropic macrophage subpopulat ion 
In chronic plaque psoriasis there is a decreased number o f CD1a+ Langerhans cells but 
the ones still residing in the epidermis show increased expression of the HLA class II 
molecules -DR, -DP, and -DQ[107] This suggests an enhanced antigen presenting 
capacity. 
Another cell populat ion of interest are the dermal dendrocytes which are mainly 
found in the epidermis and are thought to be derived f rom peripheral b lood 
monocy*es[108] In psoriasis the number of dermal dendrocytes is markedly increased, 
and these cells are mainly localised in the papillary dermis and around the basement 
membrane[109] Dermal dendrocytes can be distinguished from other dendritic cells by 
their expression of clott ing factor Xll la In addi t ion these cells express markers of the 
monocyte/macrophage lineage, such as 1CAM-1 and LeuM3, and stain positive for 
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CD4, HLA-DR. and C D l l a / CD18[110]. Dermal dendrocytes may serve as antigen-
presenting cells. 
1.7.5 T-lymphocytes 
The mononuclear cell infi ltrate in chronic plaque psoriasis is dominated by T-
lymphocytes, whereas B-lymphocytes are rarely found in lesionai skin[111]. T-
lymphocytes in psoriatic lesions are in an activated state, as shown by an increased 
expression of activation markers like the interleukin-2 receptor, and HLA class II 
antigens[112]. Expression of HLA-DR has been demonstrated on CD4+ cells derived 
f rom guttäte as we l l as chronic plaque psoriasis[113]. 
In lesionai skin f rom patients w i th active plaque psoriasis, T-lymphocytes expressed 
another surface molecule of yet unknown relevance: CDw60[114]. By 
immunohistochemical techniques, this marker was found to be present on 7 6 % of all 
T-lymphocytes. C D w 6 0 + lymphocytes seem to compartmentalise in the psoriatic 
lesion, as only 17% of T-lymphocytes derived f rom peripheral b lood f rom psoriatic 
patients were C d w 6 0 + . Τ cells expressing the gamma-delta Τ cell receptor is a n e w l y 
recognised subset of Τ cells present in the psoriatic infi ltrate[115]. 
According t o the activational state of psoriasis, a predominance of different T-
lymphocyte subpopulations can be found. Patients w i t h plaque psoriasis w h o exhibit 
the Koebner p h e n o m e n o n show a predominance in C D 4 + T-helper cells (CD4/CD8 
ratio: 1.68), whereas in patients w i t h a negative Koebner response, the C D 8 + T-
suppressor cells were more abundantly present (CD4/CD8 ratio: 0.75)[116]. The larger 
p r o p o r t i o n of T-helper cells in patients w h o exhibited a Koebner response was f o u n d 
t o result f rom a decrease in C D 8 + cells rather than an increase in C D 4 + cells[117]. 
Clones of T-lymphocytes derived f r o m psoriatic skin lesions have been analysed for 
their pattern of cytokine expression[118]. CD4+/CD45 R O + T-lymphocytes der ived 
f r o m guttäte psoriasis secrete interleukin-2 (IL-2), interleukin-10 (IL-10), 
granulocyte/macrophage colony-stimulating factor (GM-CSF), and interferon-γ (IFN-γ) 
in response t o group A streptococcal antigen[119]. Production of t u m o u r necrosis 
factor α (TNF-α) or interleukin-4 (IL-4) was not detected[120]. After lectin st imulat ion 
of clones of T-lymphocytes derived f r o m chronic plaque psoriasis, a slightly different 
pattern of cytokine excretion was f o u n d . These C D 4 + clones produced IL-2 and IFN-γ 
whereas only some of them produced IL-4, IL-10 and TNF-oc. 
T- lymphocyte activation in psoriatic lesions may be caused by presence of bacterial 
superantigens. Superantigens act through the variable β chain of the Τ cell receptor 
(Vp). In lesionai skin f r o m guttäte and chronic plaque psoriasis, expression of Vß2 and 
Vß5.1 chains has been reported[121]. In patients w i t h guttäte psoriasis fo l low ing a 
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streptococcal infection of the upper respiratory tract, Τ lymphocyte proliferation could 
be induced by streptococcal enterotoxin B, a known superantigen 
The response was mediated through the Vß12 Τ cell receptor[122] However, this 
phenomenon was only observed in Τ lymphocytes derived from skin, and not in those 
from peripheral blood 
176 Adhesion molecules and inflammatory mediators in psoriasis 
Potential sites of pathogen entry are under constant surveillance of circulating blood 
leukocytes that are rapidly moving from blood into tissue in order to mediate 
effective host defence The PMN influx that characterises the immediate response is 
followed by the infiltration of antigen specific mononuclear cells In psoriasis this 
system appears inappropriate, with inflammatory cells infiltrating the skin in an 
ongoing response to an unidentified antigen 
Cohnheim used intravital microscopy to visualise the inflammatory response in 
rabbit ears after topical application of croton oil[123] He was the first to observe that 
migration from blood into tissue occurred in steps with initial rolling of leukocytes 
along the capillary endothelium, stopping, and finally performing transendothelial 
migration 
After passing through the vessel wall, further complex interactions between 
leukocytes and tissue matrix determine direction and speed of leukocyte movement as 
well as their subsequent retention in skin or return to the general circulation 
These events are mediated by a combination of receptors and ligands known as 
adhesion molecules, which are expressed on endothelial cells tissue matrices and 
leukocytes[124] Through a sequence of events these molecules organise and direct 
cutaneous cell trafficking, in close collaboration with chemoattractants[125] Based on 
shared structural and functional characteristics, three main groups of adhesion 
molecules can be recognised selectins, members of the immunoglobulin supergene 
family, and mtegrins[126] 
17 7 I η tegrins 
Integnns consist of an a- and a ß-chain which are non-covalently linked They have an 
extracellular binding site and an intracellular portion which is linked to the 
cytoskeleton[127] Integnns are subdivided into various families according to the 
associated ß-cham[128] A particular ß-subunit can form an integrin heterodimer with 
various different a-subunits and an ct-subumt, in turn, can associate with various 
different ß-units In this way, an enormous diversity of integrin heterodimers can be 
accomplished Integnns are responsible for mediating leukocyte adhesion to capillary 
endothelium and tissue matrices Additionally they are involved in antigen 
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presentation and probably in terminal keratinocyte differentiation[129] Keratmocytes 
are also found to express various integnn receptors 
Firm integnn mediated binding to capillary endothelium depends upon leukocyte 
activation In vivo this functional integnn upregulation is induced by locally released 
chemoattractants and occurs almost instantaneously Different chemoattractants 
appear to act preferentially on different leukocyte subpopulations, thereby constituting 
an enormous flexibility of mtegnn-mediated adhesion Leukocyte function-associated 
antigen 1 (CD11a/CD18), and CD11b/CD18 are both ß2 integnns but whereas CDlla / 
CD18 is present on all leukocytes, CDllb / CD18 is only expressed by PMN, monocytes 
and eosinophils[130] Both molecules bind to members of the immunoglobulin 
supergene family CDlla / CD18 to intercellular adhesion molecule 1 (ICAM-1 CD54), 
ICAM2, and ICAM-3, whereas CDllb / CD18 binds to ICAM 1[131] Another 
important ligand for CDllb / CD18 is C3bi, which is a component of the complement 
system 
In the psoriatic inflammatory infiltrate very late antigen of activation (VLA-4 CD29 
/ CD49d) is present on Τ lymphocytes A known ligand is fibronectin which is a 
constituent of tissue matrix and may be of particular importance in lymphocyte 
migration There is in vitro and in vivo evidence suggesting a major role for CDlla / 
CD18 - ICAM 1 interaction in the epidermal accumulation of lymphocytes in 
psonasis[132,133] Keratmocytes are known to express certain integnn subsets In 
normal skin, integnn expression is confined largely to the basal layer of keratmocytes, 
whereas in the psoriatic epidermis focal suprabasal areas of keratmocytes expressing 
CD29 / CD49c (VLA 3) and CD29 / CD49f (VLA 6) have been reported[134,135] 
In psoriatic epidermis, numerous CDla+ dendritic cells are found to express ß2 
integnns[107] These are potentially involved in Langerhans cell adhesion to lymphatic 
and vascular endothelium in psoriasis, and other inflammatory dermatoses CDllb and 
CD18 expression are increased on inflammatory cells residing in the psoriatic infiltrate 
In pustular psoriasis CDlla / CD18 and CDllb / CD18 are increased on infiltrate 
cells[129,136] On endothelial cells underlying a psoriatic plaque the av ß3 integnn 
expression is increased, whereas a decreased expression of ß4 integnns is 
observed [137] 
17 8 Immunoglobulin supergene family 
Members of the immunoglobulin supergene family consist of single chain molecules 
with a variable number of immunoglobulin-like extracellular domains They include 
ICAM 1 ICAM 2 and VCAM 1[131 138,139] ICAM 1 possesses two distinct binding 
sites for CDlla / CD18 (LFA 1) and CDllb / CD18 (Mac 1), and is constitutively 
expressed on human umbilical vein endothelial cells and normal dermal endothelium 
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cells in vivo[\4Q] TNF-a, IFN γ and IL-1 upregulate endothelial ICAM 1 expression in a 
process which requires gene transcription and protein synthesis ICAM 2 is also 
strongly constitutively expressed on isolated vascular endothelium cells, but does not 
appear to be regulated by cytokines 
Therefore, it may play a role in leukocyte trafficking in uninflamed tissue VCAM 1 
is not present on unstimulated vascular endothelium cells but, in parallel to ICAM-1, it 
is upregulated by various cytokines including IL-1 and TNF-a 
ICAM-1 is significantly upregulated on vascular endothelium directly overlying the 
psoriatic lesion[141] This increased expression appears to be functionally relevant, for 
in vitro studies show increased T-lymphocyte binding onto frozen sections from 
psoriatic plaques Binding was confined to dermal endothelium within the papillary 
tips, whereas no binding occurred in non lesionai skin This adhesion is ICAM-1/|32 
mtegrin dependent, since it is partially inhibited by monoclonal antibodies to 
CD18[142,143] 
In clinically unmvolved skin from patients with active psoriasis, there is an increased 
expression of ICAM-1 and E-selectin[141] Thus cutaneous vasculature of psoriatics 
appears to be 'primed' for leukocyte extravasation Psoriatic keratinocytes are found 
to express ICAM-1 whereas keratinocytes from unmvolved psoriatic skin are lacking 
this feature[140] 
Measurement of circulating adhesion molecules may be of some prognostic value, 
because in psoriasis, levels of ICAM-1, VCAM-1, and E-selectin correlate with disease 
activity and show significant elevations in pustular and erythrodermic 
psonasis[144,145] Specificity of these findings, however, remains to be investigated 
/ 7 9 Select ins 
Selectins are glycoproteins that are characterised by an N-termmal lectin like domain, 
homologous to Ca2+-dependent lectms[146] Until present, three selectins have been 
identified E-selectm (ELAM-1). P-selectm, and L-selectm (LEC-CAM-1) 
P-selectin and E-selectin act as ligands for PMN, eosinophils, monocytes, and 
memory T-lymphocytes[147-149] The expression of both molecules requires activation 
of endothelial cells P-selectin is present within resting vascular endothelial cells as 
granules, known as Weibel-Palade bodies[150]. Following stimulation by mediators of 
acute inflammation (such as histamine, thrombin, or components of complement like 
C5b) these cytoplasmic granules rapidly fuse with the cell membrane reaching peak 
expression after ten minutes[151] Contrastingly, the E-selectin expression on human 
umbilical vein endothelial cells (HUVEC) and in human skin in vivo, reaches peak 
expression after 4 hours and requires de novo mRNA and protein synthesis[152,153] 
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L-selectin ¡s expressed by all circulating leukocytes with the exception of a subset of 
memory T-lymphocytes. 
Selectins bind to the sialylated carbohydrate groups that are closely related to sialyl 
Lewis X and its isomer sialyl Lewis A[154-156]. P-selectin and E-selectin mediate the 
initial and potentially reversible leukocyte tethering to, and rolling along, the 
endothelial cell surface. The expression of E-selectin on dermal psoriatic endothelium is 
increased, particularly at the tips of dermal papillae. This correlates well with intra-
and peri-vascular sites of maximal PMN and lymphocyte accumulation. 
Results from dynamic in vitro and in vivo studies examining leukocyte adhesion to 
endothelia under various conditions of flow indicate that the different groups of 
adhesion molecules operate in a sequential and interdependent manner[157]. At sites 
of inflammation, local vasodilatation causes the margination of leukocytes to the 
peripheral, slow-flowing bloodstream. Vascular P- and E-selectins capture these still 
inactive leukocytes and cause them to roll along the surface of the vascular 
endothelium[157,158]. If leukocyte activation occurs, the weak selectin-mediated 
adhesion is superseded by interactions between integrins and immunoglobulins. 
Chemoattractants play a pivotal role in facilitating the switch from weak, selectin-
mediated adhesion to firm, integrin-mediated adhesion[159,160]. Platelet activating 
factor was one of the first substances shown to activate neutrophils in this process[161-
163]. Later, metabolites from the arachidonic acid cascade were shown to have potent 
effects on PMN integrin upregulation[96]. 
Recent studies have shown that a group of polypeptide chemoattractants known as 
chemokines, demonstrate specificity for different subsets of leukocytes, based on the 
differential distribution of their counterreceptors on the leukocyte cell surface. 
Chemokines can be subdivided into two families according to the arrangement of 
peptide sequences around cysteine residues. 
Alpha chemokines include 1L-8, IFN-γ and Gro-a and act predominantly on PMN. 
whereas beta chemokines such as monocyte chemoattractant protein 1 (MCP-1), 
macrophage inflammatory protein 1 (MIP-1), and RANTES act mainly on monocytes, 
eosinophils and lymphocytes[164-167]. However, the functional aspect of this 
classification is not absolute, as some a-chemokines сап also exhibit chemoattractant 
properties to, for example, monocytes[168]. Gro-a and MCP-1 have shown to be 
increased in the psoriatic epidermis[169-171]. 
Chemokine molecules posses proteoglycan binding sites which allow immobilisation 
on the endothelial cell surface. This provides a concentrated focus of leukocyte 
activating chemoattractant at sites of leukocyte rolling[165,172]. Cytokines released in 
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As described in this section, the trafficking of infiltrate cells is of relevance in the 
pathogenesis of psoriasis. The differential expression of adhesion molecules on cells of 
the inflammatory infiltrate is of paramount importance for migration and other 
biological functions of these cells. Interference of drugs with leukocyte migration is a 
promising research target. 
1.8 METHODOLOGY AND TECHNIQUES 
1.8.1 Models 
Models for cutaneous inflammation and epidermal proliferation are useful tools to 
study inflammation. These models are of value for investigation of the effects of drugs 
on specific aspects of these disorders. The following models were used in this thesis: 
The margin zone of a spreading psoriatic lesion 
To study the sequence of changes in the evolution of the psoriatic lesion we used the 
model of the margin zone of an actively spreading psoriatic lesion. It has been 
suggested that initial psoriatic lesions are most clearly mimicked at the edge of 
centrifugally extending lesions[173]. 
The sellotape stripping model 
Layers of corneocytes are removed by application of multiple successive strips of 
adhesive tape to the same area of the skin. This results in a reproducible mitotic 
response in the basal epidermal cell layer and the lower region of the stratum 
spinosum[174]. The peak of this mitotic response can be observed at 48-72 hours[175]. 
However, the timepoint on which the mitotic response is detected depends on the 
method and antibody used[176]. 
After 12 hours the stratum granulosum is lost and after 24 hours a parakeratotic 
stratum corneum starts to form, accompanied by regeneration of the stratum 
granulosum[177]. Sellotape stripping provides a useful model to study synchronised 
epidermal growth and offers an accurate method to study influences of drugs on 
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epidermal cell biological characteristics in the absence of a significant inflammatory 
infiltrate[178]. 
Epicutaneous Leukotriene B4 (L TB J application 
Topical application of LTB4 to normal human skin results in cutaneous inflammation 
and epidermal hyperproliferation[179,180]. Initially the inflammatory infiltrate is 
dominated by PMN reaching maximum density after 24 hours[181]. This is followed 
by formation of a perivascular mononuclear cell infiltrate after 48 hours and an 
epidermal hyperproliferative response, reaching peak levels at 72-96 hours depending 
on the methods used[181,182]. The cutaneous cell biological reactions are dose 
dependent and well reproducible, therefore this method has been used previously to 
investigate the influences of various topical and systemic therapies on transcutaneous 
migration of PMN in i//Vo[183,184]. 
In vitro CD!lb upregulation assay[85,185] 
The CDIlb upregulation assay is an in vitro assay which is performed on freshly 
obtained viable PMN derived from peripheral blood. In vitro 300 picogram of the 
chemoattractant leukotriene B4 is added to whole blood which, under normal 
circumstances, results in an upregulation of CD11b molecules on the cell surface. After 
lysis of the erythrocytes the density of CDIlb molecules on the individual cells in the 
leukocyte suspension can be assessed by flow cytometry. Different optical 
characteristics of individual cells enable the division of PMN from other leukocyte 
subsets such as monocytes or lymphocytes on physical parameters such as cell size and 
granularity of its surface. 
We used this technique to astess the CDIlb expression on PMN derived from 
psoriatic patients, and to quantify the blocking potential of an LTB4 receptor 
antagonist (chapter 2 and 3). 
/. 8.2 Clinical assessment 
Psoriasis Area and Severity Index fPAS/J 
The psoriasis area and severity index was used in an attempt to quantify and monitor 
the clinical effects of the treatment modalities tested. The PAS1 score is the result of a 
calculation in which the extent and severity of body involvement are included. The 
total PASI is composed of differential severity assessments in four different body areas: 
head, trunk, upper extremities, and lower extremities. Extent of the affected body area 
(A) is quantified using a six point scale: 0 = no involvement, 1 = < 10% Involvement, 
2 = 11-29%, 3 = 30-49%, 4 = 50-69%, 5 = 70-89%, 6 = 90-100% of body area 
involved. Additionally an estimation of the clinical severity was made, based on the 
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intensity of erythema (E), induration (1), and desquamation (D) For quantification of 
these three parameters, a four point scale was used 0 = absent, 1 = slight presence, 
2 = moderate presence, 3 = severe presence, 4 = severest possible presence 
The total PASI score was calculated as follows 
head (0 1 A) χ (E+l+D) + 
trunk (0 3 A) χ (E+l+D) + 
upper extremities (0 2 A) χ (E+l+D) + 
lower extremities (0 4 A) χ (E+l+D) 
18 3 Immunohistochemical and flow cytometncal techniques 
In vitro CD!lb upregulation assay and flow cytometry 
Peripheral blood (4 ml) was collected through venepuncture, kept in EDTA at 4°C and 
processed within 3 hours after collection to prevent non-specific upregulation of CD1lb 
expression as a result of neutrophil activation 
Blood samples were processed in triplicate using 90 μΙ aliquots which were incubated 
with LTB4 (10 μΐ 1x107 M) in Hanks' balanced salt solution (HBSS, Sigma chemical corp , 
St Louis, USA) containing 0 1% bovine serum albumin (HBSS-BSA). or with HBSS-BSA 
(10 μΙ) alone for 30 minutes at 37°C Samples were then cooled and incubated in the 
dark for 30 minutes at 4°C with 10μΙ (0 045 g/1) anti-human CDllb fluorescein 
conjugate (Mo-1-FITC, Coulter Corp , Hialeah, USA) Erythrocytes were lysed (with 10% 
FACS® Lysmg Solution in demin water, Becton Dickinson, San Jose, CA, USA) and the 
remaining cells were washed with HBSS-BSA fixed in 1% paraformaldehyde solution 
and stored at 4°C until analysis 
All specimens were analysed on an Epics Elite" flow cytometer (Coulter, Luton, 
UK) Cells were excited with an air-cooled 488 nm argon laser set at 15 mW Green 
fluorescence (FITC) was measured through a 525 nm band pass filter (band width 30 
nm) Calibration and sensitivity were checked in every experiment by using 
fluorescein labelled beads (Standard Brite, Coulter Source, Hialeah USA) Forward 
(FS) and side scatter (RAS) were used for gating only granulocytes For each sample 
5,000 gated cells were analysed 
Immunohistochemistry 
Processing of biopsies for immunohistochemical assessment 
Biopsies were taken after injection of a local anaesthetic The biopsies were washed in 
phosphate buffered saline (PBS), embedded in Tissue Тек OCT compound (Miles 
Scientific, Napierville, USA), snap frozen in liquid nitrogen and stored at -80°C until use 
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Cryostat sections of 7 μπι were cut and fixed for 10 minutes in acetone/ether (60/40 
vol.%) for Mib-1, or in acetone alone for staining with the other antibodies. 
Prior to staining of infiltrate cells, an additional incubation step was used to block the 
enzyme endogenous peroxidase which is known to be present in cells of the 
inflammatory infiltrate. This was done to prevent unspecific staining. 
We used the substrate 3-amino-9-ethyl-carbazole which gives a red- to brown-
coloured end product by reaction with the enzyme peroxidase. In the CDllb and 
CD18 stainings endogenous peroxidase activity was blocked by incubation with 1 % 
sodium azide (Merck, Darmstadt, Germany) and 0.3% H 2 0 2 for 5 minutes. For 
elastase staining, blocking of the endogenous peroxidase activity was performed by 
incubation in methanol (Merck, Darmstadt. Germany) containing 0.3% H 2 0 2 for 20 
minutes. In the T6, T i l , and WT14 stainings background staining was blocked by 
incubation with 5 0 % normal rabbit serum (NRS) in phosphate-buffered saline (PBS) 
for 20 minutes. 
Table 3 depicts the various markers used in this thesis. 
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Table 3. Monoclonal antibodies used in this thesis 
Antibody Specificity Dilution 
Anti-elastase 
T11 
T6 
WT14 
Neutrophil elastase, in PMN, 
sporadic in monocytes 
CD2. present on T-lymphocytes 
CDla, present on Langerhans cells 
CD14, present on monocytes and macrophages 
1 100 
1100 
1 100 
1 100 
Mib-1 
Mon150 
Ki67 nuclear antigen present in the late Gi, S and С г + М 
phases of the cell cycle (cycling cells) 
Involucnn 
1 50 
1 50 
Anti-filaggnn Filaggnn 1 500 
PAL-E Endothelial cells without lymph vessels 1 25 
PN-E2 Endoglm positive cells 1 25 
Ks8.12 
6 В 10 
1 C 7 
RKSE60 
Anti CD18 
Ant i-CDl lb (in skin) 
Cytokeratm 16 present in hyperprohferative epidermis, 1 50 
cross reaction w i t h cytokeratm 13 which is 
mainly present in hair follicles 
Cytokeratm 4, present in stratifying, non-cornifying Undiluted 
suprabasal cells 
Cytokeratm 13, present in stratifying, non-cornifying Undiluted 
suprabasal cells 
Cytokeratm 10, present in stratifying, cormfying 1 10 
suprabasal cells 
Peripheral blood leukocytes 1 100 
P M N , some monocytes and macrophages 1 50 
1CAM-1 CD54 
Anti C D l l b (in blood) P M N , some monocytes and macrophages 
1 100 1 200 
Undiluted 
3 4 
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Incubation t ime 
(min) 
Technique Manufacturer 
30 Indirect immunoperoxidase Dakopatts, Copenhagen, Denmark 
60 Peroxidase anti peroxidase 
60 Peroxidase anti peroxidase 
60 Indirect immunoperoxidase 
45 Indirect immunoperoxidase 
Dakopatts. Copenhagen. Denmark 
Dakopatts, Copenhagen, Denmark 
Dept of Nephrology University 
Hospital Nijmegen, the Netherlands 
Immunotech, Marseille, France 
60 
60 
60 
60 
30 
Indirect immunoperoxidase 
Indirect immunoperoxidase 
Indirect immunoperoxidase 
Indirect immunoperoxidase 
Indirect immunoperoxidase 
H van Duijnhoven. St Elisabeth 
Hospital Tilburg, the Netherlands 
Biomedical Technologies Ine 
Stoughton MA, USA 
Dept of Pathology. University 
Hospital Nijmegen, the Netherlands 
Dept of Pathology, University 
Hospital Nijmegen, the Netherlands 
Sigma, St Louis, M O , USA 
60 
60 
60 
60 
60 
45 
30 
Indirect immunoperoxidase 
Indirect immunoperoxidase 
Indirect immunoperoxidase 
Avidin Biotin Complex method 
Indirect immunoperoxidase 
Indirect immunoperoxidase 
Direct staining method by 
fluorescent tag 
Dept of Pathology. University 
Hospital Nijmegen, the Netherlands 
Dept of Pathology, University 
Hospital Nijmegen the Netherlands 
Dept of Pathology, University 
Hospital Nijmegen, the Netherlands 
Dakopatts. Copenhagen, Denmark 
Monosan, Uden. 
the Netherlands 
Immunotech, Marseille, France 
Coulter Corporation 
Hialeah, FL. USA 
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For assessment of epidermal proliferation the monoclonal antibody Mib 1 was used 
This antibody is directed against the nuclear Ki67 antigen which is present in actively 
cycling cells The Ki-67 antigen is expressed in the late Gl , S-, G2 , and M-phase of the 
cell cycle[186] 
To assess epidermal keratinisation and differentiation, antibodies against cytokeratms 
and other components of the cornified envelope were used Cytokeratin proteins are 
components of the cytoskeleton The keratin expression pattern changes during terminal 
keratmocyte differentiation[187,188] We have used antibodies directed against keratin 4 
(6B10). keratin 10 (RKSE60). keratin 13 (1C7), and keratin 13 and 16 (Ks8 12) 
Cytokeratin 4 is present in stratifying suprabasal keratinocytes which do not show a 
tendency towards the formation of a cornified envelope, whereas cytokeratin 10 is 
present in keratinocytes at suprabasal localisation that are actively involved in the 
formation of a cornified envelope Cytokeratin 13 is absent in normal adult human skin, 
but is expressed in hair follicles and fetal skin Keratin 16 is expressed in 
hyperprohferative skin conditions 
Other markers used for assessment of epidermal differentiation are filaggrin and 
involucnn[189,190] Filaggrin is involved in the formation of keratohyalm granules, 
whereas the involucrm protein is a cytoplasmic precursor of the cornified envelope In 
normal skin filaggrin is present in the stratum granulosum and stratum corneum 
Involucrm is detected in the upper part of the stratum spinosum and the stratum 
granulosum 
A panel of monoclonal antibodies was chosen for assessment of various cell types 
present in the psoriatic inflammatory infiltrate and for detection of changes in the 
capillary endothelium present in the inflamed skin For assessment of PMN, a 
monoclonal antibody directed against elastase was used[191 192] However, elastase is 
not a marker exclusively for PMN monocytes are reported to contain 5% of PMN 
elastase activity[191] CDllb and CD18 positive cells were detected by using monoclonal 
antibodies CDllb is expressed mainly by PMN and also to some extent by monocytes 
and macrophages, and CD18 is expressed by all mature lymphoid and myeloid cells On 
PMN CDllb is known to form a heterodimer with CD18 constituting the CDllb / CD18 
integnn receptor A known ligand for this receptor is ICAM 1 which we detected using a 
monoclonal antibody ICAM-1 is present on monocytes, granulocytes and endothelium 
cells Another marker which we used for staining of endothelial cells, but with exception 
of lymphatic vessels, was the PAL E antibody PN-E2 was used for the detection of 
endoglin-positive cells[193] T-lymphocytes were detected with a pan Τ cell marker 
directed against CD2[194] Langerhans cells were stained using an antibody directed 
against CDla[195] An antibody directed against CD14 was used to detect monocytes 
and macrophages[196] 
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Staining with Ks8 12, Mib-1, anti-elastase, anti-CDllb and anti-ICAM 1 was performed 
using an indirect immunoperoxidase technique. Slides were incubated with the 
monoclonal antibodies, and after 2 washes with PBS, incubated for 30 minutes with 
rabbit anti-mouse antibody conjugated with peroxidase (RAM, Dakopatts, Copenhagen, 
Denmark) Staining with T i l and T6 was done using a peroxidase anti-peroxidase 
technique (PAP-technique) Slides were incubated with the monoclonal antibodies After 
2 washes with PBS the slides were incubated with RAM immunoglobulins for 20 minutes 
(RAM Ig, Dakopatts, Copenhagen, Denmark) and after 2 more washes with PBS, PAP 
complexes were added and left to incubate for 20 minutes (Dakopatts, Copenhagen, 
Denmark) The incubation with RAM-lg and PAP was repeated once Staining with anti-
CD18 was performed using the avidin-biotin-complex method (Vectastain Vector, 
Burlingame, USA) After pre-incubation with 2 0 % normal horse serum in PBS for 10 
minutes, monoclonal antibodies were added After 2 washes in PBS, slides were 
incubated with 0 0 5 % lgG labelled biotin for 30 minutes, followed by incubation with 
2% avidin-biotin complexes for 30 minutes 
After 2 washes with PBS and pre incubation with sodium acetate buffer, pH 4 9, all 
slides were stained with sodium acetate buffer containing 200 mg/l 3 amino 9-ethyl-
carbazole (AEC-solution, Sigma Chemical Corp, St Louis MO, USA) and 0 0 1 % H 2 0 2 
for 10 minutes at 37°C in the dark 
All slides were washed in demmeralised water and slightly counterstamed with 
Mayer's Haematoxylin (Sigma, St Louis, MO, USA) Slides were finally mounted in 
glycerine gelatine and studied by light microscopy 
Histological assessments 
The number of Mib-1 positive nuclei was counted per mm length of section (chapter 3 
and 4) 
Staining with anti involucrin, anti filaggrin, RKSE60. Ks8 12, 6B10 and 1C7, was 
studied in the basal and suprabasal epidermal compartments using a semi-quantitahve 
scale (chapter 3 and 4) The histological markers for inflammation (anti elastase, anti 
CDIlb, anti CD18, T6, T i l ) as well as ICAM-1, PAL-Ε and PN-E2 were assessed in both 
the epidermal and dermal compartment using a semi-quantitative scale (chapters 2.3 
and 4) 
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1.9 OUTLINES AND AIMS OF THIS THESIS 
/. 9.1 Niches in our understanding of the pathogenesis of psoriasis 
The expression of CDIlb and CD18 is of major importance to leukocyte migration. 
These molecules are upregulated by inflammatory mediators. Upregulation of CDIlb 
and CD18 by LTB4 has been studied extensively. 
LTB4 is abundantly present in lesionai psoriatic skin, and increased presence of LTB4-
like material is reported from uninvolved psoriatic skin as well[197]. PMN are present 
in early stages of psoriatic plaque development. PMN are known to express both 
CDIlb and CD18. After PMN activation these molecules are upregulated. CDIlb and 
CD18 are important in PMN migration. Remarkably, the expression of CDIlb and 
CD18, so far. has not been investigated in the various stages of the pathogenesis of 
psoriasis. Therefore, the aim of this thesis is to investigate the relevance of CDIlb and 
CD18 in the pathogenesis of psoriasis. 
/. 9.2 New opportunities to modulate inflammatory aspects of psoriasis 
As introduced under 1.5.4, several new therapeutic approaches became available. In 
the present thesis experimental drugs with a potential effect on CDIlb- and CD18-
positive cells were studied. Clinical efficacy and general histopathological changes were 
investigated, as well as effects on CDIlb- and CD18-positive cell populations. 
Additional aims were defined as to study the effects of (I) modulation of LTB4 
metabolism and (ii), the effects of retinoid modulation, on CDIlb and CD18 ¡ntegrins. 
Two drugs were selected, one of which had proven effects on CDIlb and CD18 
expression. However, their efficacy in psoriasis has not been investigated so far. These 
drugs are the 5-lipoxygenase inhibitor R-85355, and the LTB4 receptor antagonist 
LY293111 /VML295. 
Retinoids are well established in the treatment of psoriasis. Recently the cytochrome 
P-450 inhibitor liarozole proved to be an important new treatment modality with 
retinoid-modulating features. The clinical efficacy of liarozole in psoriasis has already 
been shown in controlled studies. Although retinoids interfere with the functioning of 
PMN, the possible interference with PMN expression of CDIlb and CD18 has never 
been studied. 
Therefore we investigated the effects of liarozole on CDIlb- and CD18-positive cell 
populations in psoriasis. The retinoid acitretin was studied for its effects on epidermal 
proliferation and differentiation. 
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193 Aims of thesis 
Aim is to investigate the relevance of CDIIb and CD18 in the pathogenesis and 
treatment of psoriasis Our investigation is directed at three targets 
/ The relevance of CDIIb- and CDI8 positive cells in the pathogenesis of psoriasis 
CDllb and CD18-positive cells will be studied in various phases of the psoriatic lesion, 
and CDllb expression on leukocytes derived from peripheral blood from psoriatic 
patients will be compared with CDllb expression on peripheral blood leukocytes of 
normal subjects We addressed the following questions 
A Do circulating blood leukocytes from psoriatic patients have abnormal expression 
of C D l l b ' 
В In what stage of the psoriatic process are CDllb and CD18 positive cells 
involved' 
С To what extent does the expression of CDllb and/or CD18 provide an 
explanation for the sharp demarcation of the psoriatic lesion' 
D To what extent does the expression of endoglm contribute to the sharp 
demarcation of the lesion' 
2 Effects of modulation of LTB4 metabolism on CDIIb and CDI8 integnns 
The effects of a systemically applied leukotnene B4 receptor antagonist will be studied 
in healthy volunteers and psoriatic patients The effects of a topical 5 LO inhibitor on 
clinical and cell biological parameters will be assessed in psoriatic patients The 
following questions will be addressed 
A To what extent does the specific leukotnene B4 receptor antagonist LY293111 
(VML295) inhibit leukotnene B4 induced upregulation of CDllb on peripheral 
blood leukocytes' 
В To what extent does the leukotnene B4 receptor antagonist LY293111 (VML295) 
modify the clinical aspects of psoriasis and in what way does it affect cell 
biological characteristics of the psoriatic phenotype' 
С To what extent does the 5-lipoxygenase inhibitor R85355 modify the clinical 
aspects of psoriasis and in what way does it affect cell biological characteristics in 
the psoriatic phenotype' 
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3 Effects of retinoid modulation on CD/lb and CD18 mtegnns 
The clinical and cell biological effects of a novel cytochrome P-450 inhibitor on skin 
will be evaluated in the treatment of severe plaque psoriasis These effects will be 
compared to the effects of acitretin treatment The following questions were 
addressed 
A To what extent do acitretin and liarozole affect epidermal proliferation and 
differentiation, and aspects of cutaneous inflammation' 
В To what extent does liarozole affect CDIIb and CD18 expression during 
treatment of psoriatic plaques' 
С Do these changes in CD11b and CD18 expression during liarozole treatment 
correlate with the changes in clinical parameters of the psoriatic plaque' 
19 4 Experimental phasing of the thesis 
In part 2 two models were used to study the various aspects of the psoriatic 
phenotype, which could be of importance in the time course of a developing psoriatic 
lesion Firstly, the transition zone from clinically uninvolved psoriatic skin to lesionai 
skin of a spreading psoriatic plaque was investigated as an in vivo model to study the 
sequence of events in the pathogenesis of psoriasis Secondly, the surface CDllb 
expression was assessed on peripheral blood PMN of psoriatic patients and healthy 
controls An m vitro CDl lb upregulation assay was used in which PMN were 
stimulated with a standardised quantity of leukotnene B4 (LTB4) This was done in 
order to assess to what extent CDllb expression on psoriatic PMN can be upregulated 
In part 3 the effects of a novel leukotnene B4 receptor antagonist were studied In 
healthy volunteers a model for cutaneous inflammation and epidermal proliferation 
(epicutaneous application of LTB„) was used in order to study the effects on CDllb 
and CD18 expression The clinical and cell biological effects of the leukotnene B4 
receptor antagonist were assessed in psoriatic patients Therapeutic effects of a 
topically applied inhibitor of the 5 lipoxygenase enzyme were investigated in patients 
with psoriasis 
In part 4 the effects of retinoids and compounds with retinoid like effects on 
epidermal proliferation, differentiation and cutaneous inflammation were studied An 
imidazole derivative with retinoid-like properties was evaluated as a systemic 
treatment for psoriatic patients The effects of modulation of retinoid metabolism on 
CDl lb and CD18 mtegnns were studied in severe and extensive plaque psoriasis in 
conjunction with the clinical severity scores 
In addition, the effects on epidermal proliferation and cutaneous differentiation 
were studied in uninvolved skin of psoriatic patients treated with acitretin using the 
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sellotape stripping model, which is a model for the induction of epidermal 
hyperproliferation and differentiation. 
In part 5 the conclusions from all individual studies that constitute this thesis, will be 
discussed. 
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Relevance of CDU b- and CDW-positive cells in the pathogenesis of psoriasis 
2.1 ABSTRACT 
Aim of the present investigation was to study the distribution of CDllb, CD18. and 
ICAM-1 over the various cell populations present in the margin zone of the actively 
spreading psoriatic lesion and distant uninvolved psoriatic skin. This study was 
performed in order to obtain more insight in the relevance of these receptor molecules 
in the early phase of psoriatic plaque development. 
Skin biopsies were taken and inflammation markers were assessed using 
immunohistochemical techniques. 
All dermal changes in the margin zone preceded those in the epidermis. In the 
margin zone the most peripheral change was a decrease in dermal lCAM-1-expression, 
followed by an increase in dermal CDllb-expression. CDllb-positive cells showed a 
different tissue distribution from polymorphonuclear leukocytes and were more 
abundantly present, suggesting significant amounts of CDllb-bearing cell populations 
other than polymorphonuclear leukocytes in the early phase of psoriasis. Decreased 
numbers of CD18-positive cells in distant uninvolved skin suggest the existence of a 
selective modulating mechanism altering the trafficking of myeloid subpopulations. 
Polymorphonuclear leukocytes appeared to invade the skin well after the appearance 
of CDllb- and CD18-positive cells. 
2.2 INTRODUCTION 
The inflammatory infiltrate in psoriatic skin is characterised immunohistochemically by 
different subsets of immunocompetent cells. T-lymphocytes, monocytes, macrophages, 
mast cells and polymorphonuclear leukocytes (PMN) can be recognised. 
There are data indicating that the earliest cutaneous changes in the development of 
a psoriatic plaque occur in the dermal compartment[l]. Various cell types have been 
suggested as first elicitor of the psoriatic process[2]. The intra-epidermal accumulation 
of PMN constitutes an early phenomenon, adopting psoriasis specific configurations as 
micropustules of Kogoj and micro-abscesses of Munro[3]. 
The process of adhesion and migration is essential for the transition of 
immunocompetent cells from the circulating blood pool to the tissue adherent pool[4-
6]. Both selectins and integrins can regulate adhesion of PMN to the endothelium[7,8]. 
However when selectins mediate adhesion, integrins are still required for the 
subsequent event of transendothelial migration[9,10]. Their presence and function is 
therefore of crucial importance[11]. 
Integrins are dimers consisting of an a- and a ß-chain which are non-covalently 
linked. Under normal conditions the ß2 integrin molecule CD18 is present on the cell 
surface of all myeloid immunocompetent cells. The CDUb/CD18 receptor complex, 
which is mainly present on PMN, is important in various biological functions including 
59 
Chapter 2 
adhesion to endothelium, aggregation, Chemotaxis and migration, the particle induced 
oxidative burst and degranulation[12-14]. An important ligand for Mac-1 is ICAM-1 
(CD54). ICAM-1 is expressed in normal skin by endothelial cells, sparsely and focally 
on keratinocytes and on infiltrating cells. 
Horrocks et al. showed that there is a substantial accumulation of CDllb- and Com-
positive cells in the psoriatic plaque[15]. In the symptomless skin of three patients, no 
substantial change from normal skin was reported by these authors in the number of 
CDllb- and CD18-positive cells. 
The aim of the present study was to evaluate in which phase of the psoriatic process 
the number of CDllb- and CD18-positive cells are increased compared to the skin of 
normal subjects. Therefore the presence of these receptor molecules, as well as its 
ligand ICAM-1 were assessed in the symptomless skin and margin of the spreading 
psoriatic plaque. As the epidermal accumulation of PMN in the psoriatic plaques is 
considered to be an early and psoriasis specific phenomenon, the question was 
addressed to what extent the appearance of CDllb- and CD18-positive cells correlates 
with the appearance of elastase-positive cells. 
2.3 MATERIALS AND METHODS 
2.3.1 Patients and biopsies 
Prior to the study, approval of the ethics committee was obtained and all participating 
individuals gave their informed consent. 
Eight psoriatic patients in an unstable phase of the disease with spreading psoriatic 
lesions participated in this study (male: female; 6:2, mean age 47 years). The extent of 
the psoriatic lesions was less than 5% of the body surface. They had received no 
topical antipsoriatic treatment for at least 2 weeks and no systemic treatment for at 
least 1 year. In every patient the most actively spreading lesion was selected. After 
infiltration with a local anaesthetic, three biopsy specimens were taken. In each patient 
a 4 mm punch biopsy was taken from the centre of the lesion and a 6 mm punch 
biopsy was taken across the margin of the lesion. In the latter specimen both involved 
and uninvolved psoriatic skin was present. Another 4 mm punch biopsy was taken 
from uninvolved skin, which was at least 10 cm apart from any psoriatic plaque. 
From eight healthy male volunteers (mean age 27 years) without any history or 
signs of skin disease, a 4 mm punchbiopsy was taken after infiltration with a local 
anaesthetic. 
All biopsy specimens were embedded in Tissue Tec OCT compound (Miles 
Scientific, Napierville, USA), snap frozen in liquid nitrogen and stored at -80°C until 
use. 
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2.3.2 Immunohistochemical evaluation 
The antibodies used for histological staining are depicted in Table 1. 
Cell type Antibody lg-type Ligand Clone Specificity Cone. Manufacturer 
(mg/ml) 
PMN Anti- IgG] neutro- NP57 
elastase kappa phil mouse 
elastase 
CDl lb- Anti- IgGj C D l l b Bear-1 
positive C D l l b mouse 
cells 
CD18- Anti- CD18 IgGi CD18 M H M 2 3 
positive kappa mouse 
cells 
ICAM-1 ICAM-1 IgG] CD54 84H10 
positive mouse 
cells 
Neutrophil 
elastase 
P M N , sporadic 
in monocytes 
PMN, some 
monocytes and 
macrophages 
Peripheral 
blood 
leukocytes 
CD54 
61.5 
345 
200 
Dakopatts, 
Copenhagen, 
Denmark 
Monosan, Uden, 
the Netherlands 
Dakopatts, 
Copenhagen, 
Denmark 
Immunotech, 
Marseille. France 
Table 1. Monoclonal antibodies used 
From all specimens 6 μπη cryostat sections were cut which were fixed in acetone 
(4°C) for 10 minutes and stored at -80°C until staining. Staining with anti-CDllb, anti 
CD54 and anti-elastase was performed using an indirect immunoperoxidase technique. 
Slides were incubated with the monoclonal antibodies for 30 minutes. After two 
washes with phosphate buffered saline (PBS), incubation for 30 minutes followed, 
with rabbit-anti-mouse antibody (RAM, Dakopatts, Copenhagen, Denmark) 
conjugated with peroxidase, and diluted in PBS containing 5% human AB serum. After 
two more washes with PBS and pre-incubation with sodium acetate buffer (pH 4.9), 
slides were stained with sodium acetate buffer containing 200 mg/l 3-amino-9-ethyl-
carbazole (AEC-solution) and 0.01% H2O2 for 10 minutes in the dark at 37°C. 
Staining with anti-CD18 was performed using the avidin-biotin-complex method 
(Vectastain, Vector, Burlingame, USA). Endogenous peroxidase activity was blocked by 
incubation with 1 % sodium azide (Merck, Darmstadt, Germany) and 0.3% H2O2 for 
5 minutes. After pre-incubation with 2 0 % normal horse serum in PBS for 10 minutes, 
monoclonal antibodies were left to incubate for 60 minutes. After two washes in PBS, 
slides were incubated with 0.05% IgG-labelled biotin for 30 minutes, followed by 
incubation with 2% avidin-biotin complexes for 30 minutes. After two more washes 
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with PBS and pre-incubation with sodium acetate buffer (pH 4.9), slides were stained 
with AEC-solution and 0.01% H202 for 10 minutes in the dark at 37°C. 
All slides were counterstained with Mayer's haematoxylin (Sigma, St. Louis, MO, 
USA), mounted in glycerine-gelatine and studied by light microscopy. From every 
biopsy four slides were prepared and the most representative slide was analysed. 
2.3.3 Scoring methods 
All stainings were assessed blindly. In involved psoriatic skin, uninvolved skin and skin 
from normal healthy volunteers the density of elastase-, CDllb- and CD18-positive 
cells were assessed in epidermis and dermis using a semi quantitative 7 point scale. 
Epidermis: 0 = no positive cells observed, 1 = sporadic staining, 2 = minimal 
presence, 3 = moderate presence, 4 = moderate/pronounced presence, 5 = 
pronounced presence, 6 = complete staining. The dermal infiltrate was subdivided in 
perivascular and diffuse localisation. Dermis: 0 = no positive cells, 1 = sporadic, 2 = 1-
25% of infiltrate cells stained, 3 = 26-50%, 4 = 51-75%, 5 = 76-99%, 6 = 100%. In 
addition, an estimation of the total infiltrate was made using a 4 point scale: 0 = no 
infiltrate present, 1 = minimal infiltrate, 2 = moderate infiltrate, 3 = pronounced 
infiltrate. In the margin of an actively spreading psoriatic lesion, a modification of this 
quantification method was used. 
The change from orthokeratotic into parakeratotic stratum corneum was taken as a 
marker for the edge of the spreading lesion (margin section 0). From this point the 
extent of staining was assessed separately within 0.5 mm wide zones using the same 
scale as mentioned above. Three zones were scored in the direction of the psoriatic 
plaque (+1 to +3) and three zones in the direction of uninvolved psoriatic skin 
(-1 to -3). ICAM-1 staining was quantified in epidermis and dermis using a 5 point 
scale: 0 = no staining, 1 = 1-25%, 2 = 26-50%,3 = 51-75%, 4 = 76-100%. 
Statistical analysis was carried out using the Mann-Whitney test. 
2.4 RESULTS 
In all biopsies from the margin zone, a continuous non interrupted stratum corneum 
was present. The transition from orthokeratosis into parakeratosis was well 
demarcated in all biopsies. Staining results are illustrated in Figures 1 and 2. 
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Figure la-c. The number of CDllb- and CDW-positive cells in normal skin, distant uninvolved 
skin, the margin zone, and the centre of the psoriatic lesion (mean ± standard error of the 
mean). The margin zone is represented as follows: 0= transition-point between ortho- and 
para-keratosis. +1 to +3: towards the centre of the lesion, -1 to -3: towards uninvolved 
psoriatic skin. 
63 
Chapter 2 
ICAM-1- and elastase-expression in the epidermis 
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Figure 2a-c. The number of ICAM-1- and elastase-positive cells In normal skin, distant 
unlnvolved skin, the margin zone, and the centre of the psoriatic lesion (mean ± standard 
error of the mean). The margin zone is represented as follows: 0= transition-point between 
ortho- and para-keratosis, +1 to +3: towards the centre of the lesion. -I to -3: towards 
un in vol ved psoriatic skin. 
2.4.1 The centre of the psoriatic lesion 
In the centre of the lesion a significant increase in CDIIb-expression was observed in all 
cutaneous compartments as compared t o distant clinicaly uninvolved skin and normal 
skin ( p < 0 . 0 5 ) . In all skin specimens there was more CD1 lb-expression diffusely in the 
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dermis compared to the epidermis. The number of elastase positive cells was 
significantly increased in the psoriatic lesion compared to the distant clinically 
uninvolved skin and normal skin. Cutaneous ICAM-1 expression was mainly localised 
dermally in the perivascular area. ICAM-1 expression was more pronounced in 
involved psoriatic skin compared to the uninvolved skin (p<0.01). Epidermal ICAM-1 
was expressed in clusters of keratinocytes. 
2.4.2 The distan t clinically un in volved skin 
In distant uninvolved skin the number of CDllb-positive cells at perivascular 
localisation was significantly increased compared to skin of normal subjects (p<0.01). 
This increase was not expressed diffusely in the dermis and epidermis. The number of 
CD18-positive cells at perivascular and epidermal levels were essentially normal, but a 
decreased CD18-expression was seen diffusely in the dermis compared to the situation 
in normal skin (p<0.03). No differences were detected between distant uninvolved 
and normal skin with respect to the number of elastase- and ICAM-1-positive cells. The 
number of inflammatory infiltrate cells in distant uninvolved psoriatic skin was 
equivalent to the number in of normal skin. 
2.4.3 The margin zone of the spreading psoriatic lesion 
The localisation of transition from ortho- into parakeratosis was chosen as an 
immunohistochemical reference point, because it was universally present and well 
demarcated (margin section 0). The first significant increase in inflammatory infiltrate 
was found in the -1 region (p<0.01). The largest concentration of infiltrate cells was 
observed in the +2 region and the density of infiltrate cells in this sector was above the 
density observed in the centre of the lesion (p = 0.02). 
Comparing uninvolved psoriatic skin to the margin of a spreading psoriatic plaque, 
the first significant increase in CD1 lb-expression was observed at dermal diffuse 
localisation in the -2 region (p=0.05). From this point on the CDllb-expression 
remained increased. In the dermal perivascular and epidermal compartments the first 
increase in expression occurred at the +3 (p = 0.02) and +2 (p = 0.05) region 
respectively (Figure 3). 
In the epidermis and diffuse in the dermis an increase in CD18-expression was 
observed in the -1 region (p=0.08 and p = 0.03 respectively). The first increase of 
perivascular CD18-expression occurred in the +1 region of the margin zone (p<0.01. 
Figure 4). 
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Figure 3. Presence of CD1 lb-positive cells in the margin of an 
actively spreading psoriatic lesion (magnification: ЮОх). The 
arrowhead Indicates the border between ortho- and parakeratosis. 
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Figure 4. Presence of CDJ8-posltive cells in the margin of an actively 
spreading psoriatic lesion (magnification: lOOxJ. The arrowhead indicates 
the border between ortho- and para-keratosls. A gradual increase in 
CDW-positive cells can be observed over the margin zone. 
Relevance of С DI lb- and CDI8-positive cells in the pathogenesis of psoriasis 
In the margin of a lesion, the first significant increase of elastase-expression occurs in 
the +2 region (epidermis; p = 0.01 and dermal perivascular; p = 0.01). 
In the dermis of the marginzone ICAM-1 expression was decreased, compared to 
involved and uninvolved psoriatic skin. The decrease reached statistical significance in 
the -3 to +1 regions at dermal diffuse localisation (p = 0.03, p = 0.01, p = 0.01 and 
p = 0.05 respectively). At perivascular localisation the same phenomenon was observed 
in the -3 to -1 regions (p=0.01, p<0.01 and p=0.02 respectively). 
More centrally in the margin zone the first significant increase in epidermal ICAM-1 
expression occurred in the +1 region (p = 0.05). 
2.5 DISCUSSION 
In the present study we have investigated the distribution pattern of the adhesion 
molecules CDllb, CD18, its ligand ICAM-1, and elastase in the margin of actively 
spreading psoriatic lesions, in distant uninvolved and central involved psoriatic skin 
and skin of normal subjects. With respect to the methodology it should be emphasised 
that the semiquantitative approach used does not allow exact quantification. The 
method does not give information on the amount of epitope per cell. However, the 
method is very useful to obtain information on the distribution of a particular cell 
population over the epidermal and dermal skin compartments[16,17]. 
Early changes in psoriasis can be studied in the margin of the psoriatic lesion, 
provided that exclusively actively spreading psoriatic lesions are selected. However, it 
remains difficult to exclude the possibility that even in clinically spreading lesions the 
most peripheral changes might be induced by humoural factors released by the 
psoriatic plaque itself. The process of expansion may be different from the initiation of 
new lesions, therefore additional studies on other models such as repeated tape 
stripping, and the psoriatic pin point lesion might be of value. 
Based on the results of the various stainings we can construct a synthesis of the 
sequence of events during the transition from symptomless into lesionai psoriatic skin: 
Figures. 1 and 2 illustrate this concept. The first significant change in the margin zone 
was a decrease of ICAM-1 in the dermal compartment. This was followed by an 
increase of CD1 lb-positive cells at dermal diffuse localisation. Just outside the transition 
point from ortho-into parakeratotic stratum corneum, CD18-positive cells were 
increased in the epidermis and diffuse in the dermis. Where parakeratosis was present, 
the first epidermal changes occurred which consist of an increase in CD18-positive 
infiltrate cells, and increased ICAM-1 staining. In the dermal compartment the initial 
decrease of ICAM-1 had now abolished and reached the same level of expression as in 
involved psoriatic skin. Following this, increased amounts of CDllb- and elastase-
positive cells are observed in the epidermal and dermal perivascular compartments. It 
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is only in the most central part of the margin that perivascular CDllb-positive cells are 
increased 
In the margin of an actively spreading psoriatic plaque, the first changes in the 
investigated parameters occur in the dermis and are later being followed by changes in 
the epidermis Indeed previous studies indicated that early changes in the progression 
of psoriatic plaques are seen in the dermal compartment, such as increased laser 
Doppler flow and increased alkaline phosphatase activity indicating endothelial 
involvement[18,19] 
The observation that dermal ICAM-1 expression is diminished in the outer part of 
the margin zone is remarkable It could imply that other ligands are of more 
importance in the early inflammatory reactions in the spreading margin It is also 
possible that the ICAM-1 receptor is being masked or down-regulated To the best of 
our knowledge, however, no down regulators have been described in literature 
The increased presence of CDllb-, CD18- and elastase-positive cells in the centre of 
a psoriatic lesion as observed in the present study is in accordance with the findings of 
Horrocks et al [15] 
In the distant clinically unmvolved skin a statistically significant increase of the 
number of CDllb-positive cells at perivascular localisation was shown However the 
number of CD18-positive cells in distant unmvolved skin at perivascular localisation 
was normal, whereas the number of CD18 positive cells was decreased diffusely in the 
dermis Since the number of elastase-positive cells was very sparse (dermal diffuse) or 
absent (perivascular and epidermal), these changes cannot be attributed to a change in 
the PMN but rather represent a different composition of the mononuclear infiltrate 
The increased expression of the CDllb-mtegnn suggests an increased number or 
activation of the monocyte-macrophage population in the distant unmvolved skin and 
outer segment of the margin zone The decreased CD18 positive population diffuse in 
the dermis of the distant unmvolved skin is compatible with an abnormal trafficking of 
myeloid cell lines within the dermis Abnormal trafficking of PMN in the distant 
unmvolved skin has been observed following epicutaneous application of leukotnene 
B4 (LTB4)[20,21] Both groups demonstrated a significant decrease in the 
accumulation of PMN following epicutaneous application of an aliquot of LTB4 to 
psoriatic skin In the distant unmvolved skin of psoriatics increased release of 
arachidonic acid and an increased activity of the enzyme Phospholipase A2 - the rate 
limiting step in the arachidonic acid synthesis - has been reported[22] Decreased 
trafficking of PMN through normal human skin has also been reported following 
repeated application of LTB4 to the skin It is attractive to speculate that pro-
inflammatory events cause an increase of CDllb-positive monocytes/macrophages in 
the distant unmvolved skin 
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However, an anti-inflammatory mechanism is induced preventing the development 
of overt inflammation, resulting in a decreased number of CD18-positive cells diffusely 
in the dermis and down-regulation of 1CAM-1. A decreased expression, or masking of 
adhesion molecules might impair extravasation of myeloid cells and inhibit spreading 
of these cells from perivascular to diffuse dermal localisation. Indeed, recently it has 
been reported that ICAM-1-expression in the distant uninvolved skin of psoriatics was 
decreased compared to the skin of normal subjects[23]. 
The present study reconfirms that elastase-positive cells participate in the 
pathogenesis of psoriasis in the phase of consolidation, and are not of relevance in the 
earliest stages in development of the psoriatic lesion. In the margin zone of the 
spreading plaque a change of intracutaneous cell trafficking anticipates extravasation of 
infiltrate cells. 
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3.1 ABSTRACT 
Endoglin is a glycoprotein which is predominantly expressed on endothelial cells. 
Endoglin is upregulated under inflammatory conditions as well as in skin lesions where 
endothelial cell proliferation occurs. Endoglin has TGF-ß binding capacity and as such 
might reduce the bioavailability of TGF-ß. TGF-ß has a growth inhibiting effect on 
keratinocytes and has a restraining influence on the extravasation of peripheral white 
blood cells. 
In order to find out how endoglin is expressed in the margin zone of psoriatic 
plaques and how it correlates with the appearance of inflammatory infiltrate, punch 
biopsies were taken from the margin zone of actively spreading psoriatic plaques in 8 
patients. Indirect immunoperoxidase staining was performed using PAL-Ε (vascular 
endothelium), PN-E2 (anti-endoglin) and T i l (T-lymphocytes). 
In all patients it was found that the appearance of parakeratosis correlated with a 
clear increase of PN-E2 expression. PAL-Ε and PN-E2 expression was assessed, using a 
5-point scale. Thus a tendency to decreased PN-E2 expression in the uninvolved skin 
compared to PAL-Ε expression was found within the margin zone (1.6 ± 0.4 and 
2.2 ± 0.4 respectively), whereas in the involved skin PN-E2 and PAL-Ε expression 
were in agreement (2.6 ± 0.5 and 2.6 ± 0.5 respectively), suggesting that in the overt 
plaque all endothelium is in a so-called activated state. Also correlating with PN-E2 
expression was the appearance of a huge dermal lymphocytic infiltrate and likewise of 
epidermal T-lymphocytic expression. 
The present study lends further support for a permissive role of endoglin expression 
in the development of the psoriatic lesion. 
3.2 INTRODUCTION 
Endoglin is a glycoprotein, present on the luminal membrane of dermal endothelial 
cells, activated monocytes and macrophages[1]. Endoglin is involved in adhesion 
processes and has transforming growth factor beta (TGF-ß) binding capacity[l,2]. It 
binds TGF-ß, and TGF-ß3 with high affinity and has virtually no affinity for TGF-ß2[2] 
TGF-ß has a restraining effect on the extravasation of peripheral white blood cells and 
inhibits epidermal proliferation[3-6]. Endoglin expression has been reported to be 
considerably upregulated in conditions characterised by cutaneous inflammation and 
endothelial cell proliferation[7]. Therefore, a decreased availability of TGF-ß under 
these conditions might be an inflammation enhancing factor. 
Psoriasis is characterised by epidermal hyperproliferation, premature keratinisation 
and cutaneous inflammation with accumulation of T-lymphocytes, polymorphonuclear 
leukocytes, monocytes and macrophages. In psoriasis angioneogenesis occurs as well. 
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In the symptomless skin, however, immediately outside the sharply demarcated 
lesion, no major inflammatory changes are observed histologically In the distant 
clinically uninvolved skin the activity of phospholipase A2, the rate limiting step in the 
production of inflammatory eicosanoids, is increased as well as the production of 
leukotnene B„ (LTB4) Nevertheless, the inflammatory response to epicutaneous 
application of LTB4 has been reported to be decreased[8 11] Therefore in addition to 
proinflammatory events also antiinflammatory principles exist in the symptomless skin 
In a previous communication we reported on the distribution of endoglm 
expression in lesionai and distant clinically uninvolved skin In contrast to its increased 
expression in lesionai skin, a markedly reduced expression in the distant clinically 
uninvolved skin was observed[12] If endoglin acts as a scavenger by decreasing the 
biological availability of TGF-ß such implies decreased availability of TGF-ß in the 
lesionai skin and increased availability of TGF-ß in the distant clinically uninvolved 
skin This would functionally imply enhancement of inflammation in the lesionai skin 
and inhibition of inflammation in the distant clinically uninvolved skin 
It is attractive to hypothesise that the sharp demarcation of the psoriatic lesion is 
caused by the dual role of the expression of endoglin as an inflammation-enhancing 
factor in the lesion and an antiinflammatory factor in the symptomless skin 
In the present study the expression of endoglin in the margin zone of spreading 
psoriatic plaques was studied in order to find out 
Whether the transition between decreased expression and increased expression 
of endoglin is sharply demarcated or more gradual 
In which stage of the transition from uninvolved into clinically involved 
psoriatic skin the change of endoglin occurs 
3.3 MATERIALS AND METHODS 
3 3 1 Patients 
Eight psoriatic patients (5 males and 3 females) participated in the present study after 
giving informed consent The patients had a mean age of 47 years and the extent of 
their lesions was less than 5% of the body surface They had received no topical 
antipsonatic treatment for at least 2 weeks and no systemic treatment for at least one 
year In every patient an actively spreading lesion was selected, characterised by 
pinpoint papules just outside the lesion, and/or a previous history of expansion of the 
lesion during the previous two weeks. 
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3.3.2 Biopsies 
In each patient a punch biopsy (6 mm diameter) was taken across the border of the 
psoriatic lesion after infiltration with a local anaesthetic. All biopsy specimens were 
embedded in Tissue Тек OCT compound (Miles Scientific, Napierville, USA), snap 
frozen in liquid nitrogen and stored at -80°C until use. Subsequently, 7 μηη frozen 
sections were cut and fixed in acetone for 10 minutes. 
3.3.3 Immunohistochemistry 
In order to visualise the vascular endothelium, without staining the lymphatic vessels, 
PAL-Ε, a monoclonal antibody, diluted 1:25 (Department of Pathology, University 
Hospital Nijmegen, the Netherlands) was used[13,14]. For the assessment of endoglin 
expression, the monoclonal antibody PN-E2 diluted 1:25 (Department of Pathology, 
University Hospital Nijmegen, the Netherlands) was used. Pan T-lymphocytes were 
stained by the monoclonal antibody DAKO-T11 diluted 1:100 (Dakopatts, 
Copenhagen, Denmark). 
Slides were rehydrated in phosphate buffered saline (PBS) and then incubated with 
the monoclonal antibody for 60 min. After three washes in PBS they were incubated 
for 30 min with peroxidase-conjugated rabbit-anti-mouse antibody (RAMPO, 
Dakopatts, Copenhagen, Denmark). Three more washes preceded a pre-incubation 
with sodium acetate buffer (pH 4.9) after which the slides were stained with freshly 
prepared 3-amino-9-ethyl-carbazole 200 mg/l in sodium acetate buffer and 0.01% 
H 2 0 2 (AEC solution). 
All slides were finally washed with demineralized water, counterstained with 
Mayer's haematoxylin (Sigma, St. Louis, MO) and mounted in glycerine gelatine. Slides 
were studied by light microscopy and the staining pattern was assessed at the papillary 
and subpapillary region of the dermis using a five-point scale. Not staining intensity 
but staining area was scored. 
3.4 RESULTS 
In the more central part of the margin zone ("involved") the architecture was 
psoriasiform with parakeratosis, acanthosis and a mixed inflammatory infiltrate. In the 
more distal part ("uninvolved") the architecture was that of normal skin. The 
transition between involved and uninvolved psoriatic skin was sharp with respect to 
the transition between orthokeratosis and parakeratosis but more gradual with respect 
to acanthosis and infiltrate formation. The staining results of PAL-Ε and PN-E2 are 
summarised in Table 1. 
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Margin zone 
Involved (parakeratotic zone) Uninvolved (orthokeratotic zone) 
Papillary dermis Subpapillary dermis Papillary dermis Subpapillary dermis 
PAL E staining 2 6 ± 0 5 2 4 ± 0 2 2 2 ± 0 4 2 0 ± 0 3 
PN Ej staining 2 6 + 0 5 2 1 + 0 2 16 + 0 4 16 + 0 2 
Table 1 Assessment of PAL E- and PN-E2 positive areas in the margin 
of the spreading psoriatic plaque (mean ± SEM) 
It can be seen that in involved part of the margin zone the density of PN-E2 
positive vascular endothelium approximated the density of vascular endothelium, as 
visualised by PAL-Ε In contrast, PN-E2 staining was markedly reduced in the 
uninvolved part of the margin zone Although the differences within the margin zone 
between "involved" and "uninvolved ' parts are substantial, no statistical significance 
was reached at the number of eight patients The transition between the involved and 
uninvolved part of the margin zone comprised only a few papillae PN-E2 staining in 
the margin zone is visualised in Figure 1. The appearance of a pronounced dermal 
infiltrate of T-lymphocytes and epidermal accumulation of these cells correlated with 
the PN-E2 expression 
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Figure 1. PN-E2 expression in the margin zone of the psoriatic plaque: 
(a) "involvedpart" (magn. ÌOOx). and (b) "uninvolvedpart" (magn. 75x). 
79 
Chapter 3 
3.5 DISCUSSION 
In normal skin of healthy volunteers, and also in the psoriatic plaque the ratio of PAL-
E positive endothelium to PN-E2 positive endothelium was 1:1[12]. 
In a previous communication it has been reported that the expression of PAL-E, 
indicating total vascular endothelium, was reduced in the distant clinically uninvolved 
skin. In addition, less endothelium expressing endoglin was demonstrated in the 
distant clinically uninvolved skin as compared to normal skin[12]. 
The relatively reduced expression of endoglin in the distant clinically uninvolved 
skin proved to advance into the margin zone of the spreading lesion, showing an 
abrupt transition into a marked expression, in the "involved part" of the margin zone. 
The transition from normal into acanthotic epidermis, orthokeratosis into parakeratosis 
and low density into high density lymphocytic infiltration coincides with this abrupt 
transition of endoglin expression. 
Although a major reduction of vascular endothelium (PAL-Ε positive cells) does exist 
in the distant uninvolved skin as compared to the skin of normal volunteers[12]. The 
expression of PAL-Ε in the uninvolved part of the margin zone approaches the 
markedly increased expression in the lesionai skin. 
Increased bloodflow, increased alkaline phosphatase activity and increased tenascin 
expression in an annular zone around the psoriatic plaque, indicate early involvement 
of the microvasculature and stroma in the development of the lesion[15-17]. 
The sharp demarcation of the psoriatic plaque is reflected in a sharp transition of 
endoglin expression. It is attractive to speculate that within the lesion the relatively 
high expression of endoglin decreases the availability of TGF-ß, hence enhancing 
inflammation. In contrast, the decreased expression of endoglin in the distant 
uninvolved skin is likely to result in increased TGF-ß levels and hence might counteract 
inflammatory stimuli. 
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4.1 ABSTRACT 
In psoriasis, polymorphonuclear leukocytes are consistently present in the early 
psoriatic lesion and in actively spreading plaques C D l l b , which is part of the ß2 
integnn receptor Mac-1, plays an important role in various biological functions of the 
polymorphonuclear leukocyte such as leukocyte adhesion to endothel ium, 
extravasation, tissue migrat ion and degranulation In the present study we investigated 
the possibility of systemic differences in leukocyte C D l l b expression between patients 
w i t h extensive plaque psoriasis and healthy volunteers 
Venous b lood samples were obtained f rom 15 patients w i th extensive plaque 
psoriasis (Psoriasis Area and Severity Index greater than 10 0), and f rom 15 matched 
healthy controls Both unstimulated and in vitro leukotnene B4-stimulated leukocytes 
were stained for C D l l b which was quanti f ied using f l ow cytometry methods A 
tendency towards decreased basal C D l l b expression was observed on leukocytes f rom 
psoriatic patients compared to healthy subjects After in vitro st imulation w i t h 
leukotnene B4 (LTB4) the difference between psoriatics and controls increased further 
and was statistically significant Patients w i t h unstable psoriasis (increasing size of 
individual lesions and / or pinpoint papules around chronic plaques) proved to have 
even lower unstimulated and LTB4-stimulated C D l l b expression N o correlat ion was 
found between C D l l b expression and severity of psoriasis using the PASI-score 
Interestingly, the relative C D l l b up regulation (ratio CDllbmM «mealed / С011Ь
и г
,5,т и Ы е <і) 
was virtual ly the same in both groups Therefore the signalling pathway f r o m 
leukotnene B4 receptor binding up t o C D l l b expression on the leukocyte surface was 
essentially normal in psoriasis It is hypothesised that the decreased C D l l b expression 
in psoriatics is caused by leukocyte compartmental isation 
4 . 2 I N T R O D U C T I O N 
Cutaneous inf lammat ion is an important aspect of the psoriatic lesion Already in 
p inpoint psoriatic lesions, in the peripheral zone of the margin of psoriatic plaques, 
and dur ing early relapse f o l l o w i n g discontinuation of treatment, accumulation of Τ 
lymphocytes, monocytes, mast cells and polymorphonuclear leukocytes (PMN) can be 
observed[ l] N o substantial inf lammatory changes have been seen in the symptomless 
skin distant f r o m the psoriatic lesion, although some authors claim increased density of 
T-lymphocytes[2 4] Unti l n o w no consensus has been reached on which cells are first 
in invading the "pre psoriatic skin" 
The invasion by polymorphonuclear leukocytes (PMN) in psoriatic skin is an early 
feature The epidermal accumulation of P M N adopts the psoriasis-specific 
configurations of spongiform pustules of Kogoj in the stratum Malp ighi , and micro 
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abscesses of Munro as intracorneal accumulations. In pustular psoriasis, PMN 
accumulation is the dominating feature[5,6]. In peripheral blood, functional and 
biochemical characterisation has revealed normal, decreased and increased expression 
of PMN activation features[7]. The activity of the psoriatic process whether expanding 
or stable proved to be an important denominator of the characteristics of peripheral 
blood PMN [8]. 
Integrin adhesion molecules are of great importance in intercellular and cell-matrix 
interactions[9]. They consist of non-covalently linked a- and ß-chains and are 
categorised by their ß-chain [10]. The Мас-1-integrin (CD11b/CD18) which is part of the 
ß2-subpopulation, is known to be of particular importance to various PMN 
functions[11-13]. It is pivotal to PMN adhesion to vascular endothelium, extravasation, 
tissue migration, the oxidative burst, and degranulation. 
The Mac-1-receptor can be up-regulated by various biochemical compounds such as 
formyl-Met-Leu-Phe, platelet activating factor, interleukin 8, and leukotriene B4[14-17]. 
To the best of our knowledge, there are no known active down-modulators of Mac-1. 
In particular, the up-regulation of CDIlb by leukotriene B4 (LTB4) is of interest since 
LTB4 is produced in large quantities in psoriatic lesionai skin[18-21]. 
LTB4 which is formed in the arachidonic acid cascade, is a potent upregulator of 
CDIlb. It causes a rapid increase in cell-surface presence through qualitative and 
quantitative up-regulation[ll,22-24]. We chose to evaluate CDIlb as it is far more 
specific for PMN than CD18 which is also present on other leukocyte subsets. 
In psoriatic skin, up to the most peripheral zone of the psoriatic lesion the amount 
of CD1 lb-positive cells is increased compared to normal skin[25], which suggests that 
the expression of CDIlb by PMN is an important factor in the pathogenesis of 
psoriasis. So far, no information is available on CDIlb expression by peripheral blood 
PMN of psoriatic patients. 
A flow cytometrical study was performed in order to investigate whether there are 
any systemic changes detectable in the basal levels of PMN CDIlb expression in 
patients with extensive plaque psoriasis compared to healthy volunteers. Secondly, we 
assessed whether PMN from psoriatics respond abnormally to ex vivo LTB4-
stimulation, with respect to CDllb-up-regulation. 
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4.3 MATERIALS AND METHODS 
4.3.1 Subjects 
Venous blood samples were obtained from 15 patients with extensive plaque psoriasis. 
All systemic antipsoriatic treatments were stopped for at least three months prior to 
the Investigation, and local antipsoriatic therapy was stopped for at least two weeks. 
Fifteen healthy volunteers, without any history or signs of skin disease, served as the 
control group. Subjects were at least 20 years of age. Both groups were matched for 
gender and age. No systemic anti-inflammatory or immunomodulating drugs were 
allowed. The severity of plaque psoriasis was assessed by the psoriasis area and 
severity index (PASI). Patients were judged to have extensive plaque psoriasis when 
PASI was greater than 10.0. 
Unstable plaque psoriasis was defined as an increasing size of the individual lesions 
during the two weeks preceding the study and/or the occurrence of pinpoint papules 
around chronic plaques. In stable psoriasis, these signs were not present. 
4.3.2 CDlIb integrin upregulation assay[26] 
Blood specimens for assessment of ex vivo neutrophil CDllb surface-expression were 
obtained. Peripheral blood (4 ml) was collected through venepuncture, kept in 
ethylene-di-amine-tetra-acetic-acid (EDTA) at 4°C and processed within 3 h of 
collection to prevent non-specific up-regulation of CDllb- expression as a result of 
neutrophil activation. 
Blood samples were processed in triplicate using 90 μΐ aliquots which were 
incubated with LTB4 (10 μΙ 1x107 M) in Hanks' balanced salt solution (Sigma chemical 
corp., St. Louis, USA) containing 0 . 1 % bovine serum albumin (HBSS-BSA), or with 
HBSS (10 μΙ) alone for 30 min at 37°C. Samples were then cooled and incubated in the 
dark for 30 min at 4°C with 10μΙ (0.045 g/l) anti-human CDllb-fluorescein conjugate 
(Mo-1-FlTC, Coulter Corp., Hialeah, USA). Erythrocytes were lysed and the remaining 
cells were washed with HBSS-BSA, fixed in 1 % paraformaldehyde solution and stored 
at 4°C until analysis. 
The analysis was always performed within one week after preparation of the 
leukocyte suspensions, because previous experiments showed that assessment within 7 
days minimises storage artefacts. 
4.3.3 Flow cytometric analysis 
All specimens were analysed on an Epics Elite® Flow Cytometer (Coulter, Luton, UK). 
Cells were excited with an air-cooled 488 nm argon laser set at 15 mW, Green 
fluorescence (FITC) was measured through a 525 nm (band width 30 nm) band pass 
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filter Calibration and sensitivity were checked by using FITC-labelled beads (Standard-
Bnte, Coulter Source. Hialeah, USA) Forward and side scatter were used for gating 
only granulocytes For each sample 5,000 gated cells were analysed (Figure 1) 
0 1023 
Figure 1 Right angle scatter (RAS) versus forward scatter (FS) of a leukocyte suspension 
Several distinct cell populations can be recognised (a) unlysed erythrocytes and debris, 
(b) lymphocytes, (c) monocytes, (d) PMN This population of PMN is gated out to assess 
the FITC-fluorescence of every cell which correlates with the amount of CDIIb molecules 
present on the cell surface 
4 3 4 Statistical analysis 
For comparison between different groups, the Mann-Whitney test was used 
Correlation between disease activity and CDllb-expression, and between CDl lb-
expression before and after in vitro LTB4-stimulation was calculated using the Pearson-
test 
4 . 4 RESULTS 
Psoriatic patients (N = 15) and healthy controls (N = 15) were matched for gender and 
age Table 1 summarises the age of patients and healthy controls as well as the severity 
of psoriasis indicated in the PASI-score 
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Patients / Subject} 
Healthy controls 
Psoriatic patients (overall group) 
Patients w i t h unstable psoriasis 
Patients w i t h stable psoriasis 
N 
15 
15 
8 
7 
M / F 
12/3 
12/3 
6/2 
6/1 
Years of age 
(mean ± SEM) 
46.2 ± 3.8 
47.7 ± 2.9 
50 6 ± 3.8 
44.4 ± 4.3 
PASI 
(mean ± SEM) 
not applicable 
17.9 ± 1.7 
19 9 ± 2.9 
15.6 ± 1.0 
Table 1. Mean and standard error of the mean (SEM) of age. psoriasis area and severity index 
(PASI). and neutrophil CD!lb-expression in the patient and volunteer group. Additionally, the 
psoriatics were divided in those who had stable and those who had unstable plaque psoriasis. 
A m o n g the 15 patients w i t h psoriasis, 8 patients had unstable psoriasis, characterised 
by aggravation of the lesions during t w o weeks preceding the experiments and 
p inpoint papules around the chronic plaques. 
The ages of patients and healthy controls were comparable. All patients were 
suffering f r o m severe plaque psoriasis as indicated by the PASI-score. The extent of skin 
involvement d i d not differ between patients w i t h unstable and stable psoriasis. 
The mean P M N CD11b expression, as measured by f l o w cytometry in psoriatic 
patients and healthy volunteers, is summarised in Figure 2. 
CD11b-expn»sion of PMN in Extensive plaque psonasis and Healthy volunteer* 
20 
18 
16 
с 
S ,4 « 
ІЛ 
ff 12 
о. 
Я ю 
Buffer LTB4-stimulated 
• Healthy volunteers 
Ш Extensive plaque psoriasis (overall results) 
D Unstable psoriasis 
в Stable psoriasis 
LTB4-stimulated / 
unstimulated 
LTB4-slimulated -
unstimulated 
Figure 2. CDIIb surface-expression (mean fluorescent units per cell) of PMN in psoriatic 
patients and healthy volunteers. 
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The basal CDl lb expression in the total group of psoriatic patients was 4.48 ±0.72 
(mean fluorescence units per cell ± SEM) and in healthy volunteers 6.50 ±0.84 (mean 
fluorescence units per cell ± SEM). The difference between psoriatic and normal 
unstimulated CDllb expression was not significant (p=0.06). However, there seemed 
to be a tendency towards a decreased CDllb expression in psoriatics compared to 
controls. 
The PMN CDllb-expression after in vitro stimulation with LTB., showed a highly 
significant difference between patient- and control-group (p = 0.001). In the patient 
group the presence of CDllb on the cell surface of PMN was 10.7±1.77 compared to 
17.6±1.13 in healthy volunteers. No relation was found between the individual 
severity of psoriasis as expressed by PASI, and PMN CDllb-expression. 
In order to compensate for the interindividual variation of CDllb expression the 
relative "CDl lb up-regulatability" for every individual (PMN CDllb-expression after 
LTB4-stimulation divided by CDllb-expression present on unstimulated PMN) was 
calculated. Remarkably, this relative PMN CDllb up-regulation in psoriatic patients did 
not differ from that in healthy volunteers (2.51 ±0.23 and 3.03±0.25 respectively, 
p=0.19). Subtraction of the basal level of PMN CDllb-expression from the level that 
was reached after in vitro LTB4 up-regulation revealed that the absolute LTB4-induced 
increase in PMN CDIlb-surface molecules was significantly lower in psoriatics 
compared to healthy volunteers (6.26±1.31 and 11.10±0.69 respectively, p = 0.001). 
No differences were observed between patients with stable and unstable psoriasis 
with respect to basal levels of PMN CDllb-expression, and LTB4-stimulated PMN 
CDllb expression. However, when comparing patients with unstable psoriasis to 
healthy volunteers, the differences were more pronounced than they were between 
the overall group of psoriatics and healthy volunteers. Both unstimulated and in vitro 
LTB4-stimulated PMN CDllb-expression were far lower in patients with unstable 
psoriasis (p = 0.02 and p<0.001 respectively). 
In order to assess whether the number of CDllb-molecules present on unstimulated 
blood-PMN is of relevance for the total amount of these molecules present after in 
vitro upregulation with LTB4, the correlation between these two parameters was 
calculated in psoriatics and healthy volunteers (Figure 3). 
There is a clear correlation between unstimulated and LTB4-stimulated CDllb-
expression in both groups (p < 0.001). 
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Figure 3. Correlation between amount of CDUb-molecules present on unstimulated peripheral 
blood PMN and the increased amount that Is present on these PMN after in vitro stimulation 
with LTB4. 
4.5 DISCUSSION 
The present study showed a tendency t o decreased expression of P M N C D l l b in 
psoriatic patients compared t o healthy volunteers. After in vitro st imulation of P M N 
by LTB4 there was a clear decrease in P M N C D l l b expression in psoriatic patients 
compared t o healthy volunteers. N o correlation was observed between the severity of 
psoriasis as expressed by the PASI-score, and P M N C D l l b expression. Comparison o f 
patients w i t h unstable psoriasis and healthy subjects accentuated the difference 
between patients and healthy controls considerably. However, in contrast t o the 
difference w i t h respect t o absolute values, the relative C D l l b up-regulation was 
virtual ly identical in patients and healthy subjects. 
Experimental variabi l i ty of f l o w cytometrical C D l l b assessment proved t o be b e l o w 
1 0 % comparing the triplicate measurements. Therefore, the present investigation 
reconfirms the high experimental reproducibi l i ty of the methods used. 
In patients and healthy volunteers, the CD1 lb-levels o n peripheral b l o o d P M N 
f o l l o w i n g st imulation w i t h LTB4 correlate w i t h the basal levels of C D l l b , as i l lustrated 
in Figure 3. Therefore, unstimulated P M N C D l l b expression determines LTB4-induced 
P M N C D l l b expression. The correlation between unstimulated and stimulated C D l l b -
levels in psoriatic patients and healthy controls seem t o be comparable since there is 
no difference in relative C D l l b up-regulation between both groups. This provides a 
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strong indication that the signalling from LTB4-receptor binding up to CDllb 
expression on peripheral blood PMN is essentially normal in psoriasis 
The tendency to decreased basal expression of CDllb and the significantly decreased 
LTB4-induced psoriatic PMN CDllb expression compared to normal PMN indicates a 
decreased number of CDllb-hemireceptors on psoriatic PMN The decreased 
expression of CDllb on peripheral blood PMN, further decreasing in unstable psoriasis 
is in sharp contrast with the m vitro Chemotaxis and protease activity which increases 
in unstable psonasis[8] 
Three explanations for the decreased CDllb expression of circulating psoriatic PMN 
may be hypothesised (1) compartmentalisation of PMN subpopulations, (2) 
Habituation to increased levels of leukotnene B„. (3) active down modulation of 
CDllb-levels on psoriatic peripheral blood PMN 
The hypothesis of compartmentalisation of circulating blood PMN is based on PMN 
subset selection It is probable that the PMN-subpopulation with the highest CDllb 
expression is most likely to be recruited to invade the inflamed psoriatic skin, whereas 
PMN with a more modest density of CDllb remain in the blood circulation Indeed, 
patients with unstable psoriasis proved to have an even lower CDllb expression on 
peripheral blood PMN than the overall group of psoriatic patients In active psoriatic 
lesions, PMN-influx has been reported in 78% of patients and in chronic plaque 
lesions PMN-influx proved to occur in 4 1 % of patients[27] 
An alternative explanation is habituation of peripheral blood PMN to increased 
LTB4-Ievels present in psoriatic skin This hypothesis is supported by the observation 
that in psoriatic uninvolved skin a decreased accumulation of PMN occurs following a 
standardised stimulus with LTB4[28,29] Repeated LTB4-apphcations resulted in a 
decreased PMN accumulation as compared to the response following a single 
application[29] However, in view of the fact that the relative CDllb up-regulation by 
LTB4 in psoriatics proved to be essentially normal, this hypothesis is not supported by 
the observations in the present study 
Active down modulation of CDllb is another possible mechanism that could 
explain the decreased PMN CDllb expression in psoriatic patients It may be possible 
that such a defence mechanism exists in order to prevent massive cutaneous damage 
due to abundant skin presence of PMN To the best of our knowledge there are no 
known active down modulators of CDllb until present However, integnn α-units, like 
CDllb need divalent cations (calcium or magnesium) for their adhesive functions, and 
receptor function can be rapidly modulated through phosphorylation reactions[9] It 
might well be possible that CDllb can be down modulated on a functional level by 
changes in cation concentrations and Phosphorylase activity 
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Since LTB„-induced signalling in psoriatic PMN is essentially normal, the question 
arises to what extent LTB4 is relevant to the CDllb up regulation of psoriatic PMN in 
vivo The role of LTB4 in psoriasis has been challenged further by the modest effects of 
5 lipoxygenase inhibitors in the treatment of psonasis[30-33] 
The decreased CDllb expression on peripheral blood PMN in psoriasis remains an 
intriguing finding, and further studies should be aimed at mediators and factors 
involved in PMN compartmentalisation in psoriasis, and at mechanisms involved in 
the in vivo regulation of CDllb in psoriatic patients 
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5.1 ABSTRACT 
CDIIb is part of the ß2-integrin Mac-1 and plays an important role in neutrophil 
adhesion. Leukotriene B4 (LTB4) is an active upregulator of neutrophil CDU fa-
expression, acts as a potent chemoattractant to neutrophils and is also known to 
upmodulate epidermal proliferation. 
We performed a placebo-controlled study on LY293111, an oral LTB4-receptor 
antagonist. Twenty healthy male volunteers were randomised over 3 treatment groups 
that received placebo, 48 mg or 200 mg drug twice daily for 10 days. Before and after 
treatment flow cytometrical CDllb assessment was performed on in vitro LTB4-
stimulated peripheral blood neutrophils. Additionally, skin biopsies were taken at 24 
and 72 h after epicutaneous LTB4 application, before and after treatment. The effects 
on skin were assessed immunohistochemically using various markers. 
All observed effects were dose related. CDllb upregulation on blood neutrophils 
was significantly suppressed in both treatment groups compared to placebo. In skin, a 
significant suppression of inflammation and hyperproliferation occurred. Pronounced 
inhibition was observed on neutrophil migration into the epidermis and the 
inflammatory infiltrate was decreased. A similar but weaker response was seen in the 
dermis. The number of cycling cells as well as suprabasal keratin-16 expression were 
decreased in both treatment groups. LY293111 proved to be a potent inhibitor of LTB4-
induced cutaneous inflammation and hyperproliferation. The potent anti-
inflammatory effect in vivo and the fact that in the present study the compound 
showed no clinically significant side effects make it an interesting drug in the future 
treatment of inflammatory conditions predominated by neutrophils. 
5.2 INTRODUCTION 
The arachidonic acid cascade plays an important role in inflammation. It is the 
precursor of prostaglandins, thromboxanes, hydroxyeicosatetraenoic acids and 
leukotrienes[l]. This latter group is important in the induction of polymorphonuclear 
leukocyte (PMN) aggregation and adhesion, production of superoxides, and 
chemotaxis[2,3]. Leukotrienes are 5-lipoxygenase products of arachidonic acid and 
consist of various inflammatory eicosanoids[4]. 
Leukotriene B4 (LTB4) is a potent chemoattractant for PMN and might together with 
12-hydroxyeicosatetraenoic acid play an important role in many inflammatory 
processes[4]. Indeed inhibitors of the enzyme 5-lipoxygenase have proven to be 
beneficial in the treatment of several inflammatory conditions[5,6,7]. 
PMN play an important role in acute inflammation. These cells have an established 
role in the initiation and possibly the maintenance of various inflammatory 
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diseases[8,9,10] PMN are attracted by numerous chemokines and metabolites of the 
arachidonic acid cascade, interleukins and GRO-a[11] 
Migration of PMN from the intravascular compartment to the extravascular space is 
a mechanism that requires interaction through adhesion molecules on the cell surface 
of PMN as well as on tissue cells and matrix Human PMN adherence to endothelial 
cells can be enhanced by a variety of inflammatory mediators in v/tro[]2] For PMN 
interaction with other cells and matrix, the amß2 integnns and in particular CD11/CD18 
are considered to be important[12-14] The significance of individual integnn 
heterodimers in the various stages of PMN migration in vivo is not yet fully clarified 
The clinical relevance, however, is demonstrated in Leukocyte Adhesion Deficiency 
syndrome, in which PMN lack surface expression of ß2 integnns, and is associated with 
a short life expectancy due to severe inflammatory complications[15] CDllb/CD18 is 
usually referred to as the Mo-1 or Mac-1 receptor Known hgands are C3bi, Fx, Fb and 
Intercellular adhesion molecule 1 (ICAM 1)[16,17] ICAM 1 is mainly expressed by 
endothelial cells and to a lesser extent by keratinocytes[18] 
Epicutaneous application of LTB4 on human skin results in a reproducible dose 
dependent cutaneous inflammatory response, initially dominated by PMN with a 
maximum presence at 24 h, and followed by a dermal Τ cell infiltrate which is most 
pronounced after 72 h[19] Epidermal hyperproliferation occurs reaching a maximum 
after 72-96 h Therefore, this model has been used previously to study sequential 
changes of aspects of cutaneous inflammation and interference in this process by 
antiinflammatory therapies[3] 
Recently, the new specific oral LTB4 receptor antagonist LY293111 (Lilly Research 
Laboratories, IN, USA) has been developed In vitro it has proven to be a potent 
inhibitor of the LTB4 receptor[20] In addition it specifically inhibits chemotactic 
activity, calcium mobilisation, chemilluminescence, superoxide generation and 
induction of CD11b/CD18 integnn up modulation in LTB4 stimulated neutrophils in 
v/tro[20] 
In this study, the following questions were addressed first, is LTB4-mduced PMN 
accumulation in normal skin inhibited by a 10 days treatment course with LY293111 as 
compared to placebo, second, does LY293111 reduce the CDllb expression on PMN in 
blood or skin and to what extent, third, are late effects of epicutaneous LTB4 
application modified (epidermal hyperproliferation and T-cell influx), and last, what is 
the clinical tolerability of the drug' 
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5.3 MATERIALS AND METHODS 
5.3.1 Study design 
Prior to initiation of the study, approval from the Medical Ethics Committee was 
obtained. The trial was performed in a double-blind, placebo-controlled randomised 
fashion with 3 parallel groups. Twenty healthy male volunteers (20-42 years of age, 
mean age 27 years) participated in this study. Informed consent was obtained from all 
volunteers, none of whom had any history or signs of skin disease. No medication 
other than the compound was to be administered for at least 7 days before and during 
the study. For minor complaints paracetamol was allowed. 
All volunteers were treated with LY293111 or placebo for 10 days Six volunteers 
received LY293111 orally at a dose of 200 mg twice daily, 7 volunteers received the 
compound at a dose of 48 mg twice daily, and seven volunteers received placebo. The 
study period lasted 32 days. 
5.3.2. Clinical and laboratory safety measurements 
Prior to starting medication, a general physical examination and laboratory 
measurements were performed. The laboratory measurements consisted of 
haematology (total and differential white blood cell counts, erythrocyte count, mean 
cell volume, mean cell haemoglobin, mean cell haemoglobin concentration, 
haemoglobin, haematocrit, and platelet count); blood chemistry (ASAT, ALAT, 
bilirubin, alkaline phosphatase, gamma-GT, urea, Creatinin, uric acid, phosphorus, 
calcium, total protein, creatin kinase, and thyroid function tests), electrolytes (sodium, 
potassium, chloride, bicarbonate): and random blood glucose. In addition, urinalysis 
was performed (specific gravity, pH, protein, glucose, ketones, bilirubin, urobilinogen, 
and sediment). 
During the study-period, the haematology, blood chemistry, and urinalysis were 
repeated at day 1,15 and the last day of the study. 
5.3.3 L ТВ4 application and biopsy procedures 
LTB4 was applied epicutaneously to all volunteers before treatment and after 8 days of 
treatment. A 4-mm punch biopsy was taken on each volunteer before application to 
assess histology of the unchallenged skin. Aliquots of 100 ng LTB4 (Paesel GmbH. 
Frankfurt, Germany) dissolved in 10 μΙ of ethanol were applied on the skin of the 
upper part of the back of the volunteers via a plastic cylinder (6.5 mm diameter) and 
the ethanol was evaporated under a stream of nitrogen The test sites were covered 
with impermeable dressings (Silver patch, van der Bend BV, Bnelle, the Netherlands) 
and held in place with leukosilk tape (Beiersdorf, Hamburg, Germany). Biopsies were 
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taken on day 2 and 4 (before administration of the compound), and on day 16 and 18 
(during the 10 day treatment course with the compound) after injection of a local 
anaesthetic. The biopsies were washed in phosphate-buffered saline (PBS), embedded 
in Tissue Тек OCT compound (Miles Scientific, Elkhart, IN, USA), snap frozen in liquid 
nitrogen and stored at -80°C until use. 
5.3.4 CD Jib integnn upregulation assay 
Blood specimens for assessment of ex iz/VoCDllb surface expression were obtained on 
day 1 prior to the first LTB4 challenge and on day 15 (after 7.5 days of treatment with 
LY293111 or placebo) prior to the second LTB4 challenge. 
Peripheral blood (4 ml) was collected through venepuncture, kept in ethylene-di-
amme-tetra-acetic-acid (EDTA) at 4°C and processed within 3 h after collection to 
prevent non-specific upregulation of CDllb surface expression as a result of neutrophil 
activation. Blood samples were processed in triplicate using 90 μΙ aliquots that were 
incubated with LTB4 (10 μΙ 1x107 M) in Hanks' balanced salt solution (HBSS, Sigma 
Chemical Corp., St. Louis, MO, USA) containing 0.1% bovine serum albumin (BSA), or 
with HBSS (10 μΐ) alone for 30 min at 37°C Samples were then cooled and incubated 
in the dark for 30 mm at 4°C with 10μΙ (0 045 g/l) antihuman CDllb-fluorescein 
conjugate (Mo-1-FlTC, Coulter Corp , Hialeah, FL, USA). Erythrocytes were lysed and 
the remaining cells were washed with HBSS-BSA, fixed m 1% paraformaldehyde 
solution and stored at 4°C until analysis The analysis was always performed within 1 
week after preparation of the leukocyte suspensions 
5.3.5 Flow cytometric analysis 
All specimens were analysed on an Epics Elite® Flow Cytometer (Coulter, Luton. UK) 
Cells were excited with an air-cooled 488 nm argon laser set at 15 mW FITC 
fluorescence was measured through a 525 nm (band width 30 nm) band pass filter. 
Calibration and sensitivity were checked by using FITC-labelled beads (Standard-Bnte, 
Coulter Source, Hialeah, USA). Forward and side scatter were used for gating 
granulocytes only For each sample 5,000 gated cells were analysed 
5.3.6 Immunohistochemical staining procedures 
Cryostat sections of 7 μιη were cut and fixed for 10 mm in acetone/ether (60/40 
vol.%) for Mib-1, or in acetone for staining with the other antibodies Table 1 depicts 
the various markers used. 
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Cell type 
PMN 
T-lympho-
cytes 
Langerhans 
cells 
Cycling 
cells 
Cytokeratin 
16-positive 
cells 
CDllb-
positive 
cells 
(in skin) 
ICAM-l -
positive 
cells 
CDIIb-
positive 
cells 
(in blood) 
Antibody 
anti-
elastase 
T i l 
T6 
Mib-1 
Ks8 12 
anti-
C D l l b 
ICAM-l 
anli-
C D l l b 
•g-
t y p e 
IgC, 
kappa 
IgC, 
kappa 
lgC2 s 
kappa 
IgC 
IgC, 
IgC, 
IgC, 
IgM 
kappa 
Ligand 
neutro­
phil 
elastase 
CD2 
CDla 
Ю67 
Cyto­
keratin 
16 
C D l l b 
CD54 
C D l l b 
Clone 
NP57 
mouse 
MT910 
mouse 
NAV34 
mouse 
Mib-1 
mouse 
K8.12 
mouse 
Bear-1 
mouse 
84НЮ 
mouse 
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Specificity 
neutrophil 
elastase 
PMN, sporadic 
in monocytes 
CD2 
CDla 
nuclear antigen 
present in the late 
C . S and C 2 + M 
phases of the cell 
cycle 
hyperprohferative 
epidermis, cross 
reaction with 
cytokeratin 13. 
which is mainly 
present in hair 
follicles 
PMN, some 
monocytes and 
macrophages 
CD54 
PMN, some 
monocytes and 
macrophages 
Concen­
tration 
((ig/mL) 
61 5 
155 
337 
200 
200 
Manufacturer 
Dakopatts, 
Copenhagen. 
Denmark 
Dakopatts, 
Copenhagen, 
Denmark 
Ortho 
Diagnostics 
Systems. Rantan. 
NJ, USA 
Immunotech, 
Marseille, France 
Sigma. St. Louis. 
M O . USA 
Monosan, Uden, 
the Netherlands 
Immunotech, 
Marseille. France 
Monosan, Uden, 
the Netherlands 
Table 1. Markers used for histology and in the CDllb upregulation assay. 
Staining w i t h Ks8.12, Mib-1, anti-elastase, ant i-CDI lb and anti-ICAM-1 was 
performed using an indirect peroxidase technique. Slides were incubated w i t h the 
monoclonal antibodies for 30 min, and after t w o washes w i t h PBS incubated w i t h 
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rabbit-anti-mouse antibody (RAM, Dakopatts, Copenhagen, Denmark) conjugated 
with peroxidase for 30 min. 
Staining with T i l and T6 was done using a peroxidase-anti-peroxidase technique 
(PAP-technique). Slides were incubated with the monoclonal antibodies for 60 min. 
After two washes with PBS the slides were incubated with RAM immunoglobulins 
(RAM-lg. Dakopatts, Copenhagen, Denmark) and after two more washes with PBS, 
PAP complexes (Dakopatts, Copenhagen, Denmark) were added. The incubation with 
RAM-lg and PAP was repeated. After two more washes with PBS and preincubation 
with sodium acetate buffer, pH 4.9, slides were stained with sodium acetate buffer 
containing 200 mg/l 3-amino-9-ethyl-carbazole (AEC-solution) and 0.01% H202 for 10 
minutes at 37°C in the dark. 
All slides were washed in demineralised water and slightly counterstained with 
Mayer's haematoxylin (Sigma, St.Louis, MO, USA). Slides were finally mounted in 
glycerine gelatine and studied by light microscopy. 
5.3.7 Histological examinations 
Epidermal proliferation was measured by counting the number of Mib-1-positive nuclei 
per mm length of section. Ks8.12 binding of the epidermis was assessed in the basal 
and suprabasal compartment using a seven-point scale: 0 = no staining, 1 = sporadic 
staining, 2 = minimal staining, 3 = moderate staining, 4 = moderate/pronounced 
staining, 5 = pronounced staining, 6 = complete staining. 
The density of PMN (elastase and CDllb stainings), T-lymphocytes and Langerhans 
cells were assessed semi-quantitatively in epidermis and dermis using a seven-point 
scale: epidermis: 0 = no positive cells observed, 1 = sporadic staining, 2 = minimal 
presence, 3 = moderate presence, 4 = moderate/pronounced presence, 5 = 
pronounced presence, 6 = complete staining. Dermis: 0 = no positive cells, 1 = 
sporadic. 2 = 1-25% of infiltrate cells stained, 3 = 26-50%. 4 = 51-75%, 5 = 76-
99%, 6 = 100%. The dermal infiltrate was subdivided in perivascular and diffuse 
localisation. ICAM-1 staining was quantified in epidermis and dermis using a five-point 
scale: 0 = no staining, 1 = 1-25%, 2 = 26-50%, 3 = 51-75%. 4 = 76-100%. In 
addition, an estimation of the total infiltrate was made using a 4 point scale: 0 = no 
infiltrate present, 1 = minimal infiltrate, 2 = moderate infiltrate, 3 = pronounced 
infiltrate. 
Statistical comparisons between groups were carried out before and after LY293111 
treatment. After treatment, the placebo group was compared to both LY293111-
treated groups. For statistical evaluation the Mann-Whitney test was used. 
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5.4 RESULTS 
5.4.1 Clinical results 
N o clinically significant toxicity was observed. There were no dropouts. The safety 
urine and b l o o d measurements remained w i t h i n normal ranges. LTB,, application was 
wel l tolerated. The histological observations w i t h i n each subgroup p r o v e d t o be 
reproducible. 
5.4.2 Flow cytometry 
Ex vivo challenge of b l o o d PMN w i t h LTB4 before treatment showed a highly 
reproducible and consistent upregulation of C D l l b expression. Before treatment, no 
statistically significant difference was seen in the relative neutrophi l C D l l b expression 
(ratio challenged/unchallenged, expressed as a fold increase) between the various 
treatment groups (Placebo: 3.12 ± 0.49 (mean ± SEM), l o w dose LY293111: 
2.60 ± 0.27, and high dose: 2.63 ± 1.02, Figure 1). 
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Figure l . Ex vivo CDllb expression in unstimulated and LTB^-stimulatedperipheral blood 
neutrophils, before and after treatment. The results are expressed as a ratio 
CDllb.umui^ed/CDUbunu.muinied per treatment group (mean ± SEM). : before treatment. 
Η / after treatment. 
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After systemic treatment, the placebo group showed no difference in the relative 
neutrophi l C D I I b expression, compared to before administration (2.34 ± 0.24). A 
highly significant reduction was reached w i t h high dose LY293111 (1.02 ± 0.02, ρ = 
0.0027). The l o w dose group also showed a significant reduction 
(1.17 ± 0.05. ρ = 0.0017, Figure 1). 
The mean relative expression of C D I I b after ex vivo LTB4 challenge o n b l o o d 
neutrophils permit ted a total separation between placebo-treated and LY293111-
treated volunteers. 
5.4.3 lmmunohistochemistry 
Epidermal p r o l i f e r a t i o n : Cycling cells. The number of cycling epidermal cells 
showed a reproducible response t o LTB4 before systemic treatment, f o l l o w i n g a slight 
reduction after 24 h, a marked increase was observed at 72 h after LTB4 challenge 
(Figure 2). 
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Figure 2. Number of Mib-1-positive nuclei indicating cycling cells. The results are expressed per 
mm length of epidermis, before and after treatment with LY293IÌ1 (median ± SDJ-HD-· 
norma/ epidermis, ΊΣ2 : before treatment 24 h after LTB4 stimulation. • § / before treatment 72 
h after LTB4 stimulation. Ш / after treatment 24 h after LTB4 stimulation. Ш / after treatment 
72 h after L TB4 stimulation. 
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During placebo treatment, LTB4-induced Mib-1 expression was comparable t o the 
response before treatment, whereas the induction of Mib-1 staining was decreased in 
the l ow dose group and virtual ly absent in the high dose group (p=0.01 and p = 0.003 
respectively, Figures 2 and 3). 
1 
Figure 3. Mib-1-stained nuclei 72 h after application of LTB4 on normal skin. 
(Scale bar: 100 μ/7?/ (A): placebo. (B): 200 mg L Y293111 BID. 
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C y t o k e r a t i n 16. Ks8.12 staining was sporadically present in normal unchallenged skin. 
After LTB4 appl ication, a statistically significant increase of keratin staining occurred 
already after 2 4 h. Skin specimens f rom volunteers receiving LY293111, showed a 
significant decrease of keratin staining after 24 h compared t o the placebo group 
(p = 0.02 in the l o w and p = 0.004 in the high dose group). In the high dose group, this 
decrease persisted until 72 h after LTB4 application (p = 0.005). 
I n f l a m m a t i o n : T o t a l inf i l trate cells. A substantial increase was observed after 2 4 
and 72 h f o l l o w i n g LTB4 challenge in all three volunteer groups before systemic 
treatment. After treatment w i t h placebo, this increase was virtual ly identical. In 
contrast, high-dose LY293111 induced a pronounced reduction of cutaneous 
inf lammat ion which was most expressed 72 h after LTB4 challenge (p=0.012). The l o w 
dose group had an intermediate response pattern (Figure 4). 
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Figure 4. Infiltrate cells, before and after treatment, (median ± SD). • : normal unchallenged 
skin.H'J : before treatment 24 h after LTB4 stimulation, M . - before treatment 72 h after LTB4 
stimulation,^^ : after treatment 24 h after LTB4 stimulation.^^. after treatment 72 h after 
L TB4 stimulation. 
Elastase staining. LTB4-challenge induced a maximum elastase expression after 24 h in 
epidermal and dermal skin compartments, one that had decreased substantially after 
72 h. Again, all three volunteer groups showed a similar response pattern before 
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systemic treatment. In contrast, during systemic treatment, the accumulation of 
elastase-positive cells was inversely correlated to the dose of LY293111: a significant 
reduction in the epidermal accumulation was seen during low-dose treatment 24 h 
after LTB4 challenge (p = 0.03), whereas in the high-dose group epidermal PMN 
accumulation was virtually completely suppressed (p=0.005). At 72 h, the differences 
between the three groups had diminished considerably but there was still a decreased 
expression in the high dose group (p=0.05). Twenty-four hours after LTB4-challenge, 
the accumulation of PMN diffusely in the dermis was suppressed during high-dose 
treatment (p=0.04). PMN accumulation was not suppressed in the dermal 
perivascular infiltrate, but remained present directly adjacent to the endothelium. 
CDllb staining. The accumulation of CDIIb-positive cells mimicked the pattern of 
elastase-positive cells. Before systemic treatment, all three groups showed a maximal 
accumulation after 24 h in all skin compartments. Again during systemic treatment 
with high-dose LY293111, the epidermal accumulation of CDllb-positive cells was 
completely suppressed both at 24 and 72 h (p=0.01, and p = 0.05. Figures 5,6) 
Placebo 48 mg BID 200 mg BID 
Figure 5. Epidermal CDllb staining before and after treatment with LY293UÌ (median ± SD) 
I I.· normalepidermis.tZZ : before treatment 24 h after LTB4 stimulation, M / before treatment 
72 h after LTB4 stimulation, И - ' after treatment 24 h after LTB4 stimulation. П . - after 
treatment 72 h after L TB4 stimulation. 
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Figure 6. CDllb-staining 24 h after application of LTB4 on normal skin 
(Scale bar: 100 μ/π/ (A): placebo. (B): 200 mg L Y293111 BID. 
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Diffusely located dermal CDIlb-positive cells were inhibited at 24 h after LTB4 
application (p = 0 02) Low-dose LY293111 resulted m a mitigated accumulation of 
epidermal CDIlb-positive cells. 
T-lymphocyte staining. In contrast to the marked interference of LY293111 with 
PMN migration, the effects on T-lymphocytes were modest Accumulation of Τ 
lymphocytes in the epidermis and diffusely in the dermis was low in all 3 treatment 
groups However, 72 h after LTB4 application, a reduction of the number of T-
lymphocytes in the dermal perivascular compartment was accomplished in the high-
dose group (p = 0 01) 
Langerhans-cell staining. T6-positive cells in the epidermis showed a decrease 72 h 
after LTB4 application before systemic treatment All three treatment groups showed a 
similar pattern after administration of the compound No significant changes in the 
epidermal T6-positive cells were recorded The dermal compartment reflected a slight 
increase of T6-positive cells at 72 h in the untreated and placebo-treated groups 
At this time point the subgroup receiving high-dose LY293111 demonstrated a 
significantly lower number of perivascular Тб-positive cells (p = 0 04) 
1CAM-1 staining. Epidermal ICAM-1 staining was focally present in normal 
unchallenged skin In the pre-treatment specimens, a consistent increase of ICAM-1 in 
epidermis and dermis was seen at 24 and 72 h after LTB4-application After treatment, 
a remarkable overexpression of epidermal ICAM-1-positive cells was observed in the 
high dose group at 24 h (p = 0 01). After 72 h, however, ICAM-1 expression in the 
epidermis was comparable to the other two groups and equivalent to before 
treatment 
In contrast, the increase of ICAM-1 diffusely in the dermis, as seen in the placebo-
treated and untreated skin, was substantially inhibited by high dose treatment at 72 h 
(p = 0 02) Perivascular ICAM-1 expression remained identical before and after 
treatment 
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5.5 DISCUSSION 
A 10-day treatment course with LY293111 showed marked influences on peripheral 
blood PMN, epidermal proliferation, and cutaneous inflammation The treatment 
showed no significant side effects A consistent observation was the potent inhibition 
of CDllb upregulation on peripheral blood PMN LTB4 induced epidermal 
hyperproliferation was virtually completely blocked, and hyperproliferation-associated 
keratins showed a decreased expression following high-dose treatment 
Infiltrate cells were modulated selectively LY293111 had a reproducible dose-
response effect on LTB4-induced PMN CDllb expression, resulting in a complete 
suppression of CDllb upregulation in volunteers treated at the high dose, and a 
significant reduction in the low-dose treatment group Migration of CDllb-posittve 
cells and elastase-positive cells was blocked at the post-penvascular level, resulting in 
an inhibition of PMN accumulation in the epidermis and diffusely in the dermis after 
24 and 72 h 
The discrepancy between marked inhibition of epidermal and diffuse dermal PMN 
accumulation on the one hand and unaffected perivascular presence of PMN on the 
other, suggests an effect of LY293111 on PMN migratory capacities from the 
perivascular space into stroma and epidermis In the perivascular compartment, the 
number of Langerhans cells was slightly decreased and T-lymphocytes were prevented 
from accumulating in the high-dose treatment group 72 h after LTB4-application 
Epidermal ICAM-1 was increased 24 h after LTB4 challenge in the high dose group, and 
decreased diffusely in the dermis 72 h after application in contrast to the other two 
treatment groups Perivascular ICAM-1 upregulation persisted after treatment with 
LY293111 Based on these observations we may construct the following response 
pattern to LY293111 in LTB4 induced cutaneous inflammation PMN (as assessed by 
elastase) accumulate in the perivascular zone but fail to migrate into the stroma and 
epidermis CDllb-positive cells showed the same distribution pattern During 
treatment, the decreased presence of T-lymphocytes in the perivascular zone suggests 
inhibition of accumulation of Τ lymphocytes Diffusely in the dermis, the relative 
scarcity of PMN and T-cells is accompanied by a lack of ICAM 1 expression The late 
events following LTB4-application (ι e epidermal hyperproliferation and expression of 
keratin 16) are prevented by pre treatment with LY293111 
LY293111, a specific LTB4 receptor antagonist, proved to suppress CDllb induction 
on peripheral blood PMN The observation that PMN in skin keep their ability to 
adhere to endothelium and move through the vessel walls, but lose their ability to 
migrate through the stroma, gives rise to a speculation about specific functions of 
CDllb Indeed, Fune et al studied the adhesion to and migration of neutrophils across 
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human umbilical vein endothelial cells (HUVEC) in an in vitro model[21] Monoclonal 
antibodies to CDllb substantially inhibited migration of neutrophils 
Monoclonal antibodies to ICAM-1 decreased transendothelial Chemotaxis This 
effect is mediated by binding of the antibody to ICAM-1 on HUVEC and not by a 
direct effect on neutrophils Therefore, migration seems dependent on CDllb and 
transendothelial Chemotaxis on ICAM-1 In addition, Vedder et al showed that 
ICAM1 is essential in adherence of PMN to endothelium, and that increased 
expression of CDllb/CD18 is not[22] 
This might explain why PMN still adhere to endothelium and show diapedesis but 
fail to migrate into the stroma when CDllb is decreased during treatment with 
LY293111 It is striking that late events in the LTB4 model do not take place when PMN 
are restricted to the perivascular compartment, although LTB4 itself might induce these 
late effects In the high-dose group hyperproliferation and epidermal PMN influx were 
strongly inhibited By contrast, hyperproliferation did not occur in the low dose 
group, whereas a small percentage of PMN were still able to migrate into the 
epidermis One might speculate that epidermal hyperproliferation and associated 
features are possibly modulated by the LTB4 receptor antagonist and not exclusively 
secondary to the intraepidermal migration of PMN 
ICAM-1 has been reported to be expressed by activated endothelial cells, 
monocytes, B- and T-lymphocytes, and keratinocytes[23] Increased ICAM 1 
expression has been described on cells in inflammatory conditions such as psoriasis, 
atopic dermatitis, lichen planus and rheumatoid synovium[24,25,26] In psoriasis, the 
development of manifest lesions is linked with the appearance of ICAM 1 positivity on 
keratinocytes[27] After LTB4 application, an increase of dermal diffuse ICAM-1 was 
observed after 72 h, on that is prevented by LY293111 It is feasible that LY293111 is 
capable of preventing upregulation of ICAM-1 in incipient psoriatic lesions thereby 
preventing the induction or spreading of the disease There is a substantial variability 
of epidermal ICAM-1 expression possible between different individuals This could be 
an explanation for the profound increase in epidermal ICAM-1 expression in the high-
dose group However, the difference with the other 2 treatment groups is striking 
Blocking of CDllb using monoclonal antibodies prevents PMN adhesion to 
keratmocytes[28] Furthermore, functional CDllb has been reported to be decreased 
in the development of auto immune neutropenia[29] Wu et al [30] showed that 
CDllb/CD18 may participate in the acute expression of glomerular damage in 
nephrotoxic nephritis In addition, CDllb/CD18 has been reported to be of 
importance in septic liver mjury[31], and in reperfusion-mduced albumin leakage 
inducing microvascular dysfunction[30] 
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Therefore. CDl lb seems likely to play an important role in many diseases and 
interference with upregulation may form an important clinical target in management 
of these diseases 
A total separation between placebo-treated volunteers and LY293111 treated 
volunteers was possible with respect to PMN CDllb upregulation in blood In skin, 
however, high dose treatment is necessary to achieve complete blocking of PMN 
influx LY293111 decreases LTB4-induced cutaneous proliferation, prohibits spreading of 
PMN and decreases extravasation of T-lymphocytes LTB4 levels are increased in 
psoriatic skin lesions[32], and immunohistochemical changes as seen after epicutaneous 
LTB4-application have been found in lesionai skin of psoriatic patients[33,24] Various 
compounds that interfere with LTB4 metabolism such as 5-lipoxygenase inhibitors, 
proved to be effective in psonasis[5,6] Unfortunately, side effects have limited their 
use until now The present study suggests that the pharmacological profile of LY293111 
is very attractive substantial effects on cutaneous inflammation, and absence of 
clinically significant side effects in the 20 subjects at the dosage used In diseases that 
are initiated, dominated or maintained by PMN, LY293111 may well be beneficial 
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Effects of modulation of LTB4-metabolism on CDllb and CD18 integnns 
6.1 ABSTRACT 
Aim of the present study was to investigate efficacy and clinical tolerability of the 
specific leukotriene B4 receptor antagonist VML295 in the treatment of stable plaque 
psoriasis, lmmunohistochemical and flow cytometrical methods were used to assess 
effects on inflammation and epidermal proliferation. The use of VML295 in the 
treatment of chronic plaque psoriasis showed to be safe and well tolerated. After 
treatment there was a statistically significant difference between patients treated with 
VML295 and patients treated with placebo with respect to the leukotriene B4-induced 
CDllb upregulation on the cell surface of polymorphonuclear leukocytes derived from 
peripheral blood. Ex vivo CDllb upregulation in the VML295 treated group was 
completely inhibited after 7 days of treatment (p = 0.001). This effect persisted until the 
end of the treatment period (p=0.004 on day 15 and p<0.0001 after four weeks) 
whereas CDllb upregulation in the placebo group remained unaffected. 
There was no statistically significant difference in the median psoriasis area and 
severity index between both treatment groups at the end of the treatment period. 
During treatment no significant histological changes were observed in the markers for 
cutaneous inflammation and epidermal proliferation. Although not statistically 
significant, a tendency of increased expression of some markers for cutaneous 
inflammation and epidermal proliferation was observed after one week of treatment 
with VML295 and a decreased expression of these markers was seen after four weeks 
of treatment with VML295. This observation could indicate anti-inflammatory effects 
of VML295 appearing between two and four weeks after institution of treatment. 
Therefore it is possible that extension of the treatment period might reveal clinical 
effects. 
6.2 INTRODUCTION 
Psoriatic plaques are characterised histologically by cutaneous inflammation, increased 
epidermal proliferation and abnormal keratinisation[l-3]. Although the cause of 
psoriasis is unknown at present, changes in inflammatory control mechanisms, 
immunological dysregulation, and abnormal epidermal growth and keratinisation have 
been suggested to be of pathogenetic relevance[4-6]. 
Trafficking of polymorphonuclear leukocytes (PMN) is a mechanism of relevance in 
an early stage of the pathogenesis of psoriasis, particularly in unstable psoriasis[7]. 
Indeed in an early stage of lesion development numerous PMN are observed invading 
the epidermis[3]. 
Chemoattractants are present in the psoriatic plaque in large amounts, one of which 
is the very potent arachidonic acid derivative leukotriene B« (LTB4)[8-12]. LTB4 exerts 
123 
Chapter 6 
various effects on PMN it is involved in the promotion of adhesion, Chemotaxis, 
migration and degranulation[13-18] Integnns are of crucial importance in PMN 
rrugration[19,20] Therefore, inhibition of LTB4-regulated biological effects might be an 
approach to treat psoriatic lesions 
In psoriasis, the mtegnn expression pattern of keratmocytes and infiltrate cells is 
altered[21 25] In normal keratmocytes of the epidermis mtegnn expression is confined 
to the basal (germinative) layer whereas in hyperproliferative conditions, like psoriasis, 
integnns are also expressed on suprabasal keratmocytes On psoriatic infiltrate cells 
some integnns show overexpression whereas others are downregulated 
Recently the LTB4 receptor antagonist VML295 became available[26] The IUPAC-
name (International Union of Pure and Applied Chemistry) is 2 [3 [3-[(5-ethyl-4' 
fluoro-2 hydroxy[1,T-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic acid 
sodium salt VML295 (formerly called LY293111) binds specifically to the LTB4 
receptor[27,28] In a previous study performed by our group it has shown to have 
potent inhibitory effects on epidermal PMN accumulation and epidermal 
hyperproliferation induced by epicutaneous application of LTB4[29] It has also shown 
to block the ex vivo LTB4-induced CDllb upregulation on peripheral blood PMN of 
healthy volunteers treated with systemic LY293111 (VML295) for 10 days[28,29] 
The aim of the present investigation was to assess clinical and immunohistochemical 
effects on psoriatic plaques as well as safety and tolerability of VML295 during a 4 
weeks' treatment period 
A placebo controlled parallel group randomised prospective study was designed in 
which psoriatic patients were treated with systemic VML295 or placebo The effects of 
VML295 on peripheral blood PMN were quantified flow cytometncally by assessment 
of in vitro LTB4-mediated CDllb upregulation[30] 
6.3 MATERIALS AND METHODS 
6 3 1 Patients and biopsies 
The trial was performed in a double-blind, placebo-controlled randomised fashion 
Twenty-four patients with stable plaque psoriasis participated in this study Informed 
consent was obtained from all patients All volunteers were treated with either 
VML295, 200 mg BID, or placebo for four weeks. In addition only petrolatum was 
allowed for treatment of the clinically involved skin 
The effects of VML295 on the extent of body involvement, histological parameters, 
and LTB4-induced CDllb expression on PMN derived from peripheral blood were 
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investigated. From involved psoriatic skin three punch-biopsies (4 mm) were taken 
under local anaesthesia: at day 1, after one, and four weeks of treatment. 
6.3.2 Clinical and laboratory safety measurements 
Prior to starting medication, a general physical examination and laboratory 
measurements consisting of haematology, serum chemistry, serum electrolytes, random 
blood glucose, and urinalysis were performed. During the study-period the 
haematology, serum chemistry and urinalysis were repeated at day 1, 8, 15, and 29 of 
the treatment period and at the last day of follow-up (14 days post-treatment). Before 
and after treatment an electrocardiograph was performed. 
Severity of psoriasis was assessed and monitored using the Psoriasis Area and Severity 
Index (PAS1) before treatment and after 1, 2 and 4 weeks of treatment. 
6.3.3 CDllb integrin upregulation assay 
Blood specimens for assessment of ex vivo neutrophil CDllb surface-expression were 
obtained before treatment, after one and two weeks of treatment and at the end of 
the treatment period. 
Peripheral blood (4 ml) was collected through venepuncture, kept in ethylene-di-
amine-tetra-acetic-acid (EDTA) at 4°C and processed within 3 hours after collection to 
prevent non-specific upregulation of CDllb expression as a result of neutrophil 
activation. 
Blood samples were processed in triplicate using 90 μΙ aliquots which were incubated 
with LTB4 (10 μΙ IxlO·7 M) in Hanks' balanced salt solution (HBSS, Sigma chemical corp., 
St. Louis, USA) containing 0.1% bovine serum albumin (HBSS-BSA), or with HBSS-BSA 
(10 μ!) alone for 30 minutes at 37°C. Samples were then cooled and incubated in the 
dark for 30 minutes at 4°C with 10μΙ (0.045 g/l) anti-human CDllb-fluorescein 
conjugate (Mo-1-FITC, Coulter Corp., Hialeah, USA). Erythrocytes were lysed (with 10% 
FACS® Lysing Solution in demin. water, Becton Dickinson, San Jose, CA, USA) and the 
remaining cells were washed with HBSS-BSA, fixed in 1 % paraformaldehyde solution 
and stored at 4°C until analysis. 
The analysis was always performed within one week after preparation of the 
leukocyte suspensions in order to prevent the possibility of artefacts caused by prolonged 
storage. 
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6.3.4 Flow cytometric analysis 
All specimens were analysed on an Epics Elite® flow cytometer (Coulter, Luton, UK). 
Cells were excited with an air-cooled 488 nm argon laser set at 15 mW. Green 
fluorescence (FITC) was measured through a 525 nm band pass filter (band width 30 
nm). 
Calibration and sensitivity were checked in every experiment by using FITC-labelled 
beads (Standard-Brite, Coulter Source, Hialeah, USA). Forward (FS) and side scatter 
(RAS) were used for gating only granulocytes. For each sample 5,000 gated cells were 
analysed. 
6.3.5 Imrnunohistochemical staining procedures 
Cryostat sections of 7 ц т were cut and fixed for 10 minutes in acetone/ether (60/40 
v/v %) for Mib-1, or in acetone for staining with the other antibodies. All stainings 
were performed using indirect peroxidase techniques. The antibodies used are depicted 
in Table 1. 
Cell type Antibody lg-type Ligand Clone Specificity Manufacturer 
PMN Anti-elastase I g d kappa Neutrophil NP57 Neutrophil Dakopatts, 
elastase mouse elastase PMN, Copenhagen, 
sporadic in Denmark 
monocytes 
Cycling cells Mib-1 
CDllb-positive Anti C D l l b 
cells (in skin) 
ICAM-1- ICAM-1 
positive cells 
CDllb-positive Anti C D l l b 
cells (in blood) 
IgG, 
IgC, 
IgG, 
КІ67 
C D l l b 
CD54 
IgM kappa C D l l b 
Mib-1 
mouse 
Bear-1 
mouse 
84H10 
mouse 
94 
nuclear antigen, 
present in the 
late Ci-, S- and 
Gi+M-phases of 
the cell cycle 
P M N , some 
monocytes and 
macrophages 
CD54 
P M N , some 
monocytes and 
macrophages 
Immunotech. 
Marseille. 
France 
Monosan, Uden, 
the Netherlands 
Immunotech. 
Marseille. 
France 
Monosan. Uden, 
the Netherlands 
Table 1. The imrnunohistochemical and flow cytometric markers used 
Slides were incubated with the monoclonal antibodies for 30 min., followed by 2 
washes with PBS and incubated for 30 min. with rabbit-anti-mouse antibody 
conjugated with peroxidase (RAMPO, Dakopatts, Copenhagen, Denmark). After 2 
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more washes with PBS and pre-incubation with sodium acetate buffer (pH 4 9) slides 
were stained with sodium acetate buffer containing 200 mg/1 3 amino 9 ethyl-
carbazole (AEC-solution) and 0 0 1 % H 2 0 2 for 10 minutes at 37°C in the dark 
All slides were washed in demm water and slightly counterstamed with Mayer's 
haematoxylin (Sigma, St Louis, USA) Slides were finally mounted in glycerol gelatine 
(Sigma, St Louis, USA ) and studied by light microscopy 
6 3 6 Histological examinations 
All stamings were assessed by two investigators before the study was unblmded and 
the results obtained were expressed as an average of the two assessments Epidermal 
proliferation was measured by counting the number of Mib-1 positive nuclei per mm 
length of section 
The density of infiltrate cells (elastase- and CDIIb stamings) were assessed 
semiquantitatively in epidermis and dermis using a 7 point scale epidermis 0 = no 
positive cells observed, 1 = sporadic staining, 2 = minimal presence, 3 = moderate 
presence, 4 = moderate/pronounced presence, 5 = pronounced presence, 6 = 
complete staining Dermis 0 = no positive cells, 1 = sporadic, 2 = 1 25% of infiltrate 
cells stained, 3 = 26-50% 4 = 51-75%, 5 = 76-99%, 6 = 100% The dermal infiltrate 
was divided in perivascular and diffuse localisation ICAM-1 staining was quantified in 
epidermis and dermis using a 5 point scale 0 = no staining, 1 = 1 25%, 2 = 26-50%, 3 
= 51-75%, 4 = 76-100% 
In addition, an estimation of the total infiltrate was made using a 4 point scale 0 = 
no infiltrate present, 1 = minimal infiltrate, 2 = moderate infiltrate 3 = pronounced 
infiltrate 
For comparison of the histology results between different groups the Mann Whitney 
test was used For comparison in the same treatment group the Wilcoxon signed ranking 
test was used 
6.4 RESULTS 
6 4 1 Clinical efficacy and tolerability 
Sixteen patients received treatment with VML295 and eight patients received placebo 
Patients in both treatment groups were well matched for demographic and baseline 
characteristics (VML295 group mean age 46 years, range 24-78 years, sex-ratio m f as 
14 2, placebo group mean age 48 3 years, range 18 67 years, sex-ratio m f as 5 3) A 
total of 23 patients completed the study One patient did not proceed to the follow-
up phase due to inadequate therapeutic response There were no major changes in 
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laboratory values or electrocardiograph readings. The treatment was well tolerated 
and only mild or moderate adverse events were reported (14 patients in the VML295-
treated group and 8 patients in the placebo-treated group). 
The most frequent adverse events in the VML295-treated group were skin itching, 
headache, diarrhoea and hyperlipidaemia (on fasted blood samples) while the overall 
frequency of adverse events was similar in both treatment groups. 
Before treatment the psoriasis severity as assessed by the PASI-score was comparable 
in both groups (8.19 ± 0.87 in the VML295 treated group and 7.89 ± 1.11 in the 
placebo group, mean ± SEM). During the four weeks' treatment period no statistically 
significant differences in PASI occurred between both groups (after treatment: 8.36 ± 
1.07 in the VML295-treated group and 6.56 ± 1.14 in the placebo group, mean ± 
SEM) and baseline values did not differ from PASI after four weeks of treatment. 
6.4.2 CDIIb integriti upregulation assay 
Basal CDllb levels present on the cell surface of peripheral blood PMN were 
comparable in the VML295 and placebo group before treatment (4.56 ± 0.53 and 5.36 
±1.18 respectively, mean ± SEM). In vitro stimulation of PMN with LTB4 showed a 
highly consistent upregulation of CDllb expression (11.15 ± 1.12 and 11.79 ± 1.43 
respectively) which was comparable in both groups. Before treatment no statistically 
significant difference was seen in the relative PMN CDllb expression (ratio 
challenged/unchallenged, expressed as a fold increase) between both treatment groups 
(VML295: 2.55 ± 0.15 and placebo: 2.56 ± 0.29). During systemic treatment, there 
were no differences in unstimulated PMN CDllb-levels between both groups, and levels 
remained comparable to the values before treatment. 
The placebo group showed no difference in relative neutrophil CD1 lb-expression 
after four weeks of treatment, compared to baseline values (2.48 ± 0.21). However, 
with VML295 the relative neutrophil CDllb expression was significantly reduced (1.12 
± 0.04, ρ = 0.001) at day 8 and this inhibition of upregulation persisted throughout 
the four weeks' treatment period with the same level of significance (Figure 1). 
Calculating the relative expression of CDllb on blood PMN in every individual 
showed a total separation between placebo- and VML295-treated patients. 
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Figure 1. £v vivo CDllb expression of unstimulated and LTB^-stimulated peripheral blood PMN. 
before treatment and after one. two and four weeks of treatment. The results are expressed as 
the relative CDllb upregulation: CD1 !bir,m¡¡üre</CDllbu„,„m,ii¿red. 
6.4.3 Immunohistochemical parameters 
Expression of C D l l b , ICAM-1, elastase, and Mib-1 d id not show a statistically significant 
difference between the VML295-treated group and the placebo group. 
Al though no statistical significance was found, a tendency of an increase of mean 
values was observed after one week of treatment w i t h VML295 . This tendency was 
consistent in all stainings. 
After four weeks of treatment a decrease of these parameters occurred w i t h mean 
values similar to baseline or slightly be low (Figures 2a-d). 
In the placebo group the reversed pattern was seen: after a tendency of a decrease 
at day 8 which was observed in all inf lammation markers, mean values remained the 
same or showed a slight increase at day 29. 
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Figures 2a-d. Immunohistochemical results from the inflammation markers CDIlb and elastase 
and from the proliferation marker Mib-1. The differences between groups do not reach 
statistical significance. Results are expressed as a percentage from baseline values. 
6.5 DISCUSSION 
In the presented placebo-controlled study 16 psoriatic patients have been treated for 
four weeks with the LTB4-receptor antagonist VML295. The treatment proved to be 
well tolerated: in both treatment groups complaints were mild and comparable in 
frequency and intensity. Treatment with VML295 proved to be safe: all parameters 
obtained from physical and laboratory examinations remained within safety limits. 
Ex vivo LTB<i-induced CDIlb upregulation on peripheral blood PMN from psoriatic 
patients was almost completely blocked by VML295. Ninety percent inhibition was 
reached after 7 days of treatment and this inhibition persisted during the four weeks' 
treatment period. These results are similar to those from previous experiments in 
which healthy volunteers were treated with VML295 (formerly called LY293111) 200 
mg BID for ten days[29]. The degree of inhibition of ex vivo LTB4-induced PMN 
CDIlb upregulation by VML295 proved to be slightly more pronounced in healthy 
volunteers compared to psoriatic patients in the present study (1.02 ± 0.02 and 1.11 ± 
0.02 respectively, p = 0.03). However, the group of healthy volunteers in the previous 
130 
Effects of modulation of LTBi-metabolism on CDIIb and CD18 integrins 
study was relatively small (n = 6) and the inhibition was profound in both healthy 
volunteers and psoriatic patients. 
In contrast to the marked effects in peripheral blood, no significant effects were 
observed on clinical severity scores (PASI) nor on histological parameters for 
inflammation and epidermal proliferation. There are several possible explanations for 
these apparently negative clinical and histological results. (I) The treatment period of 
four weeks might have been too short. It is well known from other established 
systemic antipsoriatic treatments like methotrexate and acitretin that it may last six to 
eight weeks before the first clinical improvement appears[31]. (II) There is a moderate 
contribution of PMN to the inflammatory infiltrate present in stable plaque 
psoriasis[32]. Based on the assumption that antagonism of the effects elicited by LTB4 
has most impact on the PMN subset of inflammatory cells, it is reasonable to assume 
that stable plaque psoriasis, treated with VML295 for a limited period of four weeks, is 
not the most suitable model for assessment of clinical efficacy. For this reason, more 
promising indications might be the pustular forms of psoriasis or unstable expanding 
psoriasis as in these manifestations of psoriasis the contribution of PMN to the 
inflammatory infiltrate is much more pronounced[33]. 
(Ill) A third possibility is that the concentration of VML295 in skin is not adequate 
for complete suppression of LTB4-induced biological effects on PMN. However, in 
blood the concentration proved to be adequate for complete inhibition of LTB4-
induced CDllb upregulation on PMN in all VML295-treated patients. It is probable 
that the skin concentrations were sufficient for a cutaneous effect. 
Indeed, in a previous study performed by our group in which effects of systemic 
LY293111 (VML295) were examined on LTB4-induced inflammation in normal skin, a 
pronounced inhibitory effect was observed on cutaneous inflammation and epidermal 
proliferation at an identical dosage regimen[29]. Therefore this possibility seems 
unlikely. (IV) LTB4 may be of limited pathogenetic importance in the maintenance of 
stable plaque psoriasis and therefore of little therapeutic relevance. 
A consistent pattern in the mean values of elastase, CDllb and Mib-1, although not 
statistically significant, was observed in the VML295-treated group. A tendency of 
increase was observed in all inflammation and proliferation markers at day 8 of 
treatment, which was followed by a decrease after four weeks of treatment. In the 
placebo group the inverse pattern was seen: after an initial decrease in all 
inflammation markers at day 8, mean values persisted at the same level until the end 
of the treatment period. 
We would like to hypothesise that the tendency of increase after 1 week of 
treatment results from a compensation mechanism within the network of cytokines, 
characterised by an attempt to reduce the anti-inflammatory effect of VML295. 
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Following the reduction of LTB4-binding caused by VML295 it might well be possible 
that its functional loss is compensated on mediator-level by an increased availability or 
receptor binding of mediators other than LTB„[34]. 
The tendency to decreased inflammation after four weeks of treatment suggests that 
the hypothetical compensation mechanism is transient and does not totally counteract 
the anti-inflammatory and antiproliferative effect of VML295 in vivo. The tendency 
for a decrease in inflammation after four weeks of treatment lends support for 
extension of the study period in order to investigate if this observation is based on 
random statistical noise, or whether this is the earliest phase of the cutaneous anti-
inflammatory and antiproliferative response exerted by VML295. 
In conclusion, the specific LTB4-receptor antagonist VML295 has proven to be safe 
and well tolerated during the four weeks' treatment period at a dosage of 2x200 mg 
per day. In blood the LTB„-induced CD11b upregulation on peripheral blood PMN was 
completely blocked throughout the full treatment period. In skin, no statistically 
significant changes have been observed. There are indications that extension of the 
treatment period still might reveal beneficial effects of VML295 in the treatment of 
stable plaque psoriasis. For further study it would be worthwhile to investigate the 
therapeutic effects of VML295 in the treatment of pustular manifestations of psoriasis. 
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7.1 ABSTRACT 
Inhibitors of 5-lipoxygenase have been studied with respect to antipsoriatic efficacy. Of 
these compounds, R-68151 is of particular interest as it proved to inhibit 5-
lipoxygenase without inhibiting 12-lipoxygenase, cyclooxygenase and thromboxane A2 
synthetase. R-68151 has been shown to have a mild-to-moderate therapeutic effect in 
psoriasis. In the present study a new 5-lipoxygenase. R-85355, was investigated with 
respect to its efficacy in psoriasis. R-85355 is 3 times more potent compared to R-
68151 with respect to inhibition of in vitro A-23187 stimulated leukotriene-B4 
production by polymorphonuclear leukocytes. In a left-right double-blind comparative 
study, the compound was studied at saturation with respect to its antipsoriatic efficacy 
in 11 patients with chronic stable plaque psoriasis. In addition, various markers for 
epidermal proliferation, keratinisation and inflammation were assessed. In no single 
patient was a left-right difference observed in favour of R-85355 compared to placebo 
with respect to clinical severity scores or the cell-biological markers. The present study 
indicates that a selective and highly potent 5-lipoxygenase inhibitor was not effective in 
the topical treatment of chronic plaque psoriasis. 
7.2 INTRODUCTION 
Cutaneous inflammation, epidermal proliferation and abnormal keratinisation are the 
key features of the psoriatic lesion. Various molecules have been hypothesised to be 
responsible for these abnormalities[l]. The increased production of leukotriene B4 
(LTB4) has been suggested to be of pathogenetic relevance[2,3]. Various classical 
antipsoriatic treatments have been reported to inhibit the LTB4 induced accumulation 
of polymorphonuclear leukocytes[4]. Inhibitors of 5-lipoxygenase have been studied 
with respect to antipsoriatic efficacy (Table 1). 
Compound Company Administration Efficacy Reference 
Benoxaprofen 
MK-886 
RS-43179 
(lonapalene) 
R-68151 
Eli Lilly Systemic 
Merck, Sharp & Dohme Systemic 
Syntex Topical 
Janssen Topical 
Effective[5,6] 
Not effective[7] 
Better than placebo[8] 
comparable to 
fluocinoloneacetonide[9] 
Inhibition of scaling and 
erythema[10] 
Table 1. The antipsoriatic effect of 5-lipoxygenase inhibitors. 
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Of these compounds R-68151 is of particular interest as it was shown to inhibit 5-
hpoxygenase without inhibiting 12-lipoxygenase, cyclooxygenase and thromboxane 
A2- synthetase 
Recently a new compound became available, R-85355 The full chemical name of R-
85355 is 2-[2-(4-chlorophenyl)-2-oxoethyl]- 2,4 -dihydro-4- [4 (4-hydroxyphenyl)-l-
piperazinyl] -5-methyl-3H-l,2,4 -triazol-3-one This compound was shown to inhibit 
LTB4 production in human polymorphonuclear neutrophils stimulated by calcium 
lonophore A 23187 in vitro In this model the effect of R-85355 was 3 times more 
potent compared to R-68151, whilst the specificity profile of both compounds was 
identical[ll,12] 
The aim of the present study was to investigate clinical efficacy and tolerability of 
topical R-85355 in patients with chronic plaque psoriasis using an intra subject left right 
comparative approach 
7.3 PATIENTS A N D METHODS 
73 1 Patients and treatments 
Eleven patients with symmetrical plaque psoriasis were treated in a prospective 
randomised left right comparative study, with a 0,5% R-85355 o/w cream and its 
cream base only (Janssen Pharmaceutica BV . Beerse, Belgium) All patients gave 
informed consent 
The patients (6 males and 5 females) were aged 48 ± 12 years In every patient 2 
comparable and representative psoriatic plaques were selected and evaluated by the 
modified PASl-score The modified PASI was calculated using the formula (E+l+D),.» χ 
(diametert_„/diametert_0) where E= erythema, 1= infiltration, D= desquamation, t = 
number of visits and t = o is the first visit E,l and D were scored from 0 to 4 with 0 
indicating no expression and 4 indicating the severest possible expression The mean 
PASI score at the right side was 6 5 ± 1 1 and at the left side 6 5 ± 1 3 Topical as well 
as systemic treatments had been stopped 2 and 4 weeks, respectively, before treatment 
with the study drug In this wash-out phase, patients were allowed to use the cream 
base During the double-blind period R 85355 0,5% and its cream base were applied 
thinly and evenly twice daily for 6 weeks Clinical assessment was made every 2 
weeks Haematological, biochemical and urinalysis were performed at the start and 
the end of the treatment phase 
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7.3.2 Immunohistochemical methods 
In all patients biopsies were taken from the test lesions, 1 at the start and 1 at the end 
of treatment. The biopsies were snap-frozen in liquid nitrogen and stored at -80°C 
until processing. Slices of 4 ц т were cut and fixed in acetone for 10 min. The 
monoclonal antibodies, summarised in Table 2, were used to characterise epidermal 
proliferation and differentiation as well as epidermal and dermal inflammation. 
Antibody Staining specificity Marker for 
Differentiation 
6 В 10 
1 C 7 
RKSE60 
Ks8.12 
Inflammation 
Anti-elastase 
T i l 
WT14 
O K T 6 
Proliferation 
Ki67 
Cytokeratin 4 
Cytokeratin 13 
Cytokeratin 10 
Cytokeratin 13+16 
Elastase 
CD 2 
CD 14 
CD la 
Nuclear antigen 
Stratifying, non cornifying suprabasal cells 
Stratifying, non cornifying suprabasal cells 
Stratifying, cornifying suprabasal cells 
13: fetal skin 
16: hyperproliferative keratinocytes 
Polymorphonuclear leukocytes 
T-lymphocytes 
Monocytes and macrophages 
Langerhans cells 
Cycling cells in C1-S-C2M phases 
Table 2. Antibodies. 
An indirect alkaline phosphatase technique was used for staining with the antibodies 
Ki67 and anti-elastase. Tissue sections were incubated for 60 min with the primary 
antibodies. After washing in phosphate-buffered saline (PBS) the slices were incubated 
with a solution of rabbit-anti-mouse immunoglobulin conjugated with alkaline 
phosphatase for 30 min. After washing in PBS, sections were stained with fast red, 
counterstained with Mayer's haematoxylin and mounted in glycerine gelatine. Staining 
with the remaining monoclonal antibodies was carried out using an indirect peroxidase 
technique. Slices were incubated for 60 min with the primary antibody. After washing 
in PBS, the sections were incubated with a solution of rabbit-anti-mouse 
immunoglobulin conjugated with peroxidase for 30 min. 
After washing in PBS, the peroxidase label was visualised by incubation with 3.3-
diaminobenzidinetetrahydrochloride solution as a substrate. Subsequently, the sections 
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were incubated with CuS04 for 5 min, counterstained with Mayer's haematoxylin, 
dehydrated, and mounted in permount. The procedures were performed at room 
temperature. Ki67-positive nuclei were counted per millimetre length of section. 
Presence in the epidermis and dermis of the remaining stained structure were 
assessed using the following semiquantitative scale: epidermis-. 0= no staining; 1 = 
sporadic staining; 2= minimal staining; 3= moderate staining; 4= moderate-to-
pronounced staining; 5= pronounced staining; and 6= whole epidermis stained; dermis-, 
0= no presence: 1= sporadic presence; 2= 1-25% of infiltrate cell stained; 3= 26-50% 
of infiltrate cells stained; 4= 51-75% of infiltrate cells stained; 5= 76 = 99% of infiltrate 
cells stained: 6= 100% of infiltrate stained. 
7.4 RESULTS 
In 8 patients the treatment was carried out during the full study period of 6 weeks. In 
4 patients deterioration was observed in the double-blind treatment period and in 3 
cases treatment was discontinued between 2 and 4 weeks. Side effects, consisting of 
itching and burning on both sides, also led to these patients dropping out (patients 
No. 2, 3, 9 and 10). The severity of psoriasis remained stable or improved moderately 
in 3 patients (patients No. 4, 6 and 11). However, no left-right difference was noticed 
in these 3 patients. Temporary unilateral improvement was achieved in 4 patients, 
which disappeared at the end of the treatment period (patients No. 1, 5, 7 and 8). 
No significant change or tendency of change was observed with respect to the 
markers for proliferation, keratinisation and infiltrate formation during treatment. 
7.5 DISCUSSION 
Until now, drugs with an inhibiting effect on 5-lipoxygenase had variable effects in the 
treatment of psoriasis. A lack of efficacy has been reported for MK-886 at a dosage 
causing a substantial inhibition of LTB4 production and reducing the accumulation of 
PMN in the psoriatic leslon[7]. On the other hand , RS-43179-gel caused a relevant 
antipsoriatic effect, comparable with fluocinolone acetonide-gel[8,9]. The extent to 
which a 5-lipoxygenase inhibitor is indeed 5-lipoxygenase-specific must be addressed. 
R-68151 and R-85355 have the same specificity profile with pronounced inhibition of 
5-lipoxygenase without an effect on 12-lipoxygenase, cyclooxygenase and thromboxane-
A2 synthetase[11.12]. In a clinical investigation on the efficacy of R-68151 in psoriasis, a 
moderate effect on scaling and a slight effect on erythema was shown. In contrast, R-
85355 had no clinical effect and no effect on histological parameters (epidermal growth, 
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differentiation and inflammation) This negative observation sharply contrasts with its 
potent 5-lipoxygenase-inhibiting effect in vitro 
An important question is whether the concentration of the inhibitor was sufficient to 
inhibit 5-lipoxygenase in the skin. R-68151 and R-85355 are phenols, a class of molecules 
(including salicylic acid and resorcinol) well known for optimal penetration into the skin 
No studies of penetration in skin are available to quantify the biological availability In 
fact, following oral administration the systemic bio-availability of R-85355 has been 
reported to be better compared to R-68151 [12]. 
In the present study, the concentration of 0 5% was selected, as maximal saturation is 
reached at this concentration Therefore it can be assumed that the availability of R-
85355 in psoriatic skin is equal to that of R-68151. In this respect it is important that R-
85355 inhibits the production of LTB4 in A-23187-stimulated human blood 
polymorphonuclear neutrophils at an IC50 of 1 34 χ 10 7M, compared to an 1C50 of 3 5 
μΜ for R-68151 In vitro, R-85355 proved to be approximately 3 times more 
potent[12,13] Although definitive proof of a dissociation between lack of antipsonatic 
effect and inhibiting effect on 5-lipoxygenase can only be provided by simultaneous 
measurement of LTB4 levels in the lesionai skin before and after treatment, 
immunohistochemical studies do no lend support for a significant anti-inflammatory 
effect in vivo 
So far, no 5-lipoxygenase inhibitor has been developed that has proved to be a 
successful antipsonatic treatment 
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Effects of retinoid modulation on CDllb and CD18 integnns 
8.1 ABSTRACT 
Liarozole is a novel inhibitor of the enzyme cytochrome P-450 which has inhibitory 
effects on the 4-hydroxylation of retinole acid Previous studies have shown that 
liarozole is effective in the treatment of psoriasis We performed an 
immunohistochemical study on the lesionai skin from 7 patients with extensive plaque 
psoriasis, who were treated with systemic liarozole 75 mg BID for a period of at least 
two months In the present study the effects of liarozole treatment on clinical and 
histological parameters were investigated In particular, the effect of liarozole on the 
integnn markers CDllb and CD18 was studied 
For immunohistochemistry, three consecutive biopsies were taken before 
treatment, after four, and after eight weeks of treatment Clinical scores and side 
effects were recorded before and during treatment 
The medication was well tolerated and only mild side effects were reported, which 
were comparable with hypervitaminosis A After two months of treatment a 
statistically significant decrease of the extent of body involvement was observed In 
the psoriatic plaque markers for epidermal proliferation and cutaneous inflammation 
decreased, and markers for epidermal differentiation increased to values comparable 
to norma! skin. The first therapeutic effects in the psoriatic plaque occurred after four 
weeks of treatment, and consisted of a decreased induration, accompanied by a 
decrease of the total number of inflammatory infiltrate cells and a decreased epidermal 
ICAM 1 expression Already after four weeks of treatment, a decrease of CDllb-
positive cells was observed Subsequently, after eight weeks of treatment the 
recruitment of cycling epidermal cells and the number of involucrm positive cell layers 
decreased 
The present study demonstrates that liarozole treatment of psoriasis results in a 
reduction of aspects of cutaneous inflammation and subsequently a reduction of 
epidermal proliferation and differentiation After four weeks of treatment, effects are 
observed on the epidermal ICAM-1 expression and on the CDllb positive cell 
population 
8.2 INTRODUCTION 
Retinoids are well established as a systemic treatment of extensive plaque psonasis[l] 
In involved psoriatic skin retinoids down-modulate epidermal hyperproliferation, 
enhance epidermal differentiation, reduce erythema and pustule formation and reduce 
the accumulation of inflammatory infiltrate cells[2-5] Retinoids have profound effects 
on various biological functions of the polymorphonuclear leukocyte (PMN) 
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Retinoids promote differentiation, and inhibit PMN migration and clonal growth of 
leukaemic cell-lines in v/tro[6-]0] However, toxicity and in particular teratogenicity 
have limited their use[ll-14] 
Recently, liarozole (R085246), a novel imidazole derivative, became available It 
inhibits the cytochrome P-450-dependent 4-hydroxylation of retinole acid which is the 
physiological breakdown of all-f/a/7J"-retinoic acid[15] In cultured human dermal 
fibroblasts, liarozole significantly potentiates the retinol-mduced increase m cellular 
retinole acid binding protein (CRABP II) mRNA. indicating retinoid activity of this 
compound[16] Through this mechanism bio availability of retinole acid is 
enhanced[17] In rats, liarozole increases the concentration of retmoic acid in plasma 
and tissue[18] Liarozole has shown to have antitumour effects based on inhibition of 
degradation of retmoic acid, and vitamin D[19,20] In addition, liarozole inhibits 
various cytochrome P-450-dependent steps in steroid biosynthesis, of which the most 
important are the conversion of progestins to androgens (17-hydroxylase, 17 20-lyase), 
androgens to oestrogens (aromatase), and of 11-deoxycorticosterone to corticosterone 
(ll-hydroxylase)[21] However, in healthy male subjects administration of liarozole 
150 mg BID for ten days showed only a transient decrease of testosterone levels, 
whereas Cortisol levels and adenocorticotrophm hormone stimulated Cortisol surge 
remained unaffected[22] Furthermore, in psoriatic patients treated with liarozole in 
doses ranging from 75 to 150 mg BID, serum levels of cortisone, testosterone, and 
cholesterol remained unaffected[23] 
In humans liarozole has been shown to rise the intracellular retinoid concentration 
In the treatment of severe plaque psoriasis liarozole 75-150 mg BID has proven to be 
effective in 77% of patients[23] 
Cytochrome P-450 isozymes are involved in various biological processes through 
influencing the metabolism of retinole acid, vitamin D, and eicosanoids[24 28] All 
these processes are known to be involved in the pathogenesis of psoriasis So far it 
remains to be established whether liarozole influences the psoriatic process exclusively 
through a retmoid-like mode of action, or whether the effects are mediated to some 
extent through other metabolic pathways 
Aim of the present study was to explore the clinical and histological changes which 
occur in the psoriatic plaque during systemic treatment with liarozole In this study the 
effects of liarozole on aspects of epidermal proliferation, keratinisation, and cutaneous 
inflammation were assessed, using immunohistochemical techniques In particular, 
recruitment of cycling epidermal cells (nuclear staining to Ki67), and various markers 
for inflammation (PMN-elastase, CDllb and CD18 expression) were studied 
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8.3 MATERIALS A N D METHODS 
8 3 1 Patients and biopsies 
Patients were included in an open prospective multicentre study on long term clinical 
safety and efficacy 
At the Nijmegen centre, seven patients with extensive plaque psoriasis (mean age 
53 6 years, range 41-66 years) were treated with liarozole 75 mg BID for a minimum 
period of two months Informed consent was obtained from all patients 
For assessment of the effects of liarozole, the extent of body involvement, as well as 
histological parameters for epidermal proliferation, epidermal differentiation, and 
cutaneous inflammation were quantified In these seven patients, three punch biopsies (4 
mm) were taken from involved psoriatic skin under local anaesthesia before systemic 
treatment, after one, and two months of treatment 
For comparison, a punch biopsy from normal skin was taken in eight healthy male 
volunteers without any history or signs of skin disease (mean age 28 8 years, range 21-44 
years) The tissue samples obtained served as controls All biopsy specimens were 
embedded in Tissue Tec OCT compound (Miles Scientific. Napierville, USA) snap frozen 
in liquid nitrogen and stored at -80°C until use 
8 3 2 Clinical and laboratory safety measurements 
Prior to starting medication, a general physical examination and laboratory 
measurements consisting of haematology, serum chemistry, serum electrolytes, and 
random blood glucose were performed During the study-period the haematological 
and serum chemistry evaluations were repeated at regular intervals Before and after 
the treatment period an electrocardiograph was performed 
Severity of psoriasis was assessed and monitored using the Psoriasis Area and Severity 
Index (PAS1) before treatment, and during treatment at monthly intervals 
8 3 3 Immunohistochemical staining procedures 
Cryostat sections of 7 μηη were cut and fixed for 10 minutes in acetone/ether (60/40 
v/v %) for Mib-1, or in acetone for staining with the other antibodies For the staining 
on CDllb and CD18, endogenous peroxidase activity was blocked by incubation with 
1% sodium azide (Merck, Darmstadt, Germany) and 0 3% H 2 0 2 for 5 minutes For 
the elastase staining, endogenous peroxidase activity was blocked by incubation with 
0 3% H 2 0 2 in methanol for 20 minutes 
The staining on CD18 was performed using the avidin-biotm complex (ABC) 
staining method (Vectastain, Vector, Burlingame, USA) All other stammgs were 
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performed using indirect peroxidase techniques The antibodies used are depicted in 
Table 1. 
Cell t y p e 
Cycling cells 
PMN 
C D l l b 
positive cells 
CD18 
positive cells 
ICAM1 
positive cells 
Involucnn 
positive cells 
Antibody 
M i b l 
Anti 
elastase 
Anti C D l l b 
Anti CD18 
ICAM 1 
M O N 1 5 0 
lg-type 
IgG. 
IgC, 
kappa 
IgG, 
IgG, 
kappa 
IgG, 
Ligand 
Ki67 
Neutrophil 
elastase 
C D l l b 
CD18 
CD54 
Involucnn 
Clone 
M i b l 
mouse 
NP57 
mouse 
Bear 1 
mouse 
M H M 2 3 
mouse 
84H10 
mouse 
Mouse 
Specificity 
Nuclear antigen 
present in the late 
G, S and C12+M 
phases of the cell 
cycle 
Neutrophil elastase 
PMN sporadic in 
monocytes 
PMN some 
monocytes and 
macrophages 
Peripheral blood 
leukocytes 
CD54 
Involucnn positive 
cells 
Manufacturer 
Immunotech 
Marseille 
France 
Dakopatts 
Copenhagen 
Denmark 
Monosan Uden 
the Netherlands 
Dakopatts 
Copenhagen 
Denmark 
Immunotech 
Marseille 
France 
Η ν 
Duijnhoven 
St Elisabeth 
Hospital Tilburg 
the Netherlands 
Table 1 Panel of monoclonal antibodies used 
For the staining on CD18, slides were pre-mcubated with 2 0 % normal horse serum in 
PBS for 10 minutes, followed by incubation with anti CD18 monoclonal antibodies for 
60 minutes After 2 washes in PBS, slides were incubated with 0 0 5 % IgG labelled biotin 
for 30 minutes, followed by incubation with 2% avidin-biotin complexes for 30 
minutes 
For all other stainings, slides were incubated with the monoclonal antibodies (anti 
elastase 30 mm , Mib-1 and anti-ICAM-1 45 mm , anti CDllb and anti involucnn 60 
mm ) This was followed by 2 washes with PBS and incubation for 30 mm with rabbit-
anti mouse antibody conjugated with peroxidase (RAMPO, Dakopatts, Copenhagen, 
Denmark). 
152 
Effects of retinoid modulation on CDUb and С Dì 8 integri ns 
After 2 more washes with PBS and pre-incubation with sodium acetate buffer (pH 
4.9), slides were stained with sodium acetate buffer containing 200 mg/l 3-amino-9-
ethyl-carbazole (AEC-solution) and 0.01% H202 for 10 minutes at 37°C in the dark. All 
slides were washed in demineralised water and slightly counterstained with Mayer's 
haematoxylin (Sigma, St Louis, USA). Slides were finally mounted in glycerol gelatine 
(Sigma, St.Louis, USA ) and studied by light microscopy. 
8.3.4 Histological examinations 
All stainings were assessed by two investigators before the study was unblmded and 
the results obtained were expressed as an average of the two assessments. Epidermal 
proliferation was measured by counting the number of Mib-1-positive nuclei per mm 
length of section. 
The density of infiltrate cells (elastase-, CDIIb-, and CD18- stainings) were assessed 
semi quantitatively in epidermis and dermis using a 7 point scale: epidermis: 0 = no 
positive cells observed, 1 = sporadic staining, 2 = minimal presence, 3 = moderate 
presence, 4 = moderate/pronounced presence, 5 = pronounced presence, 6 = 
complete staining Dermis: 0 = no positive cells. 1 = sporadic, 2 = 1-25% of infiltrate 
cells stained. 3 = 26-50%. 4 = 51-75%, 5 = 76-99%, 6 = 100% The dermal infiltrate 
was divided in perivascular and diffuse localisation. 1CAM-1 staining was quantified in 
epidermis and dermis using a 5 point scale: 0 = no staining, 1 = 1-25%, 2 = 26-50%, 3 
= 51-75%, 4 = 76-100%. The involucnn expression was assessed by calculating the ratio 
positive cell layers / total cell layers of the living epidermis. This was performed at two 
sites: at the tip of a dermal papilla and between two adjacent dermal papillae. 
In addition, an estimation of the total infiltrate was made using a 4 point scale· 0 = 
no infiltrate present, 1 = minimal infiltrate, 2 = moderate infiltrate, 3 = pronounced 
infiltrate. 
The amount of parakeratosis was quantified using a 3 point scale: 0 = complete 
parakeratosis, 1 = sporadic parakeratosis, 2 = orthokeratosis. 
For comparison of the histology results between different groups, the Mann-Whitney 
test was used. For comparison in the same treatment group the Wilcoxon signed ranking 
test was used 
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8.4 RESULTS 
8.4.1 Clinical efficacy and tolerability 
The mean age of the patient group was 53.6 years (range 41-66 years), sex-ratio m:f as 
6:1. All patients completed the study. After treatment there were no major changes in 
laboratory values or electrocardiograph readings. The treatment was well tolerated 
and only mild or moderate adverse events were reported. The most frequent adverse 
events were dry lips and itching. In one patient elevation of serum cholesterol and 
triglyceride levels was observed. 
Before treatment the psoriasis severity as assessed by the PASI-score was 17.7 ± 2.9 
(mean ± SEM). Five subjects showed clinical improvement after eight weeks of 
treatment with liarozole, whereas two subjects showed an increase of PASI compared 
to baseline. For further evaluation of clinical efficacy data the patient group was 
divided in responders and non-responders. 
After one month of treatment only a small improvement of PASI could be observed 
and compared to baseline there was no statistically significant difference (mean PASI: 
14.8 ± 2.4, p = 0.08). After the second month of treatment PASI-score had improved 
significantly in the responder-group compared to baseline (mean PASI: 9.7 ± 2.8, 
p = 0.04). Induration of the psoriatic plaques present on the trunk was the first clinical 
parameter to improve significantly (from 2.4 ± 0.2 at baseline to 1.4 ± 0.2 after four 
weeks of treatment, p = 0.03). After another month of treatment, desquamation and 
erythema on the trunk improved as well (p=0.03 and p = 0.02 respectively). Psoriatic 
plaques on the head did not show significant improvement of PASI after two months 
of treatment. 
8.4.2 Immunohistochemical parameters 
Results of the Mib-1, elastase, CDIlb, and ICAM-1 stainings are summarised in 
Figures la-d. 
Before treatment, the number of Mib-1-positive epidermal cells was increased in 
psoriasis compared to normal skin from healthy volunteers (p<0.01). After four weeks 
of treatment with liarozole the number of cycling cells remained unaffected. However, 
after eight weeks of treatment, a significant decrease of the number of Mib-1-positive 
nuclei was observed in the psoriatic epidermis compared to the situation before 
treatment (p=0.03. Figures 2a-b). 
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cycling calls (Mib-1) 
a Epidermal 
• Dermal perivascular 
Ш Oermal diffuse 
О Inflammatory infiltrale 
• Ortho- / Para keratosis 
weeks Normal skin 
Figure la-d. Expression of Mib-1, ICAM-1, elastase and CDUb before, and after treatment with 
liarozole, 75 mg BID. Results are depicted as an average (error bars: standard error of the 
mean). Significant changes from baseline values in untreated psoriatic skin are marked with an 
asterisk ("). 
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Figure 2a-b. M/6-/ expression (a) before systemic treatment and 
(b) after two months of treatment (magnification: 200x). 
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At this timepomt, no difference could be observed to normal skin (p=0 35) The 
number of involucnn positive cell layers in the epidermis (expressed as a percentage of 
the total amount of cell layers) was significantly increased in the psoriatic plaque 
before treatment This increase compared to normal skin, was observed at the tip of 
the dermal papilla (p<0 05). and between two adjacent papillae (p<0 05) After four 
weeks of treatment there was no significant change with respect to involucnn 
expression, but after two months of treatment a significant decrease was observed At 
that timepomt, between two adjacent dermal papillae the levels of expression were 
comparable to the expression in normal skin, (p>0 15) 
In the involved psoriatic epidermis, parakeratosis was present in all biopsy 
specimens before treatment in contrast to the absence of parakeratosis in normal skin 
After eight weeks, complete parakeratosis was still present in those two subjects who 
did not respond to therapy 
In the subjects who did respond to therapy, however, parakeratosis clearly 
diminished (p<0 01) showing only sporadic parakeratotic foci, and no difference 
could be observed to normal skin from healthy volunteers (p=0 32) 
The epidermal ICAM-1 expression was increased in involved psoriatic skin before 
treatment (p<0 01) This over-expression decreased to the same level of expression as 
in normal skin after four weeks of treatment with liarozole After eight weeks, 1CAM-1-
expression diffusely in the dermis was decreased compared to normal skin 
Before treatment, the density of the inflammatory infiltrate in the dermis was 
increased in psoriatic skin, compared to normal skin (p<0 01) After four weeks of 
treatment the infiltrate had clearly diminished (p<0 01), but after eight weeks of 
treatment, the total amount of inflammatory infiltrate was still increased compared to 
normal skin (p = 0 2) 
The density of elastase positive cells was increased in the untreated psoriatic plaques 
compared to normal skin (p<0 01) This increased expression was observed in the 
epidermis, and in the dermis at perivascular and diffuse localisation After eight weeks 
of treatment with liarozole a statistically significant decrease in elastase expression 
could be observed (p<0 04), reaching levels of expression comparable to those of 
normal skin from healthy subjects (p>0 29) Representative elastase staining patterns 
are shown in Figures 3a-b 
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Figure 3a-b. Elastase expression (a) before systemic treatment and 
(b) after two months of treatment (magnification: lOOx). 
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In the CDllb staining, an increased number of CDIIb-positive cells was observed 
before treatment compared to normal skin (p<0.05). After 4 weeks of treatment, a 
statistically significant decrease of CDIIb-positive cells was observed in the epidermis 
and diffuse in the dermis (p<0.36), reaching the same level of expression as found in 
normal skin (p>0.2). The number of CDIIb-positive cells at perivascular localisation 
did not change during the eight weeks' treatment period. 
The number of CD18-positive cells was increased in psoriatic skin before treatment, 
compared to normal skin (p<0.01). 
After eight weeks of treatment a statistically significant decrease was observed in the 
perivascular area (p = 0.01). At this timepoint, the number of CD18-positive cells at 
perivascular localisation was comparable to that of normal skin (p = 0.17). Treatment 
with liarozole had no effects on CD18 expression in the epidermis, nor on CD18-
positive cells at diffuse dermal localisation. 
8.5 DISCUSSION 
Liarozole treatment was well tolerated and all subjects completed the study period. 
Clinical side-effects were consistent with those observed during retinoid treatment (i.e. 
dry lips, dry nose, and elevated serum triglycerides). However, side effects in the 
present series were mild. 
Five out of seven patients (71%) showed a significant clinical improvement after 
two months of treatment (averaging 55% of baseline values), whereas two patients 
did not respond. The results of the multicentre trial on long term efficacy and safety of 
oral liarozole will be reported in the near future. 
In the patients who responded to liarozole treatment, histological changes were 
pronounced. During treatment the number of actively cycling epidermal cells 
decreased to normal. Involucrin expression and parakeratosis are hallmarks of an 
altered differentiation pathway and are increased in the untreated psoriatic plaque. 
After liarozole treatment, the expression of both differentiation markers was 
decreased, reaching levels comparable to those in the skin of healthy volunteers. 
The number of elastase-positive cells in the dermis clearly diminished during 
liarozole treatment, as well as the total amount of inflammatory infiltrate cells. The 
expression of CDllb, which is abundantly present mainly on activated PMN, was 
decreased already after four weeks of treatment, reaching levels of expression that 
were comparable to those of normal skin. 
The expression of CD18, which is a marker for biological activation and present on 
the cell surface of most of the leukocyte subpopulations, was increased in the psoriatic 
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inflammatory infiltrate before treatment During liarozole treatment, the number of 
CD18-positive cells at perivascular localisation decreased to the expression pattern in 
normal skin 
In consecutive biopsies the dynamics of changes was assessed In the sequence of 
events, the first statistically significant change was a decreased induration of the 
psoriatic plaque This was accompanied by a decrease in the number of inflammatory 
infiltrate, a decreased number of CDllb-positive cells and a decreased epidermal 
ICAM-1 expression After eight weeks of treatment desquamation and erythema 
subsided, together with a decrease in epidermal hyperproliferation and an increased 
differentiation Therefore, the effects on infiltrate cells, specifically CDllb positive cells, 
and ICAM-1 anticipated on the effects on proliferation and differentiation 
This observation suggests that the cytochrome Ρ 450 inhibitor liarozole directly 
interferes with cutaneous inflammation and hence might be useful in the treatment of 
inflammatory dermatoses 
The number of PMN proved to decrease during liarozole treatment This might 
indicate that liarozole could be of benefit in the treatment of PMN mediated skin 
diseases such as the various pustular forms of psoriasis 
It remains to be investigated whether the CDllb and CD18 integrm molecules are 
down-modulated exclusively in the psoriatic plaque, or also systemically on circulating 
blood PMN. 
After eight weeks of treatment, a prominent effect on epidermal proliferation and 
differentiation was observed, suggesting that the cytochrome P-450 inhibitor might be 
of value in the treatment of disorders of keratmisation Indeed, Lucker et al recently 
reported that systemic liarozole is effective in the treatment of various ichthyoses[29] 
In conclusion, liarozole proved to have a broad effect on epidermal growth and 
differentiation as well as on inflammation characteristics It is possible that these results 
are mainly due to inhibition of retinole acid breakdown However, additional 
therapeutic effects may be caused by inhibition of other cytochrome Ρ 450 isozymes, 
resulting in inhibition of vitamin D3 catabolism, or interference with eicosanoid 
metabolism Further studies on effects of liarozole in the treatment of inflammatory 
skin conditions and disorders of keratmisation are worth while 
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9.1 ABSTRACT 
The aromatic retinoids etretinate and acitretin are widely used in the systemic 
treatment of severe psoriasis The purpose of the present investigation was to further 
elucidate the mode of action of acitretin on abnormal keratmisation and epidermal 
hyperproliferation m an m vivo model Studies on the interference of acitretin with 
epidermal hyperproliferation and abnormal keratmisation in psoriatic plaques are 
difficult to interpret, as acitretm-mduced changes might be due to direct effects of 
acitretin or be the indirect effect of retmoid-induced modulation of cutaneous 
inflammation 
Using an immunohistochemical assessment, we examined the in vivo effect of 
systemic acitretin (> 35 mg daily) on the expression of filaggrin, involucrm, and on the 
recruitment of cycling epidermal cells, in the tape-stripped uninvolved skin of psoriatic 
patients, a model which provides the opportunity to study epidermal regeneration in 
the absence of significant accumulation of Τ lymphocytes During acitretin therapy and 
3 weeks after withdrawal of acitretin, we took biopsies from the uninvolved skin 
following tape-stripping in six patients with psoriasis Six patients with psoriasis who 
had never used acitretin served as controls We did not observe a Koebner response in 
our patients after tape stripping Filaggrin expression was decreased, while the 
recruitment of cycling epidermal cells and the involucrm expression were increased in 
the biopsies taken from patients who did not use acitretin During acitretin treatment, 
however, the filaggrin expression was similar, whereas the Ki67 positive nuclei and the 
involucrm expression showed a statistically significant decrease compared to those 
parameters in the patients who did not use acitretin Our findings indicate that 
epidermal hyperproliferation and abnormal keratmisation are modulated directly by 
acitretin 
9.2 INTRODUCTION 
It has been demonstrated that retmoic acid can inhibit profilaggrin synthesis in cultured 
human epidermis keratinocytes[l] Asselmeau et al reported that retinole acid prevents 
the conversion of profilaggrin into filaggrin in cultured human epidermal 
keratmocytes[2] The transcription of the type I (epidermal) transglutaminase mRNA is 
down-regulated by retmoids[3] Transglutaminase 1 is responsible for the catalysation 
of the crosslmking of involucrm during the synthesis of the cornified envelope[4] 
In psoriatic plaques, epidermal hyperproliferation and abnormal keratmisation are 
associated with a pronounced infiltration of various cell types Therefore, in vivo 
studies on the interference with epidermal hyperproliferation and abnormal 
differentiation in psoriatic plaques are difficult to interpret, as those changes might be 
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due to direct effects of acitretin or be the indirect effect of retinoid-induced 
modulations of cutaneous inflammation. 
The purpose of the present investigation was to further elucidate the mode of 
action of acitretin on abnormal keratinisation and epidermal hyperproliferation in an 
in vivo model. We used the tape stripping model, which was first described by 
Pinkus[5]. After repeated application of sellotape, thereby removing almost all of the 
horny layer. Pinkus observed a regenerative response of the human epidermis[6]. Tape 
stripping is a useful model of synchronised growth, allowing us to study drug 
influences on cell kinetics accurately, without significant infiltrate formation[7]. 
Using an immunohistochemical assessment, we examined the in vivo effect of 
acitretin on the presence of filaggrin and involucrin, and on the recruitment of cycling 
epidermal cells in the uninvolved skin of psoriatic patients. 
9.3 MATERIALS AND METHODS 
9.3.1 Patients 
Six patients (age 41-70 years) with severe psoriasis vulgaris for 2-37 years participated 
in this study. Each patient was informed about the experiment and gave written 
consent. The mean dose of acitretin was 34.2 mg ± 9.7 (mean ± standard error of the 
mean, 0.4-0.8 mg/kg body weight/day), and all patients had mucocutaneous side-
effects. In 5 patients the acitretin-free dynamics of trauma-induced hyperproliferation 
was assessed 3 weeks following discontinuation of acitretin, whereas in one patient the 
acitretin-free phase was studied before treatment. 
Although a period of 2 years is adopted as safe with respect to teratogenicity, it was 
shown that a relapse in palmoplantar pustules occurred only 2 weeks after 
discontinuation[8]. Dierlich et al. demonstrated that it takes 3 weeks of continuing 
medication with oral retinoids to affect the accelerated epidermal cell proliferation in 
psoriatic patients[9]. This made us decide to take the biopsies after 3 weeks. 
Tape stripping was performed at day 0 and day 23 on the uninvolved skin (back) 
of the psoriatic patients. After 48 h, when epidermal proliferation is most pronounced 
(7,10,11) punch biopsies (3 mm) were taken, embedded in Tissue Тек compound, snap 
frozen in liquid nitrogen and stored at - 80°C until use. After the biopsies were taken 
on day 2, the acitretin therapy was discontinued. 
Six patients of matched age with psoriasis vulgaris for 2-21 years and who did not 
use acitretin during the experiment and had not used acitretin in the past served as 
controls. They were also tape-stripped at the uninvolved skin (back). Again after 48 h 
a punch biopsy (3 mm) was taken from the tape-stripped area. Sections of 6 ц т were 
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cut, air dried and fixed for 10 min in acetone-ether 60/40 vol % (Ki67 staining) or in 
acetone (other stainings) and stored again at - 80 °C until use 
9 3 2 Monoclonal antibodies 
To assess epidermal differentiation we used a monoclonal antibody against filaggnn 
(monoclonal mouse anti-filaggnn BT1, BT576) and involucrin MON 150 (monoclonal 
antibody against mvolucnn)[12] To characterise the epidermal proliferation we used a 
monoclonal antibody against a nuclear antigen present in the cycling cells (M1B-1 
(cellproliferation associated nuclear antigen (Ki67). Immunotech SA AMAC Ine )[13] 
9 3 3 Staining procedures 
For the staining with anti filaggnn, antt-involucrin, and Kt67 an indirect 
immunoperoxidase technique was used The slides were put in a phosphate-buffered 
stock solution (PBS solution 360 ml Na2HP04 (7 9 g Na2HP04, Merck in 500 ml 
deminerahsed water) plus 70 ml NaH2P04 (13 8 g NaH2P04, Merck, in 500 ml 
demineralised water) plus 70 ml deminerahsed water) For 60 mm the slides were 
incubated with the monoclonal antibodies MIB-1 (1 50 diluted in PBS solution 
containing azide and 1% BSA), anti filaggnn and anti involucrin (1 500 and 1 50 
diluted in PBS solution) 
After washing with phosphate buffer the slides were incubated with rabbit anti 
mouse immunoglobulin conjugated with peroxidase (1 25, RAMPO) After washing in 
the PBS solution and pre-mcubation with sodium-acetate buffer (pH 4 9), a solution of 
3-amino-9 ethylcarbazole (AEC) in sodium acetate buffer containing 0 0 1 % H202 was 
added for 10 mm 
All slides were counterstained with Mayer's haematoxylin (Sigma, St Louis MO USA) 
and mounted in glycerol gelatine 
9 3 4 Histological examination 
Epidermal proliferation was measured by counting the number of Ki67 positive nuclei 
per mm length of the section The filaggnn expression was assessed by measuring the 
percentage of the length of the stratum corneum and stratum granulosum which was 
stained The involucrin expression was assessed by calculating the ratio positive cell 
layers/total cell layers of the living epidermis This was performed at two sites at the 
tip of a dermal papilla and between two dermal papillae[14] 
9 3 5 Statistical evaluation 
For statistical analysis the Wilcoxon test for matched pairs and the Mann Whitney test 
were used 
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9.4 RESULTS 
None of the patients showed a Koebner-response. 
The histological results appear in Table 1. 
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Table 1. Epidermal proliferation and differentiation in normal, psoriatic and stripped skin. 
Comparison of the expression of filaggrin, involucrin and КІ67 positive nuclei in normal skin, 
psoriatic uninvolved skin (PUI) after tape stripping (PS) before cyclosporin A (-CsA). during 
CsA (+CsA). In the psoriatic lesion (PL)(previously presented results: *, **, ***) without 
acitretin (-Ac) and during acitretin (+Ac). Data expressed as mean ± SEM and quart ¡les. 
After tape-stripping anti-filaggrin was absent or showed discontinuous expression in 
both layers. The filaggrin expression in the stripped areas during acitretin treatment d id 
not show a significant change, compared to filaggrin in the stripped areas after 
discontinuation of acitretin (р
Я
г8гаа>0.11, p s t r c o r n > 0 . 1 5 ) . 
Whereas involucr in expression in normal human skin is present in the stratum 
granulosum and upper third of the stratum spinosum[15-16], after tape-stripping the 
involucrin expression is also observed in the lower region of the epidermis[17]. This 
induction of involucrin decreased significant during acitretin treatment (ρ„
ρ
<_0.02, 
¿Wpap.<0.04). 
The degree o f stripping induced recruitment was significantly reduced dur ing 
acitretin treatment, compared to the stripping induced recruitment 3 weeks fo l l ow ing 
discontinuation o f acitretin ( p < 0 . 0 4 ; Figures 1-3) 
The histological results of biopsies taken f rom the control group did not show a 
significant difference compared to the observation in the group of patients w h o 
stopped the acitretin for 3 weeks. 
* · « * ; * * % • # % 
Figure 1. КІ67positive nuclei in the tape-stripped uninvolved skin 
3 weeks after withdrawal of acitretin. 
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Figure 2. КІ67positive nuclei in the tape-stripped uninvolved skin during 
acitretin. 
Figure 3. КІ67 positive nuclei in the tape-stripped uninvolved skin of the 
control group. 
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9.5 DISCUSSION 
In 1951 Pinkus made the discovery that following the application of multiple strips of 
cellophane tape to normal skin, a predictable mitotic response of epidermal cells 
occurs After multiple strips of tape had been successfully applied to the same area the 
corneocytes were removed, layer by layer In 48-72 h after tape stripping he observed 
a burst of mitoses in the basal layer and in the lower region of the stratum 
spinosum[5] The peak of the mitotic response is usually after 48 h[18] The stratum 
granulosum is lost after 12 h[6] After 24 h, a parakeratotic layer starts to form and the 
stratum granulosum starts to regenerate beneath the parakeratotic cells[18] 
The present investigation confirms earlier observations of our group that epidermal 
dysregulation after tape-stripping and epidermal characteristics of the psoriatic plaque 
have important similarities with respect to recruitment of cycling epidermal cells 
filaggrin and involucrin expression (Table 1)[17] 
Following tape stripping, filaggrin expression had decreased markedly The 
observation that filaggrin expression remains decreased during acitretin treatment is in 
line with the previous in vitro findings that retinole acid can inhibit profilaggrm 
synthesis and prevent the conversion of profilaggrm into filaggrin in cultured human 
epidermal keratinocytes[l-2] Our results are also in agreement with the observation of 
Eichner et al , who demonstrated a reduction of filaggrin expression in epidermal cells 
of rhino mice after topical application with retinole acid[19] In contrast to the present 
studied single strip model, following repeated stripping we observed a substantial 
increase of filaggrin and epidermal cells, which implies that the superficial layers of the 
epidermis remain to be biochemically active[20] On the other hand, Rosenthal et al 
noted an increased number of cell layers with involucrin and filaggrin expression after 
topical retinole acid treatment in healthy volunteers[21] However, the irritation of the 
skin following topical retinoid might be responsible for this effect It is known that 
retinoids exert a different effect in normal human epidermis compared to psoriatic 
epidermis Gillenberg et al observed an increase of epidermal proliferating cells in 
normal human epidermis during therapeutic doses of oral aromatic retinoids[22] The 
reports of Lowe et al and Dierlich et al definitely demonstrate the antiproliferative 
effect of retinoids in psoriatic skin[9,23] In the present investigation using an in vivo 
model for epidermal proliferation, an inhibition of the recruitment of cycling cells 
could be substantiated The results confirm that the 3-week interval between the two 
biopsies was correct 
The observation that the stnpping-induced recruitment of cycling epidermal cells 
and involucrin expression are both reduced during systemic acitretin treatment (_>35 
mg daily) supports the hypothesis that involucrin synthesis is related to the 
proliferation rate of epidermal keratmocytes It has been reported that the number of 
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T-cells is not induced by tape-stripping in patients who do not show a positive 
Koebner-response (17). Indeed, only sporadic distributed infiltrate cells were observed 
following tape stripping in our patients. Therefore, the modulation of epidermal 
changes following tape stripping by acitretin is unlikely to be secondary to immune 
modulating effects of the drug. 
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GENERAL DISCUSSION 
In the introduction of this thesis, three major aims have been defined 
1 To assess the relevance of CDllb- and CD18-positive cells in the pathogenesis of 
psoriasis 
2 To study the effects of modulation of leukotnene B4 metabolism on CD11b and 
CD18 mtegrins 
3 To obtain more insight in retinoid modulation of CD11b and CD18 mtegrins 
In this chapter the conclusions from the various studies that have been described in this 
thesis, will be discussed 
10.1 DISCUSSION OF METHODS AND TECHNIQUES 
The methodology as used in this thesis comprises phenotypmg using antibodies against 
typological and functional cell characteristics The techniques we used are 
immunohistochernistry, flow cytometry, and assessment of clinical parameters 
10 11 Psoriasis Area and Seventy Index 
The Psoriasis Area and Severity Index (PAS1) has been introduced by Frednksson in 
1978 and is used as a simple description of a patient's clinical condition[l,2] This is 
performed by integration of the degree of erythema, induration and desquamation of 
the psoriatic plaques, in combination with the extent of involved body surface The 
result is expressed as a number between 0 (no clinical involvement) and 72 (severest 
possible clinical involvement) The PASI enables us to quantify the severity of psoriasis 
and to assess the effects of treatment An internationally accepted and standardised 
clinical description of the patient's condition is a useful tool to compare the 
assessments done by different investigators The intra-observer variability of the PASI is 
acceptable Nevertheless, the PASI has a substantial inter-observer variability 
Another disadvantage is the fact that considerable variation in clinical presentation 
may exist between two patients with an identical PASI[3-6] 
For example, a patient with a PASI of 8 5 can either have extensive body 
involvement with only mild erythema, induration and desquamation, or have only a 
few psoriatic plaques, which show the severest possible erythema, induration and 
desquamation Therefore, it is important to assess the values of the individual 
components of the PASI In spite of the limitations of PASI as a simplified one number 
index it provides a useful clinical method for the assessment of the severity of 
psoriasis 
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10 12 Flow cytometry 
Flow cytometry is a powerful tool to quantify cellular parameters of specific cell 
populations[7] Since various fluorescent dyes with different emission spectra are 
available, one can simultaneously assess multiple parameters in one individual cell The 
use of multiple lasers, permitting multiple excitation wavelengths, further enables this 
development Calibration and regular sensitivity checks make flow cytometry a 
standardised approach for an accurate comparison of results obtained by different 
investigators and / or on different timepoints However, flow cytometry also has its 
limitations It can only be performed on cell suspensions Therefore, information on 
topographical relations is lost Another limitation of this method is that it gives 
quantitative information per cell (chapter 2 and 3) Information on the distribution of 
a certain parameter over the various cellular organelles can not be obtained For the 
assay used in the present thesis, this disadvantage is of relative importance, as the 
present studies were aimed at biologically active CDllb receptors that are localised on 
the cell surface 
10 13 Immunohistochemistry 
In psoriatic plaques significant histological differences are observed as compared to 
normal skin In the present thesis immunohistochemical methods were used for 
assessment of epidermal proliferation, differentiation, and cutaneous inflammation in 
developing and regressing psoriatic lesions, as well as in various models for epidermal 
proliferation and inflammation A panel of monoclonal antibodies has been used on 
frozen tissue sections 
One of the most striking advantages of this method is that the morphology is 
preserved, which permits investigation of topographical interactions between different 
cell types such as CDllb positive cells and keratmocytes (chapters 3 1 and 3 2)[8] 
The most important disadvantage of the use of immunohistochemical methods is 
that one cannot quantify accurately the number of positively stained cells Especially 
when multiple parameters are assessed or when positively stained cells are abundantly 
present, the counting raises serious difficulties One can only distinguish between 
positively and negatively stained cells, gradual expression can not be assessed by this 
method The number of positively stained cells depends on specificity of the antibody, 
and sensitivity of the staining Only semiquantitative assessment is possible in this 
approach Flow cytometry as used in chapters 2 and 3 is an important tool to quantify 
the micromorphological changes 
Another limitation is encountered in the quantitation method of infiltrate cells as 
used in this thesis We expressed the number of positively stained infiltrate cells relative 
to the total number of infiltrate cells present In this way information is 
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obtained on the relative contribution of leukocyte subpopulations to the total 
inflammatory infiltrate. An important restriction of this approach lies in the fact that a 
decrease in the total amount of inflammatory cells is not reflected in the sum score of 
a specific leukocyte subset. Therefore, if a treatment has an aspecific effect on the 
inflammatory infiltrate, this effect is only reflected in the sum score for the amount of 
infiltrate cells, and not in sum scores of individual leukocyte subsets. 
The psoriasis area and severity index is acceptable as a general assessment of disease 
activity. However, in order to obtain further information with respect to clinical 
aspects of lesions, and on the influence of treatments on the epidermal and dermal 
compartments, other and more specific approaches are needed. 
In the understanding of a particular disease, microscopic investigation of histological 
characteristics remains an important corner stone in the acquisition of knowledge. 
Quantitative methods might provide tools for assessment and monitoring of disease 
activity. Multiparameter flow cytometrical analysis as performed in this thesis, provides 
quantitative information on the dynamics of the induction and regression of psoriatic 
lesions. 
The combined use of flow cytometry and immunohistochemistry is a 
complementary approach because it enables the combination of quantitative data of 
parameters of a particular cell type with the specific distribution of this cell type over 
epidermal and dermal skin compartments. If these cytological and histological data are 
combined with a good clinical scoring method, the possibility arises of linking specific 
clinical signs to specific cell biological processes. 
10.2 THE RELEVANCE OF CDIlb- AND CD18-POS1TIVE CELLS IN THE 
PATHOGENESIS OF PSORIASIS 
10.2.1 The CDJlb expression on circulating blood PMN from psoriatic patients 
In psoriatic patients, the resting-levels and levels of ex vivo LTB4-induced CDIlb 
expression on peripheral blood leukocytes are decreased. In unstable psoriasis this 
decrease is more pronounced compared to patients with stable plaque psoriasis. No 
correlation was found between PMN CD11b expression and the PASI. 
We have two hypotheses to explain the decreased CDIlb expression on PMN of 
psoriatic patients: 
A: there is decreased leukocyte responsiveness due to chronic stimulation. 
B: compartmentalisation of activated leukocytes takes place by accumulation in the 
skin, leaving the unstimulated subset of leukocytes in the general circulation. These 
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circulating leukocytes proved to be less easily stimulated than the leukocytes derived 
f r o m healthy volunteers. 
10.2.2 The involvement ofCDIIb- and CD18-positive cells in the psoriatic process 
In non-lesional and lesionai psoriatic skin the number of CDl lb-posit ive cells is 
elevated. In the margin of the actively spreading psoriatic plaque the change that takes 
place in the most peripheral region, is a decrease in 1CAM-1 expression. 
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Figure 1. The number of CDllb-, CD18-. /CAM-!, and elastase-positive cells in distant 
uninvolved skin, the margin zone and the centre of the psoriatic lesion, represented as 
follows: Η significant increase in relation to normal skin (p<0.05), W&. significant decrease in 
relation to normal skin (p<0.05), • significant increase in relation to distant uninvolved 
psoriatic skin p<0.05), dZ significant decrease in relation to distant uninvolved psoriatic skin 
(p<0.05). 0= transition-point between ortho- andpara-keratosis. 
This p h e n o m e n o n might be explained as an attempt t o prevent spreading of the 
lesion. At the same localisation w e observed an elevation of the number of C D l l b -
positive in f lammatory cells. At a more centripetal localisation a rise in the number of 
CD18-positive cells was observed. These inf lammatory changes take place outside the 
border between o r t h o - and parakeratosis, and thus constitute early phenomena in 
psoriatic plaque development. M o r e centrally in the actively spreading psoriatic 
plaque, elevated numbers o f P M N were f o u n d , accompanied by an increased number 
of cycling epidermal cells. 
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Elevation of the number of CDIlb and CD18 positive cells at the utmost peripheral 
edge of the psoriatic plaque suggests early involvement of these cells in the 
pathogenesis of psoriasis Therefore, we would like to hypothesise that it might be 
worthwhile to choose these cell populations as a target for antipsonatic therapy 
Studies on the effects of CDIlb- and CD18-modulating therapies would be 
particularly interesting with respect to the prevention of new lesions, and effects on 
early developing lesions in acute exacerbating psoriasis 
Indeed the present study (chapter 2) showed that CDIlb positive cells are increased 
in lesionai skin as well as in distant uninvolved psoriatic skin This lends further support 
for the hypothesis that a subset of activated CDIIb-positive cells are accumulating in 
the skin compartment of psoriatic patients (as stated under 5 2 1 B, and in chapter 2) 
Other proinflammatory changes are increased phospholipase A2 activity and LTB4 
production occurring as early events in the distant uninvolved psoriatic skin[9-11] 
Diffusely in the dermis of distant uninvolved skin the number of CD18-positive cells 
was decreased compared to normal skin This indicates and altered leukocyte 
trafficking in the dermis of psoriatic patients, well outside the clinical border of the 
psoriatic plaque We hypothesise that the altered leukocyte trafficking is caused by an 
adaptation mechanism in the skin of psoriatic patients that is aimed at the prevention 
of overt cutaneous inflammation Indeed, it has been demonstrated that the 
accumulation of PMN in symptomless psoriatic skin following LTB4 challenge is 
decreased[12,13] In symptomless skin of psoriatics the altered equilibrium with 
increased proinflammatory changes and increased antiinflammatory mechanisms 
implies an unstable situation This altered equilibrium may be dysregulated following 
injury, which can result in a psoriatic lesion This phenomenon is well known as the 
Koebner phenomenon 
10 2 3 CDIlb and CD18 expression in relation to the sharp demarcation of the 
psoriatic lesion 
As described earlier, we observed a decreased ICAM-1 expression at peripheral 
localisation in the margin zone and an increased ICAM-1 expression more centrally in 
the plaque ICAM 1 acts as a ligand for the CD11b/CD18 receptor complex At 
perivascular localisation CDIIb-positive cells are increased already well outside the 
clinical border of the plaque and into the distant clinically uninvolved skin, compared 
to skin from healthy volunteers This again indicates the presence of proinflammatory 
mechanisms in both clinically uninvolved as well as involved psoriatic skin In distant 
clinically uninvolved skin we did not find any changes in ICAM 1 expression 
In the margin of the psoriatic plaque, proximal to the parakeratotic-orthokeratotic 
border, CDIlb- and CD18-positive cells were increased in all skin compartments Their 
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increase over the margin of a spreading psoriatic plaque is gradual, and therefore the 
distribution patterns of CDUb- and CD18-positive cells do not provide a good 
explanation for the sharp demarcation of the psoriatic lesion. 
10.2.4 Endoglin expression in relation to the sharp demarcation of the psoriatic lesion 
Endoglin expression was low in the most peripheral regions of the margin of the 
actively spreading lesion. More centrally, endoglin expression abruptly increased, 
which was accompanied by the formation of an infiltrate composed mainly of T-
lymphocytes. Endoglin acts as a scavenger of TGFß. TGFß has immunosuppressing 
properties and is able to inhibit the proliferation of basal keratinocytes[14-20]. Low 
endoglin expression in the peripheral part of the margin zone could give an increased 
bioavailability of TGFß, causing immunosuppression at a localised level, whereas the 
increased endoglin expression in the centre of the psoriatic plaque decreases the 
availability of TGFß. 
This functional deficit of TGFß could enable the development of overt 
inflammation. In the margin zone, ICAM-1 was decreased in the periphery, and 
abruptly showed an increased expression more centrally in the plaque. These changes 
in expression of endoglin and ICAM-1 were observed over a small area in the margin 
zone, thus providing a possible explanation for the sharp demarcation of the psoriatic 
plaque. 
Anti-inflammatory mechanisms in the periphery of the margin, combined with lack 
of the natural ligand ICAM-1, provides an explanation for the fact that CDllb- and 
CD18-positive cells are sporadically present in the periphery of the margin zone. More 
centrally these anti-inflammatory mechanisms disappear which permits the invasion of 
cells carrying the CDllb and CD18 epitope, as well as other inflammatory cells like T-
lymphocytes. 
10.3 THE EFFECTS OF MODULATION OF LEUKOTRIENE B4 METABOLISM 
O N CDllb AND CD18 INTECRINS 
10.3.1 Effects ofLY293111/ VML295 on LTB4-induced CDllb upregulation on 
peripheral blood PMN 
LY293111 / VML295 completely blocks ex vivo leukotriene B4 induced upregulation of 
CDllb on peripheral blood leukocytes. In healthy volunteers and patients with stable 
plaque psoriasis the inhibitory effect was similar. The level of inhibition of CDllb 
upregulation proved to be dependent on the administered dose of LY293111 / 
VML295. In psoriatic patients maximum inhibition was reached after 7 days of 
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treatment which remained unaffected until the end of the 4 weeks' treatment period 
In contrast to the pronounced effect on LTB„-induced CDIIb upregulation, the LTB4 
receptor antagonist did not affect the baseline levels of CDIIb on blood PMN 
10 3 2 Effects of L Y293111 / VML295 on clinical and cell biological aspects of psoriasis 
Effects of systemic LY293111 / VML295 were tested in LTB4-mduced inflammation and 
in stable plaque psoriasis 
A clear inhibitory effect was observed on LTB4-induced epidermal 
hyperproliferation and on the cutaneous inflammatory response in the LTB4 
application model In patients with stable plaque psoriasis only minimal effects were 
observed on markers for epidermal proliferation and cutaneous inflammation, 
although the LTB4 receptor antagonist had a significant inhibitory effect on CDIIb 
upregulation on peripheral blood PMN 
Our results do not show any clinically significant effect of LY293111 / VML295 on 
stable plaque psoriasis We found two possible reasons for these negative results 
Firstly, the compound has marked effects on LTB4 induced PMN function, but since 
PMN are relatively sparee in chronic psoriatic plaques, this most common 
manifestation of psoriasis might not be the best indication for treatment with this LTB4 
receptor antagonist Secondly, the results presented in chapter 3, indicate that LTB4 
may be not the most important factor of relevance in the maintainance of an 
established stable psoriatic plaque 
It is possible that LY293111 / VML295 might have an effect on the prevention of 
new lesions in patients with acute exacerbating or pustular psoriasis since PMN are 
more abundantly present in these forms of psoriasis 
10 3 3 Effects of R 85355 on clinical aspects of psoriasis 
The topical 5-lipoxygenase inhibitor R-85355 proved to have no significant effects on 
clinical parameters of the psoriatic plaque No apparent changes of cell biological 
parameters were observed 
Previous studies have shown beneficial effects of some 5-lipoxygenase inhibitors in 
the treatment of plaque psonasis[21-24] Toxicity, however, has limited their further 
development for clinical use 
In the psoriatic plaque there is abundant presence of LTB4 and other inflammatory 
eicosanoids[25-28] Inhibitors of the enzyme 5-lipoxygenase prevent the formation of 
eicosanoids and are therefore unlikely to be effective in the treatment of stable plaque 
psoriasis, but might show effects in newly developing psoriatic plaques Nevertheless 
some 5 lipoxygenase inhibitors showed an antipsonatic effect[29-31] Although this 
antipsonatic effect might be mediated via 5-lipoxygenase inhibition, the selectivity of 
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these compounds has never been proven So far, the value of 5-lipoxygenase inhibitors 
and LTB4 receptor antagonists seems to be rather limited 
10.4 THE EFFECTS OF RETINOID MODULATION ON CDIlb AND CD18 
INTEGRINS 
10 4 1 Effects of Acitretin and Liarozole on epidermal proliferation, differentiation. 
and inflammation 
Acitretin inhibits epidermal hyperproliferation and facilitates differentiation in 
uninvolved psoriatic skin following standardised m;ury by sellotape stripping Sellotape 
stripping does not induce a substantial inflammatory response and therefore in this 
model the anti-inflammatory properties of acitretin could not be assessed 
Van de Kerkhof et al have shown that acitretin prevents the epidermal 
accumulation of PMN following epicutaneous application of LTB4, which proves that 
acitretin, in addition to its effects on epidermal proliferation and differentiation, also 
has significant effects on cutaneous inflammation[32] 
In the involved psoriatic skin of subjects with extensive plaque psoriasis, who have 
been treated with liarozole, various histological changes were observed These 
consisted of decreased epidermal hyperproliferation and increased differentiation (as 
indicated by decreased involucnn expression and decreased parakeratosis) Liarozole 
reduced inflammation in the psoriatic plaque 
One of the earliest therapeutic changes was a decrease of the total amount of 
inflammatory cells which was observed after four weeks of treatment A decrease in 
the relative contribution of the inflammatory markers CDIlb, CD18 and anti-elastase 
over the various cutaneous compartments was observed in a later phase of the 
treatment 
Acitretin and liarozole have similar effects on cutaneous inflammation, epidermal 
proliferation and differentiation 
Further studies are needed to ascertain whether liarozole acts predominantly as a 
retinoid, or whether it has significant additional modes of action The induction of the 
expression of CRABP II and of cytokeratins 4, 13, and 19 are specific results of a 
retinoid effect So far. no m vivo studies have been carried out to show the induction 
of CRABP II expression during treatment with liarozole Upregulation of keratin 13 
during treatment of ichthyoses with liarozole, has been shown by Lucker et al [33] 
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10.4.2 Effects of Liarozole on CDllb- and CD18-expression in psoriasis 
Liarozole affected the numbers of CDllb- and CD18-positive cells present in psoriatic 
skin. During treatment, the amount of CDllb- and CD18-positive cells gradually 
decreased, reaching statistical significance after eight weeks of treatment. At this 
timepoint, no differences could be observed compared to the levels present in normal 
skin of healthy volunteers. However, effects on the CDllb- and CD18-positive cell 
populations were preceded by down modulation of ICAM-1 expression and by a 
decrease in the total amount of inflammatory infiltrate cells. Therefore, liarozole 
probably has no selective effect on CDllb- or CD18-positive cell populations. 
10.4.3 Correlation of CDllb- and CDW-expression with clinical parameters of the 
psoriatic plaque 
After four weeks of treatment with liarozole, a decrease in the amount of 
inflammatory infiltrate cells present in the psoriatic plaque could be observed. This was 
accompanied by a decrease of induration of the plaque and a decreased epidermal 
ICAM-1 expression. After eight weeks of treatment the numbers of CDllb- and CD18-
positive cells have decreased from elevated to normal values. At the same timepoint 
this was associated with a significant decrease in erythema and scaling of the psoriatic 
plaque. A positive correlation is found between erythema and the amount of CDllb-
and CD18-positive cells. The relative contribution of CDllb- and CD18-positive cells to 
the total amount of inflammatory infiltrate switched towards a predominance of 
CD18-positive cells after eight weeks of treatment, indicating a more pronounced 
effect of Liarozole on the CD1 lb-positive cell population than on the CD18-positive 
cell population. The simultaneous decrease of erythema and CDIlb-positive cells lends 
support for the hypothesis that this cell population plays a prominent role in 
cutaneous inflammation in the psoriatic plaque. 
10.5 GENERAL CONCLUSIONS 
From the results presented in this thesis the following conclusions can be drawn: 
la. In psoriatic patients the CDllb expression on leukocytes is altered. In peripheral 
blood there is a decreased leukocyte CDllb expression and a decreased CDllb 
upregulation after a stimulus with leukotriene B4. This phenomenon is most clearly 
observed in subjects with unstable psoriasis. 
lb. In distant clinically uninvolved skin of psoriatic patients CDIlb-positive cells are 
increased compared to normal skin. In the spreading psoriatic plaque the number of 
CDIlb-positive cells is increased, constituting an early event in psoriatic plaque 
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development More centrally in the psoriatic plaque, an increase of CD18-positive cells 
is observed 
2 The specific leukotnene B4 receptor antagonist LY293111 / VML295 completely 
blocks the LTB4-mediated CDllb-upregulation on PMN derived from peripheral 
blood This phenomenon was observed in healthy male subjects as well as in psoriatic 
patients LY293111 / VML295 does not affect baseline levels of leukocyte CDllb 
expression 
3 The specific leukotnene B4 receptor antagonist LY293111 / VML295 inhibits 
leukotnene B4-induced epidermal hyperproliferation and cutaneous inflammation in 
healthy subjects, but fails to improve stable plaque psoriasis in a four weeks' treatment 
course 
4 Stable plaque psoriasis is not a suitable indication for LY293111 / VML295, 
possibly because there are relatively low numbers of CDllb-positive cells in this 
manifestation 
5 The 5-lipoxygenase inhibitor R-85355 is uneffective in the treatment of stable 
plaque psoriasis 
6 Liarozole improves psoriasis This compound has clear effects on epidermal 
proliferation, differentiation and cutaneous inflammation Liarozole has no 
preferential effects on the CDllb- and CD18 positive cells 
10.6 SUGGESTIONS FOR FUTURE INVESTIGATIONS 
1 To assess the clinical effects of the leukotnene B4 receptor antagonist LY293111 / 
VML295 (VML295) in early unstable expanding psoriasis, or in other inflammatory 
skin conditions dominated by presence of PMN In the present thesis it was shown that 
the compound substantially inhibited LTB4-induced PMN accumulation in skin It is 
likely that the compound will have a beneficial role in the treatment of PMN-
dependent skin conditions 
2 To study the interference of liarozole with the nuclear receptors for vitamin A 
and vitamin D and the effects of liarozole on vitamin D metabolism The intracellular 
signalling pathways of retmoic acid and vitamin D3 are communicating circuits Ligand 
induced activation of the RXR receptor and the vitamin D receptor (VDR) induces 
heterodimer formation of RXR and VDR[34-38] Therefore liarozole could well inhibit 
vitamin D3 inactivation via inhibition of the cytochrome P-450 
3 To study the effects of liarozole on eicosanoid metabolism Theoretically, 
inhibition of cytochrome P-450 has inhibitory effects on eicosanoid formation From 
previous studies we know that levels of certain eicosanoids are increased in the 
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psoriatic plaque. Therefore, inhibition of eicosanoid formation might be of relevance 
in the mode of action of liarozole. 
4. To evaluate the effects of anti CDllb antibodies as a possible immunotherapy 
for psoriasis. CDIIb-positive cells are increased in the early stages of development of a 
psoriatic plaque, and beta integrins in general, are known to be important in leukocyte 
extravasation (chapter 1). Selective blocking of CDllb without interference with other 
important leukocyte integrins might have a substantial effect specifically on psoriasis, 
without a severe immunosuppression. 
5. To investigate other mediators which might upregulate CDllb and CD18 
expression. We know that LTB4 is an important and potent upregulator of PMN 
CDllb expression, but it is yet unknown if. and to what extent, other mediators of 
inflammation are involved in the upregulation of CDllb and CD18 in vivo in the 
psoriatic process. Phorbol myristate acetate (PMA), fMLP, and sCD16 are well-
recognised upregulators of cell surface integrins. Future studies will have to unravel the 
contribution of these upregulating factors other than LTB4, of potential relevance in 
CDllb and CD18 upregulation in the psoriatic process. 
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SUMMARY 
In this thesis, the relevance of CDIlb and CD18 is investigated in the pathogenesis and 
treatment of psoriasis. Clinical efficacy of new antipsoriatic therapies with a potential 
effect on CDIlb and CD18 expression were studied. 
In part 1, psoriasis is introduced by description of ethiological and clinical 
features. The most common antipsoriatic therapies are described. A record of current 
ideas on pathogenetic processes is given, including a description of the various 
inflammatory cells involved in the psoriatic infiltrate. Adhesion molecules are 
introduced, and their relevance for processes of inflammation is outlined. The models 
for psoriasis and methods of investigation are introduced. 
In part 2, the relevance of CDIlb and CD18 integrins in the pathogenesis of 
psoriasis was investigated using an in vitro assay and an in vivo model. CDIlb 
expression on psoriatic PMN was quantified before and after in vitro stimulation with 
LTB4. CDIlb expression on psoriatic PMN was decreased compared to the expression 
on PMN from healthy volunteers, both before and after LTB4 stimulation. The 
decrease was strongest in patients with unstable psoriasis. 
The margin zone of an actively spreading psoriatic lesion was used as a model to 
study early events in psoriatic plaque development. CD1 lb-positive cells were 
increased in early stages of psoriasis and in the distant clinically uninvolved skin. CD18-
positive cells were increased already outside the parakeratotic border of the psoriatic 
plaque and therefore belongs to the early events in the pathogenesis of psoriasis. 
Remarkably, a decreased ICAM-1 expression was observed in the outer part of the 
margin zone. The patterns of ICAM-1 and endoglin expression were compatible with 
the sharply demarcated border of the psoriatic plaque, whereas a more gradual 
transition was observed in the occurrence of CDIlb- and CD18-positive cells. 
In part 3, effects of a specific leukotriene B4 receptor antagonist (LY293111 / 
VML295) were investigated on CDIlb- and CD18-positive cells in blood and skin. 
Firstly, the antagonist was studied in healthy volunteers using epicutaneous LTB4 
application as a model for inflammation and epidermal proliferation. Secondly, the 
effects of the LTB4 receptor antagonist were studied in the treatment of stable plaque 
psoriasis. 
In peripheral blood PMN the in vitro CDIlb upregulation through LTB4 was 
completely blocked, both in healthy subjects and in psoriatics. LY293111 / VML295 
inhibited LTB4-induced epidermal proliferation and cutaneous inflammation. 
However, in psoriatic patients no statistically significant changes were seen. 
Effects of the topical 5-LO-inhibitor R-85355 were investigated in psoriasis using 
a left-right comparative approach. R-85355 proved to be ineffective as a treatment for 
psoriasis. 
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In part 4, Effects of liarozole, a cytochrome P-450 inhibitor with retinoid 
modulating properties, was investigated on CDIlb- and CD18- positive cells. In 
addition, the effects of acitretin were studied on epidermal proliferation and 
differentiation induced by standardised injury. 
Liarozole was effective in the treatment of severe chronic plaque psoriasis and 
induced a decrease in the number of CDIlb- and CD18-positive cells. Since the effects 
on these cell populations were preceded by a decrease in the 1CAM-1 expression and a 
decrease in the amount of inflammatory infiltrate, it was concluded that liarozole had 
no preferential effects on the CDIlb- and CD18-posirive cells. 
In the sellotape stripping model it was shown that acitretin had antiproliferative 
and pro-differentiation effects. 
In part 5, the clinical, flow cytometrical and immunohistochemical methods used 
in this thesis are discussed. The aims of this thesis as stated in part 1 are discussed in the 
conclusions that were drawn from the various investigations. Suggestions for future 
investigations are made. 
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SAMENVATTING 
In dit proefschrift is de relevantie van de adhesiemoleculen CDllb en CD18 onderzocht 
met betrekking tot de Pathogenese en behandeling van psoriasis. De klinische 
effectiviteit van nieuwe antipsoriatische therapieën is onderzocht, en met name hun 
effecten op CDllb en CD18 expressie. 
In deel 1 wordt psoriasis geïntroduceerd door een beschrijving van etiologische en 
klinische karakteristieken. De heden tendage meest gangbare antipsoriatische 
behandelingen worden beschreven. Daarnaast wordt een samenvatting gegeven van 
de huidige ideeën omtrent de pathogenetische processen, alsmede een beschrijving van 
de verschillende groepen van ontstekingscellen die betrokken zijn bij de vorming van 
het ontstekingsinfiltraat in een psoriatische plaque. Adhesiemoleculen worden 
geïntroduceerd, en daarbij wordt hun relevantie voor ontstekingsprocessen 
aangegeven. Verscheidene modellen voor psoriasis worden geïntroduceerd, alsmede 
de verschillende onderzoekstechnieken die in dit proefschrift gebruikt zijn. 
In deel 2 wordt de relevantie van CDllb en CD18 in de Pathogenese van 
psoriasis onderzocht aan de hand van het gebruik van een in vitro assay en een in vivo 
model. De CDllb expressie op neutrofiele granulocyten van psoriasispatiënten werd 
gekwantificeerd voor en na in vitro stimulatie met LTB4. Het bleek dat CDllb expressie 
op psoriatische neutrofielen verlaagd was ten opzichte van de CDllb expressie op 
neutrofielen van gezonde vrijwilligers, zowel voor als na LTB4 stimulatie. De verlaagde 
expressie was het sterkst in patiënten met instabiele psoriasis. 
De randzone van een actieve en groeiende psoriasisplaque werd gebruikt als een 
model voor de vroege ontwikkeling van klinisch niet aangedane huid tot het 
psoriatische fenotype. De hoeveelheid CDllb positieve cellen was toegenomen in de 
vroege fase van psoriasis, alsmede in de klinisch niet aangedane huid. Er was een 
toename van CD18-positieve cellen perifeer van de grens tussen ortho- en 
parakeratose in de rand van een psoriasisplaque. Daaruit kon geconcludeerd worden 
dat beide moleculen betrokken zijn bij vroege veranderingen die plaatsvinden in de 
Pathogenese van psoriasis. Opvallend was de verlaagde ICAM-1 expressie in het 
perifeer gelegen deel van de randzone. De expressiepatronen van ICAM-1 en endoglin 
vertoonden een abrupte overgang over de randzone, wat past bij de klinisch scherpe 
grens tussen klinisch niet aangedane huid en een psoriasis plaque, terwijl de distributie 
van CDllb en CD18 positieve cellen een meer gradueel verloop over de randzone 
lieten zien. 
In deel 3 werden in huid en perifeer bloed de effecten onderzocht van een 
specifieke leukotriene B4 receptor antagonist (LY293111 / VML295) op CDllb en CD18 
positieve cellen. Allereerst zijn de effecten van deze antagonist bestudeerd bij gezonde 
193 
Chapter Ю 
vrijwilligers waarbij epicutane applicatie van LTB4 gebruikt is als model voor 
inflammatie en epidermale hyperproliferatie. Aanvullend zijn de effecten van deze 
LTB4 receptor antagonist onderzocht in de behandeling van stabiele plaque psoriasis. 
De in w'r/o CDllb upregulatie door LTB4 was volledig geblokkeerd op PMN afkomstig 
uit perifeer bloed, zowel in gezonde vrijwilligers als bij psoriasis patiënten. LY293111 / 
VML295 inhibeerde de LTB4-geïnduceerde epidermale proliferatie en cutané 
inflammatie. Desondanks werden in aangedane huid van psoriasis patiënten geen 
significante verbeteringen gezien. 
Effecten van de 5-LO-inhibitor R-85355 voor locaal gebruik werden onderzocht 
in psoriasis waarbij gebruik werd gemaakt van een links-rechts vergelijkende studie. 
Het bleek dat R-85355 ineffectief was in de behandeling van psoriasis. 
In deel 4 zijn de effecten van liarozole, een cytochroom P-450 inhibitor met 
retinoid modulerende eigenschappen, onderzocht op CDllb- en CD18- bevattende 
cellen. Liarozole was effectief bij de behandeling van ernstige chronische plaque 
psoriasis. Het induceerde een afname in de hoeveelheid CDllb- en CD18-positieve 
cellen in het ontstekingsinfiltraat. Omdat de effecten op deze celpopulaties werden 
voorafgegaan door een afname van de ICAM-1 expressie en een afname in de totale 
hoeveelheid infiltraatcellen, concludeerden wij dat liarozole geen primaire effecten 
heeft op CDllb- en CD18-positieve cellen. 
Daarnaast zijn de effecten van het synthetisch retinoid acitretin, bestudeerd op 
epidermale proliferatie en differentiatie, welke geïnduceerd werden door middel van 
gestandaardiseerde beschadiging van de huid door sellotape applicatie. 
In dit sellotape stripping model hebben we aangetoond dat acitretin 
antiproliferatieve en pro-differentiatie effecten heeft. 
In deel 5 bediscussiëren we de klinische, flowcytometrische en 
¡mmunohistochemische methoden die gebruikt zijn in dit proefschrift. De 
onderzoeksvraagstelling van dit proefschrift zoals uiteengezet in deel 1, wordt 
beantwoord aan de hand van de conclusies die uit de verschillende onderzoeken 
getrokken kunnen worden. Tot slot worden er suggesties gedaan voor toekomstig 
onderzoek. 
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STELLINGEN 
behorende bij het proefschrift 
The Relevance of CDlIb and CD18 
in the Pathogenesis 
and Treatment of Psoriasis 
Han P.A. van Pelt 
Nijmegen, 4 november 1997 

1. CDl lb en CD18 zijn beide relevant in de Pathogenese en behandeling 
van psoriasis (dit proefschrift). 
2. Expressie van CDl lb en CD18 laten over de randzone van een psoriatische 
plaque graduele veranderingen zien en bieden derhalve geen goede verklaring 
voor de klinisch scherpe overgang van niet aangedane naar 
aangedane psoriatische huid (dit proefschrift). 
3. Bij patiënten met plaque psoriasis is de CDIlb-expressie verlaagd 
op neutrofiele granulocyten afkomstig uit perifeer bloed (dit proefschrift). 
4. LY293111 / VML295 is in staat om in vivode leukotriëne B4-gemedieerde CDl lb 
upregulatie vri jwel volledig te remmen (dit proefschrift). 
5. Leukotriëne B, is niet de belangrijkste ontstekingsmediator in het onderhouden 
van de ontsteking in stabiele plaque psoriasis (dit proefschrift). 
6. Systemisch Liarozole ís effectief in de behandeling 
van uitgebreide plaque psoriasis (dit proefschrift). 
7. Een overmaat aan overleg kan indicatief zijn voor slechte communicatie. 
8. Een beginnende academische carrière is even boeiend als verbazingwekkend: 
zo doet de gemiddelde student er vier jaar over om drs. voor zijn naam 
te mogen zetten, waarbij hij zich de daaropvolgende jaren zo mogelijk 
nog harder inspant om de "s" van drs. weer wég te mogen laten... 
9. De waarde van ¡ets wordt in belangrijke mate bepaald door de moeite 
die het kost om het te bemachtigen. 
10. Nog erger dan onbemind zijn, is onbekend zijn. 
11. Geluk is een richting, geen punt (Loesje). 
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